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The aim of this project was to use the murine sepsis model of Staphylococcus aureus 
infection as a source of in vivo derived bacteria for peptidoglycan analysis. A 
characteristic of this model is the production of kidney abscesses that provide a large 
quantity of bacteria for analysis. Protocols were developed for optimal peptidoglycan 
harvesting from infected host organs. Bacteria from kidney infections are smaller and 
with thicker cell walls than those grown in vitro. Muropeptide analysis of purified 
peptidoglycan from kidney derived cells revealed less crosslinking than in vitro 
exponential phase cells, suggesting an alteration in peptidoglycan metabolism. 
 
To investigate the impact of peptidoglycan metabolism on pathogenesis, the roles of 
components with known activities were studied using a range of in vivo and cellular 
models. PBP4 is required for the observed high level of peptidoglycan crosslinking found 
in vitro. A pbp4 mutation led to increased fitness in the murine sepsis model of infection. 
This was matched by greater survival in human macrophages, suggesting not only that 
peptidoglycan crosslinking is a key virulence determinant but also that it is manifested 
during the crucial initial phase of infection during phagocyte interaction. 
Glucosaminidases hydrolyse the glycan chains in the peptidoglycan and collectively 
these are important for cell growth and viability. Here, I found differing roles for the 
enzymes in host-pathogen interaction. The major glucosaminidase SagB is required for 
virulence in multiple animal models of disease. Analysis of strains bearing mutations in 
multiple glucosaminidase encoding genes revealed that cell clustering results in reduced 
pathogenesis in the zebrafish model of infection, but this can be reversed by cluster 
disruption. This demonstrates that host-pathogen interactions at the outset of disease 
are crucial for its progression. 
 
My project has given novel insight into host-pathogen interaction and stresses the 
crucial need for in vivo studies to identify key breakpoints in infection for the 
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Chapter 1  
Introduction 
 
1.1 Overview of the bacterial cell wall 
 
The bacterial cell wall is a dynamic structure providing a physical defence from the 
intracellular and extracellular environment, whilst allowing the assimilation of nutrients 
from, and release of molecules into, the extracellular milieu (Silhavy et al., 2010). The 
cell wall also confers mechanical strength, resisting lysis from turgor pressure and 
defining the morphology of the cell (Egan et al., 2017). The cell wall also plays a role in 
virulence (Boneca, 2005), and its synthesis is the target of one of the most commonly 
used group of antibiotics, the β-lactams (Bush and Macielag, 2010). 
 
1.1.1 Structure of the cell envelope 
 
The cell envelopes of bacteria mostly fall into one of two categories based on staining 
with crystal violet and the counterstain safranin (Coico, 2006). Gram-positive cells retain 
the primary stain (crystal violet) and Gram-negative the counterstain due to the 
differences in structure of the cell walls (Silhavy et al., 2010). Despite morphological 
differences (and the presence or absence of some polysaccharides), the components 








Figure 1.1 The structure of Gram-positive and Gram-negative cell envelopes 
Generic cell envelope structures of (A) Gram-positive bacteria and (B) Gram-negative bacteria. Adapted from 




1.1.1.1 Gram-positive cell envelope 
 
The Gram-positive envelope consists of a minimum of two layers: the cell membrane 
and a comparatively thick layer of peptidoglycan (PG) (Malanovic and Lohner, 2016). The 
cell envelope may also possess an outer capsule (Rajagopal and Walker, 2017) (Figure 
1.1B). The PG layer varies in thickness from 30 to 100 nm and is made up of multiple 
layers of crosslinked PG (Vollmer et al., 2008a), accounting for around 30-70 % dry 
weight of the Gram-positive envelope (Schleifer and Kandler, 1972). The cross-bridges 
within the PG provides sites for proteins to be covalently attached to the cell wall. The 
sortase A enzyme of Gram-positive bacteria covalently bonds surface proteins to the PG 
crossbridges (Schneewind and Missiakas, 2012). Wall and lipoteichoic acids (WTA, LTA, 
Chapter 1.3.2) can also be associated with the Gram-positive cell envelope. WTA are 
covalently attached to the PG while LTA are associated with the cell membrane (Brown 
et al., 2013). An exoplasmic space has been observed within in Staphylococcus aureus 
between the cell membrane and the PG layer (Matias and Beveridge, 2006), suggesting 
this may be an overlooked feature of the Gram-positive envelope. 
 
1.1.1.2 Gram-negative cell envelope 
 
The Gram-negative envelope consists of three layers: the inner membrane, the outer 
membrane and PG. The PG is located within the periplasm; defined as the region 
between the two membranes (Silhavy et al., 2010). The inner membrane is a 
phospholipid bilayer, as in Gram-positive organisms. The outer membrane however only 
has phospholipids within the inner leaflet, with the outer leaflet being composed of 
lipopolysaccharides (LPS, Chapter 1.3.3, (Egan, 2018)). The outer membrane provides 
much of the protection from the environment, resulting in a thinner PG layer than that 
of Gram-positives, being only around 2nm thick in Pseudomonas aeruginosa and 6 nm 
thick in Escherichia coli (Vollmer and Seligman, 2010; Turner et al., 2018). The PG 
polymer is generally only one glycan thick in E. coli, although some of the glycan chains 




resistance of turgor pressure, preventing the cell from lysing and maintaining cell shape. 
The outer membrane in Gram-negative cell envelopes has also been shown to provide 
much of the stiffness in E. coli cells, as well as defining their shape (Rojas et al., 2018). 
The outer membrane acts as the attachment site for proteins, with nearly half of the 
outer membrane mass being attributed to proteins (Nikaido and Vaara, 1985). These 
proteins consist of OMP and lipoproteins (Figure 1.1) that are associated with the inner 
leaflet of the outer membrane (Ruiz et al., 2006). In E. coli, the most abundant protein in 
the outer membrane is Braun’s lipoprotein, which anchors the outer membrane to the 
PG (Cowles et al., 2011).  
 
1.1.1.3 Other cell envelope structures 
 
Mycobacterium species such as M. tuberculosis are said to be acid fast bacteria; meaning 
that they cannot be decolourised by acids during standard staining techniques (Madison, 
2001). This is due to their unique cell envelope. The PG of M. tuberculosis is multi-
layered, like that of Gram-positive envelopes, but an outer layer of other material is 
present (Zuber et al., 2008). PG is covalently bound to arabinogalactan, which are 
covalently bonded to mycolic acids. Mycolic acids are long chain fatty acids, that have 
been suggested to contribute to virulence and antibiotic resistance (Silhavy et al., 2010). 
 
1.2 Chemical Structures of the Cell Wall 
1.2.1 Peptidoglycan 
 
PG is the load bearing molecule in the cell wall of bacteria and exists as a single 
macromolecule around the cell, forming the sacculus (Turner et al., 2014). PG is 
comprised of a glycan back bone, peptide side chains and crosslinks. The constituent 
component of PG is a muropeptide, consisting of an N-Acetylmuramic acid (MurNAc) 
and an N-Acetylglucosamine (GlcNAc) residue, a peptide side chain and species-specific 






The glycans of PG are long strands of alternating units of GlcNAc and MurNAc residues, 
linked by β 1-4 glycosidic bonds (de Pedro and Cava, 2015). Glycan strands are produced 
by the polymerisation of lipid II molecules (Chapter 1.4.1.2) by transglycosylation 
(Vollmer, 2008). While the chemical structure of these glycans are conserved throughout 
bacteria, the length of the strands differs amongst species. In the Gram-positive Bacillus 
subtilis, it has been shown that glycan strands are up to 5 µm in length, with an average 
glycan length of 96 disaccharide (GlcNAc-MurNAc) units (Hayhurst et al., 2008). S. aureus 
has relatively short glycan chains compared to B. subtilis, with an average of 6 
disaccharides per chain, with only 10-15% of glycans having a length of 26 disaccharides 
or longer (Boneca et al., 2000). E. coli, a Gram-negative bacterium, has an average glycan 
length of 8.9 disaccharide units with strands of up to around 45 disaccharide units when 
measured by reverse phase high performance liquid chromatography (Vollmer and 
Bertsche, 2008). However, when measured using atomic force microscopy, glycan chains 
up to 200 nm in length were observed, much longer than the proposed maximum of 45 
disaccharide units (Vollmer and Bertsche, 2008; Turner et al., 2018). In E. coli it has been 
observed that glycan chains have a spacing of around 3 nm, with chains being an 
average of 1.4 nm wide (Turner et al., 2018). Glycan chain length can be influenced by 
PG synthases. E. coli penicillin binding protein (PBP) 1A produces glycans of around 30 
disaccharide units, whereas PBP1B will produce longer strands, up to 50 disaccharides in 
length (Wang et al., 2008). PG hydrolases can also determine glycan length. In S. aureus, 
it has been shown that the N-acetylglucosaminidase SagB is responsible for cleaving 
glycans to their mature length (Wheeler et al., 2015; Chan et al., 2016b). Glycan chain 
length contributes to cell wall mechanics, as without SagB cells show morphological and 







Figure 1.2 The generalised structure of peptidoglycan 
(A) Schematic diagram of a generic muropeptide from model Gram-positive and Gram-negative 
bacteria. Egan et al. (2017), Vollmer et al. (2008). (B) Chemical structure of an S. aureus 
muropeptide. (C) The polymerisation of muropeptides forms the polymer of peptidoglycan. Adapted 




1.2.3 Peptide side chains 
 
Peptide side chains are attached to the MurNAc residue as a substitution for the lactyl 
group present on MurNAc (Vollmer et al., 2008a). The peptide side chain contains both 
D- and L- isoforms of amino acids and is a variable section of the PG (Figure 1.2). The 
variation between species is often the result of the innate nature of the enzymes 
involved in PG biosynthesis, but can also be a result of modifications at a later stage of 
biosynthesis (Bouhss et al., 2008). 
 
The first amino acid typically bound to the MurNAc residue is L-Ala, which is common to 
Gram-positives and negatives (Figure 1.2A) (Silhavy et al., 2010). In Mycobacterium 
leprae, the L-Ala residue is replaced by a Gly residue (Mahapatra et al., 2000). The 
second amino acid is D-isoglutamate or D-isoglutamine, the latter being produced by 
amidation of D-isoglutamate (Vollmer et al., 2008a). S. aureus and other Gram-positive 
bacteria often have a L-lysine in the third position, whereas Gram-negatives, Bacilli and 
Mycobacteria have meso-diaminopimelic acid (mDAP) (Vollmer et al., 2008a). While 
these are the most common amino acids, other residues can be present. In 
Corynebacterium pointsettiae, L-homoserine is found in position 3 (Perkins, 1971), and 
bacteria of the genera Spirochaeta, Borrelia, and Treponema contain ornithine 
(Yanagihara et al., 1984). The predominant amino acid in position four is D-Ala, but in 
rare occasions Gly can also be found in this position in E. coli (Glauner et al., 1988). The 
terminal amino acid is also mostly D-Ala (Vollmer et al., 2008a), but the substitution can 
confer differing properties to the cell wall, for example, in vancomycin resistant 
Staphylococcus aureus (VRSA) D-alanine can be replaced with D-lactate by the action of 








Crosslinks in PG produce a three-dimensional mesh with strength and rigidity, compared 
to non-linked PG (Vollmer and Seligman, 2010). In E. coli between 40 and 60% of the 
muropeptides can be crosslinked (Vollmer and Bertsche, 2008), whereas in the PG of 
S. aureus up to 70 to 80 % of glycine bridges are crosslinked to other stem peptides 
(Snowden and Perkins, 1990). The levels of crosslinking within a species can change 
depending on their growth phase. S. aureus PG has been shown to have reduced 
crosslinking in stationary phase compared to exponential phase when grown in vitro in 
synthetic medium (Zhou and Cegelski, 2012), which was hypothesised to be due to 
glycine depletion. However, in B. subtilis it was determined that PG crosslinking was 
greatest in late stationary phase (Atrih et al., 1999). 
 
These crosslinks fall into two main classifications: a 3-4 or a 2-4 crosslink. The 3-4 
crosslink involves the residue in the third position of one stem peptide linked to the 
residue in the fourth position on the other stem, either directly through their own amino 
and carboxyl groups, or through an interpeptide bridge (Lovering et al., 2012). The 2-4 
link occurs in coryneform bacteria and involves the D-glutamic acid of one chain (in 
position 2) and the D-alanine of another chain (position 4) being linked (Vollmer et al., 
2008a). The interpeptide bridges can vary from one to seven amino acids long, 
containing a variety of amino acids, or a single type (Figure 1.3).  
 
Crosslinking of peptidoglycan has been shown to be important for virulence. In 
Acinetobacter baumannii, PBP-7/8, an endopeptidase responsible for cleavage of 
crosslinks (Chapter 1.4.3), has been shown to be required for virulence in both a rat soft-
tissue infection model and rat pneumonia model of infection (Russo et al., 2009). As well 
as this, it was shown that PBP-7/8 was vital for defining the correct shape of the 
bacterium, as well as survival in human serum in vitro (Russo et al., 2009). It has been 




virulence. Strains of S. aureus with reduced PG crosslinking, either induced by antibiotics 
or due to knockout of PBP4 (Chapter 1.4.2.1), induced increased production of 
interleukin 1β by the host during infection leading to increased inflammasome activation 
and a worsened pathology. Strains of S. aureus with intermediate resistance to 
vancomycin (VISA) have been described. As well as having thickened cell walls, these 
strains have also been found with reduced PG crosslinking, meaning that there are more 
D-Ala-D-Ala targets to bind vancomycin with no effect on the cell’s viability (Gardete and 








Figure 1.3 Crosslinks in different bacterial PG.  
(A) E. coli shows a direct linkage from D-alanine in position 4 to meso-A2pm in position 3 on another 
chain. (B) S. aureus has a 3-4 crosslink via a pentaglycine bridge. (C) Corynebacterium poinsettiae has 
a 2-4 crosslink using a D-ornithine bridge. (D) Micrococcus luteus has a 3-4 crosslink made from 




1.2.5 Peptidoglycan modifications 
 
PG is commonly chemically modified after its synthesis. Deacetylation of the GlcNAc 
residues in Streptococcus pneumoniae (Vollmer and Tomasz, 2002) and Listeria 
monocytogenes (Boneca et al., 2007) are known to provide resistance against host 
lysozyme, enhancing bacterial evasion of the host innate immune system. 
 
O-acetylation is a common modification of the carbon 6 atom of the MurNAc residue 
(Moynihan et al., 2014) that is associated with pathogenicity (Bera et al., 2006; Aubry et 
al., 2011), and lysozyme resistance (Bera et al., 2005). Depending on the species, strain 
and growth conditions, between 20–70 % of MurNAc residues may be O-acetylated by 
OatA (Moynihan et al., 2014). O-acetylation of GlcNAc is also observed in Lactobacillus 
plantarum, which has been shown to regulate autolysis by the N-acetylglucosaminidase 
Acm2 (Bernard et al., 2011). The O-acetylation of GlcNAc is carried out by OatB and has 
also been observed in Lactobacillus sakei and Weissella paramesenteroides (Bernard et 
al., 2011). 
 
Spore producing bacteria, such as species from the genus Bacillus, are known to produce 
spore specific muramic acid δ-lactam (Atrih et al., 1996; Popham et al., 1996a). For δ-
lactam to form, there must be no peptide attached to the lactyl group and the MurNAc 
residue must be deacetylated, allowing the conversion by the enzymes CwlD and PdaA 
in B. subtilis (Vollmer, 2008). It has been suggested that the muramic acid δ-lactam 
modification is required to act as a marker for germination-specific hydrolases required 
to cleave spore PG and allow out-growth (Popham et al., 1996b). 
 
In Gram-negative bacteria, glycans can be terminated by a 1,6-anhydroMurNAc residue 
cap (Vollmer, 2008). This modification is also seen in low levels in B. subtilis (Atrih et al., 




PG turnover (Vollmer and Höltje, 2001), which can be used as signalling molecules in 
some bacterial species, resulting in the upregulation of β-lactamase (Höltje et al., 1994; 
Jacobs et al., 1994). The protein MltG, an endolytic transglycosylase, has been shown to 
terminate the synthesis of glycan strands of the appropriate length in E. coli through the 
formation of an anhydromuropeptide (Yunck et al., 2016). 
 
1.3 Teichoic Acids 
 
The cell wall of Gram-positive bacteria is associated with other molecules important for 
virulence and cell adhesion. Teichoic acids are one such molecule and are glycopolymers 
that are either attached to the PG, called wall teichoic acid (WTA) or to the cell 
membrane, known as lipoteichoic acid (LTA, Figure 1.4) (Schade and Weidenmaier, 
2016).  
 
1.3.1 Wall teichoic acid 
 
WTA consists of a disaccharide linkage (GlcNAc-ManNAc) unit and two glycerol 
phosphate molecules covalently bound to the C6 hydroxyl of up to every ninth MurNAc 
residue within PG (Brown et al., 2013). Bound to the linkage unit are 40-60 molecules of 
a species (and strain) dependent repeat unit, which in S. aureus is commonly ribitol-
phosphate (RboP), while in B. subtilis glycerol-phosphate (GroP) and RboP units can be 
found (Schade and Weidenmaier, 2016). Further WTA diversity occurs by chemical 
modification. The WTA can be decorated with cationic D-alanine (Neuhaus and Baddiley, 
2003) which is important in modulating the bacteria’s surface charge and promotes 
virulence and neutrophil survival in S. aureus (Collins et al., 2002). WTA can also be 





WTA has multiple roles within the cell wall of Gram-positive bacteria. Rod shaped 
bacteria such as B. subtilis and L. monocytogenes lacking WTA become spherical, 
demonstrating a role for WTA in defining cellular morphology (Lazarevic and Karamata, 
1995; Soldo et al., 2002; Eugster and Loessner, 2012). It has been suggested that WTA 
allows the correct cellular localisation/assembly/activation of cell wall elongation and 
division enzymes, with PG and WTA synthesis enzymes in B. subtilis having known 
interactions (Formstone et al., 2008; Kawai et al., 2011; Brown et al., 2013). WTA also 
acts as a temporal and spatial regulator of PG metabolism, controlling the level of PG 
crosslinking in S. aureus by regulating PBP4 localization (Atilano et al., 2010). WTA plays 
a role in horizontal gene transfer, by acting as a receptor allowing bacteriophage 
infections which can transfer DNA between strains (Schade and Weidenmaier, 2016). 
For S. aureus bacteriophage ϕ11, GlcNAc modifications on RboP of WTA are essential for 
infection and potential gene transfer (Xia et al., 2011).  
 
WTA also plays a role in virulence and the formation of biofilms (Brown et al., 2013). The 
negative charge of RboP and the positively charged ester-linked D-alanine cause the 
WTA to be zwitterionic, which is a crucial factor for the development of skin abscesses in 
mice models of S. aureus infection (Wanner et al., 2017). The regulation of cell surface 
charge modulates the binding of molecules, such as host defences including human 
antibacterial fatty acids, reducing damage caused to the bacterial cell (Kohler et al., 
2009). WTA also act as an adhesin, allowing the colonisation of animal models, which 
has been observed with S. aureus and lactobacilli (Weidenmaier et al., 2005; Walter et 
al., 2007).  
 
1.3.2 Lipoteichoic acids 
 
Firmicutes, such as S. aureus, have a type 1 LTA consisting of unbranched 1-3 linked 
polyGroP linked to the cell membrane by a glycolipid anchor (Reichmann and Gründling, 




alanylation or by the addition of glycosyl groups (Percy and Gründling, 2014). In S. 
aureus, it has been shown that a depletion of the ltaS gene, required for LTA synthesis, 
results in aberrant positioning of division septa, with daughter cells producing septa 
parallel to the previous, rather than the usual perpendicular (Gründling and Schneewind, 
2007). LTA have been shown to play a role in osmo-protection, allowing resistance to 
low osmolarity environments (Oku et al., 2009). The LTAs of S. aureus are 
immunostimulatory, inducing the production of cytokines TNF-α, IL-1β, IL-6 and IL-10 in 
whole human blood (Hermann et al., 2002) and together with PG can cause shock and 
multiple organ failure in a rat model of infection (Kimpe et al., 1995). However, it has 
been suggested that the immunostimulatory effects of LTA is due to contamination by 
lipoprotein and LTA was not the cause of immune activation in previous experiments 
(Hashimoto et al., 2006; Zähringer et al., 2008). However, the use of synthetic LTA 
molecules, that could not be contaminated with lipoprotein, show the same 
immunostimulatory effect described, providing evidence for the immunostimulatory 
nature of LTA (Morath et al., 2002; Deininger et al., 2003). The purified LTA of an lgt 
mutant, which does not have lipoproteins, does not show Toll-like receptor 2 stimulation 
in a murine macrophage line (Hashimoto et al., 2006), but did in whole human blood 
(Aulock et al., 2007; Bunk et al., 2010). It was suggested that the LTA must be opsonised 
by antibodies, which results in internalisation and subsequent detection by the immune 
system (Bunk et al., 2010). Despite conflicting reports, the evidence described suggests 




LPS are endotoxins specific to Gram-negative bacteria. LPS helps the maintenance of cell 
shape, stabilisation of the cell membrane by providing a net negative charge and 
protecting the cell from chemical attacks. LPS also elicits strong immunological 








Figure 1.4 The structure of wall- and lipo- teichoic acids 
WTA (blue) consist of 40-60 repeating units covalently linked to PG by a linkage unit. LTA (yellow) are 
also formed of multiple repeating units but are linked to the cell membrane via a linkage unit. Taken 




1.4 Peptidoglycan dynamics 
 
PG is a dynamic molecule, requiring both hydrolysis and synthesis to permit the growth 
and division of the cell (Nanninga, 1991).  
 
1.4.1 Peptidoglycan biosynthesis 
 
Gram-positive and Gram-negative bacteria share a common PG synthesis pathway. PG 
synthesis begins in the cytoplasm where PG precursors are made, these membrane 
bound muropeptides are then flipped to the extracellular environment before finally 
being incorporated into existing PG (Figure 1.5) (Lovering et al., 2012). 
 
1.4.1.1 Cytoplasmic reactions 
 
The enzymes required to produce PG are found across both Gram-negative and positive 
bacteria and are essential for viability (Bouhss et al., 2008). Synthesis begins in the 
cytoplasm where MurA transfers a enolpyruvyl moiety to uridine diphosphate-GlcNAc, 
which MurB then converts to uridine diphosphate-MurNAc (Typas et al., 2012). Non-
ribosomal peptide synthesis occurs via MurC, MurD, MurE and MurF, which add the 
species-specific amino acids to the uridine diphosphate-MurNAc to produce the peptide 
stem (Chapter 1.2.3). In Chlamydia trachomatis, MurC can incorporate L-Ala, L-Ser and 
Gly with the same efficacy in an in vitro context to the first position of the peptide stem 
(Hesse et al., 2003). MurF incorporates D-Ala-D-Ala into the growing peptide stem 
(Kouidmi et al., 2014). The D-Ala-D-Ala molecule is produced in two steps. First the 
racemase Alr converts L-Ala to D-Ala, which is then ligated to another D-Ala molecule to 
form D-Ala-D-Ala, which is then incorporated into the growing peptide stem (Typas et al., 
2012). The uridine diphosphate-MurNAc-pentapeptide is then linked to a undecaprenyl 




et al., 2008). Lipid I molecules are then converted to lipid II by MurG, which adds a 
molecule of GlcNAc (Scheffers and Tol, 2015). 
 
In S. aureus, the FemABX family of non-ribosomal peptidyltransferases are needed to 
insert the pentaglycine bridge required to produce PG crosslinks. These proteins utilise 
glycyl-tRNA as a glycine donor, adding glycine residues to lipid II (Schneider et al., 2004). 
FemX incorporates the first glycine molecule into the bridge (Rohrer and Berger-Bächi, 
2003), followed by FemA incorporating glycines 2 and 3 (Strandén et al., 1997) and FemB 
adding the final two glycines in position 4 and 5 (Henze et al., 1993). The Fem proteins 
act immediately after the synthesis of lipid II before it is transported to the outside of 
the cell (Bouhss et al., 2008). Amidation of D-Glu in the peptide stem to D-Gln by 
GatD/MurT also occurs to the lipid II molecule (Figueiredo et al., 2012; Münch et al., 
2012). 
 
1.4.1.2 Translocation and incorporation of Lipid II 
 
The lipid II molecule is then translocated across the cytoplasmic membrane by the action 
of flippases, such as MurJ and Amj, to the outer leaflet (Scheffers and Tol, 2015). Lipid II 
is then incorporated into existing glycan strands by the action of transglycosylases. This 
occurs by the formation of a glycosidic bond between the MurNAc of lipid II and the 
GlcNAc of the existing glycan chain (Ward and Perkins, 1973). Undecaprenyl-
pyrophosphate is subsequently released from the PG, returned to the cytoplasm 
(Bouhss et al., 2008) and recycled in the synthesis pathway to form new lipid I after 
being dephosphorylated (Dam et al., 2009). Transpeptidase reactions then crosslink the 









Figure 1.5 PG biosynthesis pathway in S. aureus 
The PG precursor lipid II is synthesised within the cytoplasm. This is translocated across the membrane, 
where it is inserted into the existing PG by the action of transglycosylation reactions. Cross-links are added 




1.4.2 Peptidoglycan synthases 
1.4.2.1 Penicillin binding proteins 
  
Penicillin binding proteins (PBPs) complete the final stages of PG synthesis, performing 
the transglycosylation and/or the transpeptidase reactions required to incorporate new 
muropeptides into the sacculi (Goffin and Ghuysen, 1998). Bacteria contain multiple 
PBPs which can be categorised into high (HMW) or low molecular mass (LMW) PBPs. 
High molecular mass PBPs consist of a cytoplasmic tail and a transmembrane anchor, 
with a catalytic domain on the outer surface allowing PG synthesis (Sauvage et al., 
2008). The C-terminal domain of HMW PBPs possesses transpeptidase activity 
facilitating the formation of crosslinking in the PG (Sauvage et al., 2008). HMW PBPs can 
be further subdivided into class A or class B depending on the activity of the N-terminus 
of the PBP. Class A HMW PBPs have an N-terminal domain with transglycosylase activity, 
elongating glycan chains (Goffin and Ghuysen, 1998; Sauvage et al., 2008). In class B 
HMW PBP, the N-terminal domain is thought to interact with other proteins involved in 
growth and division, helping to determine morphology (Zapun et al., 2008b). LMW PBPs 
usually have either carboxypeptidase or endopeptidase activity, cleaving peptide side 
chains on PG to regulate crosslinking (Goffin and Ghuysen, 2002; Macheboeuf et al., 
2006). 
 
The number of native PBPs varies between bacterial species and even between bacterial 
strains. E. coli has a total of 12 PBP, 5 HMW and 7 LMW (Sauvage et al., 2008). Of the 5 
HMW PBP, three are class A (PBP1A, PBP1B and PBP1C) and two are class B (PBP2 and 
PBP3). The majority of PG synthesis is performed by PBP1A and PBP1B (Egan et al., 
2018), and E. coli requires at least one of these to be viable (Yousif et al., 1985; Denome 
et al., 1999). PBP1B, which possesses transglycosylase and transpeptidase activity, is 
activated by the binding of the lipoprotein LpoB (Egan et al., 2018). PBP2 and PBP3 are 
monofunctional transpeptidases, with PBP2 playing a role in cell elongation, and PBP3 a 




specific PBPs involved in sporulation and vegetative PG synthesis (Scheffers, 2005; 
Sauvage et al., 2008). 
 
S. aureus is a prolate spheroid, which elongates slightly during growth to facilitate cell 
division (Monteiro et al., 2015; Lund et al., 2018). During S. aureus cell division, PG is 
synthesised at the septum for growth (Pinho et al., 2013). S. aureus possesses 4 native 
PBPs, making it a good minimalist model of PG synthesis (Table 1.1). Two of these PBPs, 
PBP1 and PBP3, are HMW Class B (Sauvage et al., 2008). PBP1 is essential for growth 
(Wada and Watanabe, 1998), and depletion studies have shown it is required for the 
formation of division septa in cells (Pereira et al., 2007). PBP1 has transpeptidase 
activity, and a loss of this activity results in a reduction in PG crosslinking and failure of 
cells to divide, but this domain is not essential for cell viability (Pereira et al., 2009). It 
has been hypothesised that PBP1 may play a role in regulating the activity of autolysis 
on cells (Dubrac et al., 2007; Pereira et al., 2009). PBP3 is known to be non-essential for 
viability, with a C-terminal transpeptidase domain assumed to be involved in PG 
crosslinking and an N-terminal domain of unknown function (Pinho et al., 2000). Recent 
research has shown that PBP3 interacts with RodA, forming a cognate pair, important 
for the correct localisation of the proteins at the mid-cell and the insertion of PG at sites 
other than the septum (Reichmann et al., 2019). S. aureus also possesses a HMW class A 
PBP, PBP2, which localises to the septum of the cell (Pinho and Errington, 2003). PBP2 is 
essential for transglycosylation and transpeptidation, with deletion mutants not being 
viable (Pinho et al., 2001a). Methicillin resistant S. aureus (MRSA) strains possess the 
non-native PBP2A, encoded by the mecA gene (Zapun et al., 2008a). PBP2A, a HMW 
class B PBP, is important to perform transpeptidation and crosslink PG in the presence of 
β-lactam antibiotics (Fishovitz et al., 2014). In the presence of antibiotic, PBP 
transpeptidase domains are inhibited, preventing PG crosslinking. The transpeptidase 
domain of PBP2A is β-lactam insensitive and able to continue transpeptidation reactions 
in the presence of β-lactam antibiotics (Figure 1.6) (Pinho et al., 2001c), but the resulting 
PG is poorly crosslinked (Müller et al., 2015). PBP4 is the only LMW PBP present in S. 
aureus. PBP4 is known to produce highly crosslinked PG in S. aureus (Wyke et al., 




negative S. aureus COL variant), have been found to cause increased PG crosslinking and 
increased tolerance to β-lactam antibiotics (Hamilton et al., 2017; Alexander et al., 
2018). A putative interaction has been suggested between PBP4 and PBP2, as a loss of 
PBP4 resulted in the reduced transcription of PBP2 in both methicillin sensitive S. aureus 
(MSSA) and MRSA strains (Memmi et al., 2008). The expression of PBP2A was found not 
to be changed with the loss of PBP4 (Memmi et al., 2008). This has resulted in the 
hypothesis of the cooperative functioning of PBP2, PBP2A and PBP4 within S. aureus 
(Pinho et al., 2001b; Łeski and Tomasz, 2005; Memmi et al., 2008). Other studies have 
suggested that WTA is required for the co-operative action of PBP2 and PBP4 to produce 
β-lactam resistance in MRSA strains (Farha et al., 2013). 
 
PBPs are the target of the β-lactam class of antibiotics. β-lactams function by mimicking 
the terminal D-Ala-D-Ala motif in the stem peptide of PG, and irreversibly bind to and 
inhibit PBP’s function (Rajagopal and Walker, 2017). The serine in the active site of PBPs 
initiates attack on the carbonyl group of the β-lactam ring, forming a covalent acyl-
enzyme complex, which is hydrolysed extremely slowly, preventing the PBPs performing 
any further reactions (Zapun et al., 2008a). 
 
The PBPs can determine the length of the glycan chains (Chapter 1.2.2). Both PBP2 of S. 
aureus and PBP2A of Enterococcus faecalis produce glycan strands of around 15 
disaccharide units in length. E. coli PBP1A produced glycans of around 30 disaccharide 
units, and PBP1B 50 units (Wang et al., 2008). These differences show how the intrinsic 
differences in PBPs both within and between species can cause diversity in and 







Table 1.1 The PBPs encoded by S. aureus 
Adapted from Panchal (2018). 






Figure 1.6 The cooperative functioning of PBP2 and PBP2A 
With no antibiotic, it is hypothesised that both the transpeptidase and transglycosylase domains of 
PBP2 contribute to PG synthesis alongside PBP2A. In the presence of antibiotic, the transpeptidase 
domain of PBP2 is inactivated, while the transglycosylase domain remains functional. The 
transpeptidase activity of PBP2A compensated for the loss of PBP2 transpeptidase activity. Taken 




1.4.2.2 Other S. aureus peptidoglycan synthases 
 
As well as four PBP, S. aureus possesses two monofunctional transglycosylases: MGT and 
SgtA (Reed et al., 2015). MGT is a membrane-associated protein shown to have 
transglycosylase activity (Wang et al., 2001), which has also been found in other species, 
such as E. coli, and all show a high degree of similarity to the glycosyltransferase domain 
of HMW PBPs (Berardino et al., 1996). Both enzymes are not essential for cell wall 
synthesis, but mgt deletion is synthetically lethal in the absence of PBP2 transglycosylase 
activity (Reed et al., 2011). Using a bacterial two-hybrid assay, it was found that MGT 
interacted with itself, SgtA, PBP1, PBP2 and PBP2A (Reed et al., 2011). SgtA was found to 
interact with itself, MGT, PBP1 and PBP2, suggesting that both SgtA and MGT may 
function as a multimer within the cell (Reed et al., 2011). It can therefore be 
hypothesised that S. aureus PG synthases may form and function within a complex to 
facilitate synthesis, as is seen in other bacterial species (Pazos et al., 2017). 
 
FmtA of S. aureus has been shown to have weak D-Ala-D-Ala-carboxypeptidase activity in 
vitro and was able to incorporate glycine into cell walls in vitro, but with a low activity 
(Qamar and Golemi-Kotra, 2012), suggesting FmtA may have transpeptidase activity. An 
inactivation of fmtA has shown to result in reduced PG crosslinking in S. aureus, 
providing more evidence for transpeptidase activity (Komatsuzawa et al., 1999). 
However, more recent research suggests that FmtA acts as a D-amino esterase in vivo, 
acting on teichoic acids removing D-Ala residues, modulating teichoic acid charge and 
potentially regulating S. aureus division, autolysis and host colonisation (Rahman et al., 
2016). S. aureus FmtB also shares homology with known transpeptidase domains and 
has been shown to play a role in methicillin resistance. It is thought that FmtB plays a 
role in cell wall synthesis (Komatsuzawa et al., 2000; Reed et al., 2015). 
 
FtsW, a highly conserved protein amongst bacteria, is required for septum formation 
and the correct functioning of the divisome as well as the recruitment of FtsI in E. coli 




to have a role in PG synthesis as it can polymerise lipid II molecules into PG when in 
complex with PBP1, (Taguchi et al., 2019), highlighting that protein complexes are 
formed during PG synthesis. FtsW interacts with PBP1 in S. aureus which is required for 
cell viability and the synthesis of PG at the division site (Reichmann et al., 2019). S. 
aureus also possesses RodA, which has been found to interact with PBP3, which is 
required for the lateral synthesis of PG (i.e. at a site other than the septum) (Reichmann 
et al., 2019). 
 
1.4.3 Peptidoglycan hydrolases  
 
By utilising in silico screens, 21 putative PG hydrolases have been found in S. aureus COL 
(Table 1.2) (Wheeler, 2012). PG hydrolases can be categorised into one of three types 
depending on the bond in the murein sacculus that they cleave (Figure 1.7). N-
acetylmuramyl-L-alanine amidases (cell wall amidases, CWA) cleave the amide bond 
between the L-Ala at the N-terminus of the stem peptide and the N-acetylmuramic acid 
residue of the glycan (Vollmer et al., 2008b; Vermassen et al., 2019). An example is Sle1 
of S. aureus, a CWA that cleaves the N-acetylmuramyl-L-Ala bond in PG, required for cell 
separation during replication (Kajimura et al., 2005). A mutant lacking Sle1 was shown to 
be attenuated using a mouse model of infection (Kajimura et al., 2005), highlighting the 
importance of hydrolases in pathogenesis. Another S. aureus CWA is LytH, a membrane 
bound amidase that was found to remove the stem peptide from uncrosslinked glycan 
strands (Do et al., 2020b). The authors of this study propose a model whereby LytH 
regulates the density of PG assembly sites, regulating PG synthesis, promoting PG 
synthesis to relocate to the mid-cell during division (Do et al., 2020b). The removal of 
the stem peptides was also found to slow PG synthesis, regulating the expansion of the 
cell (Do et al., 2020b). LytH is activated when in complex with ActH, which is also a 






Similarly, cell wall peptidases (CWP) cleave the amide bonds between amino acids and 
can be further classified into endopeptidases and carboxypeptidases, depending on 
substrate specificity (Vollmer et al., 2008b). Lysostaphin is an endopeptidase produced 
by Staphylococcus simulans biovar staphylolyticus (Schindler and Schuhardt, 1964), 
which shows activity against staphylococci, including S. aureus (Schindler and Schuhardt, 
1965). Lysostaphin hydrolyses the pentaglycine cross-bridges present in staphylococcal 
PG, resulting in cell lysis (Gonzalez-Delgado et al., 2020). The lysostaphin SH3b domain 
has two binding sites, recognising both the cross-bridge and a peptide side chain, both 
with weak affinity. This allows lysostaphin to move rapidly around the PG, as one 
binding site is bound to the PG enabling exploring of the PG and the hydrolysis of glycine 
bonds (Gonzalez-Delgado et al., 2020). LytM is a S. aureus (glycyl-glycine) endopeptidase 
(Figure 1.7), that cleaves PG crosslinks (Lioliou et al., 2016). 
 
Cell wall glycosidases (CWG) catalyse hydrolysis of the glycosidic linkages in the glycan 
backbone of PG. CWG can also be further categorised based on substrate specificity. N-
acetyl-β-D-muramidases (muramidases) cleave specifically after the N-acetylmuramic 
acid residue in the glycan backbone, whereas N-acetyl-β-D-acetylglucosaminidases 







Table 1.2 Putative peptidoglycan hydrolases of S. aureus COL identified by an in 
silico screen 
Adapted from Wheeler (2012). (Frankel et al., 2011; Pourmand et al., 2006; Ramadurai 






Figure 1.7 The targets of PG hydrolases  
The action of hydrolases (red) on the glycan backbone and peptide sidechains of S. aureus PG. (Vollmer et al., 
2008b). (CWA – Cell wall amidase; D-iGlx – D-iso-glutamine or D-iso-glutamic acid; GlcNAc – N-






Muramidases cleave the β1,4-glycosidic bond after a MurNAc residue in the glycan 
backbone. There are two ways muramidases can achieve this. Firstly, lysozyme like 
enzymes cleave glycans resulting in a terminal reducing MurNAc residue. Alternatively, 
lytic transglycosylases produce a 1,6-anhydroMurNAc residue (Chapter 1.2.5) by an 
intramolecular transglycosylase reaction (Vollmer et al., 2008b). Two putative lytic 
transglycosylases have been identified in S. aureus: IssA and SceD (Stapleton et al., 
2007). Inactivation of sceD resulted in a clustering phenotype, with cells failing to divide, 
but this is not seen in an issA mutant (Stapleton et al., 2007). Mutants of issA and sceD 
were both shown to be attenuated in a murine septic arthritis model of infection, with 
sceD also being required for nasal colonisation (Stapleton et al., 2007). 
 
Lysozyme is a conserved anti-microbial protein forming part of the innate immune 
system by hydrolysing PG (Callewaert and Michiels, 2010). Lysozyme is found in the 
blood, liver, secretions (including at mucosal surfaces) and professional phagocytes of 
mammals (Callewaert and Michiels, 2010; Lelouard et al., 2010). While lysozyme is a 
muramidase, cleaving the glycan backbone of PG and causing lysis, human lysozyme is 
also cationic, allowing it to insert into the negatively charged membrane of bacteria, 
forming pores and killing bacteria (Ragland and Criss, 2017). 
 
The genome of the S. aureus strain Newman has not been found to encode for a 




Four putative glucosaminidases have been identified in S. aureus. Atl was the first 
glucosaminidase characterised in S. aureus in 1995 and was shown to be bifunctional, 
containing both an N-acetylmuramoyl-L-alanine amidase domain and an endo-β-N-
acetylglucosaminidase domain (Foster, 1995; Oshida et al., 1995). Atl is the major 




formation of large clusters in atl deletion mutants (Oshida et al., 1995). As well as 
playing a major role in cell division, Atl has been shown to play a role in adherence and 
biofilm formation (Götz et al., 2014). An atl mutant is deficient in the ability to adhere to 
different surfaces, including polystyrene and glass, resulting in a defect in producing 
biofilms that may play a role in virulence (Biswas et al., 2006). It has also been suggested 
that the ability of the glucosaminidase domain of Atl to bind DNA plays a role in the 
formation of biofilms (Grilo et al., 2014). As well as having a role in adhering to surfaces, 
Atl can also bind to host matrix proteins such as fibronectin and heparin, suggesting a 
further role in pathogenesis of the major autolysin (Porayath et al., 2018). 
 
SagB is a glucosaminidase that has been shown to be important for cellular growth. For 
cells to be able to grow, the newly synthesised PG of the cell wall must be hydrolysed 
enough to allow physical expansion. S. aureus has characteristically short glycan chains 
of between 3 and 10 disaccharide units (Boneca et al., 2000). SagB cleaves the glycan 
backbone from long chains to short chains, which has the effect of reducing the surface 
stiffness (Wheeler et al., 2015). The glycan processing allows the expansion of the cell as 
loss of such activity results in a growth defect in liquid medium (Wheeler et al., 2015). 
The correct physiological length of the glycan strands, and by extension the stiffness of 
the cell wall, is also important for the correct trafficking of proteins through the cell wall 
and into the extracellular environment (Chan et al., 2016b). A sagB mutant has aberrant 
protein secretion (Chan et al., 2016b).  
 
In contrast, the glucosaminidases SagA and ScaH have been poorly characterised. 
Mutants with inactive sagA or scaH genes show similar cell architecture, growth and cell 
division to wild type S. aureus (Wheeler et al., 2015; Chan et al., 2016b). Further analysis 
of these mutants is needed to understand more about the role of glucosaminidases in S. 
aureus. A degree of redundancy is seen, with mutants missing up to three of the four 
glucosaminidases being viable (Wheeler et al., 2015). Mutants that all four of the 
mutants inactive, with sagB under the control of an isopropyl β-D-1-




IPTG (Wheeler et al., 2015). For S. aureus to be viable, at least one of the four 
glucosaminidases must be active, presumably to produce the correct PG architecture 




WalK and WalR (WalKR) form a two-component system in some Gram-positive such as 
B. subtilis (where it was first identified), Streptococcus pneumoniae and S. aureus 
(Dubrac et al., 2008). In S. aureus this system is essential, and therefore a potential 
target for new novel therapeutics (Bem et al., 2015). In this system, WalK is a membrane 
bound histidine kinase and the response regulator is WalR (Dubrac et al., 2008). 
Encoded in the walKR operon are yycH and yycI, which negatively regulate WalKR in B. 
subtilis (Szurmant et al., 2007), but research has found that YycHI activates WalKR in S. 
aureus, playing a role in vancomycin resistance (Cameron et al., 2016). In S. aureus, once 
WalK detects the appropriate signal, it phosphorylates the response regulator WalR, 
which then binds to the regulon DNA promoter sequences and upregulates the 
expression of autolysins such as atl (Chapter 1.4.3.2), sle1 (Chapter 1.4.3) and lytM 
(Dubrac et al., 2007). WalKR is only active in the exponential phase of growth, becoming 
inactive during stationary phase (Dubrac et al., 2008). WalKR has also been found to be 
negatively regulated by Zn2+ (Monk et al., 2019). As well as regulating the expression of 
genes important for cell wall turnover (Dubrac et al., 2007), WalKR is associated with the 
activation of virulence genes vital for attachment to host, cytolysis and innate immune 
evasion through the activation of the SaeSR two component system (Delauné et al., 









Figure 1.8 The role of WalKR in S. aureus cell wall metabolism and virulence 
Phosphorylation of WalR by WalK leads to the upregulation of cell wall metabolism genes such as atl, sle1 
and lytM. The release of cell wall turnover products may stimulate the innate immune system and lead to 
clearance from the host. Activated WalR leads to the phosphorylation and activation of SaeR by stimulating 
the SaeS kinase, resulting in the upregulation of genes required for virulence. WalKR may therefore facilitate 




1.4.5 Staphylococcal cell division 
 
The S. aureus divisome (Figure 1.9), the group of proteins responsible for cell division, 
contains both PBPs and proteins to coordinate the division process (Lund et al., 2018). 
FtsZ is an essential protein in most bacteria that, in E. coli and B. subtilis, has been found 
to form filaments that act as a scaffold to assemble the divisome components (Bisson-
Filho et al., 2017; Yang et al., 2017). The FtsZ assembles into a structure known as the z-
ring, which is facilitated by proteins including EzrA (Adams and Errington, 2009), and 
GpsB (Eswara et al., 2018). GpsB has been shown to interact with FtsZ during initial Z-
ring formation, stabilising the structure (Eswara et al., 2018). EzrA is a membrane 
protein that is crucial for S. aureus cell division, acting as a scaffold between FtsZ division 
proteins and other components of the divisome (Steele et al., 2011). FtsZ, in Z-rings, has 
been shown to be able to create a constrictive force, and this is hypothesised to play a 
role in cell separation during division (Erickson et al., 2010). This is finely regulated to 
prevent the occlusion of the nucleoid by the septum. This is partly regulated by DivIVA , 
which binds to FtsZ, regulating constriction of the Z-ring, allowing separation of the 
chromosomes (Bottomley et al., 2017). It has been suggested that the Z-ring is required 
for the recruitment of at least 12 interacting proteins required to form the divisome 







Figure 1.9 The division machinery of S. aureus  




PG insertion must be orchestrated during division of the cell (Figure 1.10). PG is 
synthesised and hydrolysed, allowing the cell to increase in volume at a constant rate 
(Wheeler et al., 2015; Zhou et al., 2015). The shape of S. aureus changes during the cell 
cycle, which is hypothesised to be due to changing turgor pressure due to PG hydrolysis 
(Monteiro et al., 2015). As the septa begins to form, a thick band of PG, resembling a 
‘piecrust’, is laid down (Turner et al., 2010a), from which the leading edge of septal PG 
forms, which is thinner than the rest of the septum (Matias and Beveridge, 2007). While 
PG is inserted at the leading edge of the septum, it is also incorporated into the rest of 
the pre-existing cell wall (Lund et al., 2018). Once the septal annulus has closed, the 
division complex inserts more PG along the length of the septum until it is a uniform 
thickness (Lund et al., 2018). The major autolysin Atl (1.4.3.2) and other PG hydrolases 
cleave PG on the outer surface of the cell wall (Komatsuzawa et al., 1997). This results in 
the rapid separation of daughter cells (Zhou et al., 2015), with the initial ‘piecrust’ 
forming scars at the site of division, hypothesised to be a marker of division (Turner et 
al., 2010a). This can act as an epigenetic marker to allow subsequent divisions to occur 
on different orthogonal planes. 
 
1.5 Peptidoglycan architecture  
 
A major obstacle in determining the three-dimensional architecture and organisation of 
PG has been the techniques available to study the cell wall. Techniques such as atomic 
force microscopy (AFM), nuclear magnetic resonance (NMR) and cryo-electron 
microscopy have allowed new investigation of this structure (Kim et al., 2015). Two main 
models have been proposed to explain the architecture: the circumferential (planar) and 
scaffold models. In the planar model, the glycans run circumferentially around the cell, 
while in the scaffold model the glycans are arranged perpendicularly the cell (Beeby et 
al., 2013). It has been suggested that the high-level of crosslinking in S. aureus could only 
be achieved if the stem peptides were packed in the same plane and parallel to one 




50 nm wide helical cables which then run parallel around the short-axis of the cell 
(Hayhurst et al., 2008). 
 
1.6 Techniques to analyse PG  
1.6.1 Reverse Phase high performance liquid chromatography 
 
Perhaps the most common technique used to study PG has been reverse phase high 
performance liquid chromatography (RP-HPLC), which was originally proposed in 1988 
(Glauner, 1988). RP-HPLC allows differences in the chemical composition in the cell wall 
to be visualised by separating muropeptides after solubilisation of PG (Desmarais et al., 
2013). In RP-HPLC a liquid sample is transported through a hydrophobic column (the 
stationary phase) by a sodium phosphate/methanol or water/acetonitrile mobile phase. 
On entering the column, muropeptides interact with the hydrophobic column and are 
eluted by increasing concentrations of organic solvent present in the mobile phase over 
time. This produces a UV-absorbance chromatogram with peaks at different retention 
times, with each peak representing a different muropeptide species (Figure 1.11) (Jonge 
et al., 1992a). The technique is sensitive enough to detect single amino acid differences 







Figure 1.10 Model for S. aureus PG insertion and cell division 
(i, ii) Cell volume increases with a concomitant shape change, slightly elongating before septum formation. (iii) 
Septum formation begins with a ‘piecrust’ (seen in red), (iv) followed by PG being incorporated at the leading edge 
of the septum, as well as across the cell surface to allow further cell expansion. (v, vi) The septal annulus fuses and 
new PG is synthesised along the septum to produce a septum of uniform thickness. (vii) PG hydrolases present on 
the outer surface of the cell cause a split to form which is followed by rapid scission of daughter cells. (viii) Scars 







Figure 1.11 Example chromatogram of a S. aureus muropeptide RP-HPLC profile  
Example chromatogram showing the muropeptide profile of S. aureus after separation by RP-HPLC 
and detection by UV absorbance at 206nm. The numbers above each peak represent the major 
muropeptide found within each peak as described in de Jonge et al. (1992). Adapted from de Jonge 




1.6.2 Mass Spectroscopy 
 
While RP-HPLC produces UV absorbance traces of muropeptide composition, it cannot 
be used to identify muropeptide identity within a UV absorbance peak. Initially, 
individual muropeptide fractions are collected from the RP-HPLC, desalted by HPLC, and 
then analysed. One method used was to analyse the amino acids present within a 
fraction and deducing the muropeptide identity by amino acid relative abundance 
(Glauner et al., 1988). It is more common for fractions to be analysed by mass 
spectroscopy (MS) (Bern et al., 2017). This produces a spectrum individually for each 
fraction, allowing muropeptides to be identified by their mass. If a structure is unknown, 
MS/MS can be utilised, where ions are fragmented and then subject to further MS to 
allow muropeptide identification (Boneca et al., 1997). Mass spectroscopy can also be 
performed in tandem with liquid chromatography (LC-MS), were samples are separated 
by HPLC, producing a UV absorbance trace and then immediately analysed by MS or 
MS/MS as they elute from the column, simultaneously producing a ion spectrum (Patti 
et al., 2008). This methodology is time consuming as manual analysis of the ion spectra 
is required in order deduce muropeptide structures, but work has been ongoing in order 
to automate this process (Bern et al., 2017). 
 
1.6.3 Nuclear magnetic resonance 
 
Another method to identify a muropeptide is by utilising nuclear magnetic resonance 
(NMR). This technique relies on the hydrogen atoms in muropeptides absorbing and 
emitting electromagnetic radiation in characteristic and detectable ways, allowing 
identification of a muropeptide species, but requires a relatively large amount of 
material (Romaniuk and Cegelski, 2015). Solid-state NMR is utilised to analyse to 
structure of both sacculi and whole cells (Kim et al., 2015), meaning that digestion of the 
sacculi to muropeptides is not required, and PG can be analysed in a native state. NMR 
has revealed further details regarding PG architecture of Gram-positive organisms, 




periodicity of 40 Å, meaning each peptide stem is rotated 90 ° relative to the previous. 
The crosslinked peptide stems were shown to be orientated in parallel to one another 
(Kim et al., 2013, 2015). As previously described (Chapter 1.4.3), NMR has also been 
used to determine the mechanism of lysostaphin SH3b domains (Gonzalez-Delgado et 
al., 2020). 
 
1.6.4 Atomic Force Microscopy 
 
To determine the architecture of PG, as in Chapter 1.5, atomic force microscopy (AFM), 
a form of scanning probe microscopy, is often utilised (Turner et al., 2010b). This 
technique uses a sharp tip which scans along the sample, and the movement of this tip is 
converted into an image with a resolution that can be less than a nanometre (Binnig et 
al., 1986). This method does not require staining of samples, allowing the architecture to 
be studied without potential interference (Turner et al., 2010b). AFM of S. aureus sacculi 
has allowed the textures of surface PG to be determined (Touhami et al., 2004; Turner et 
al., 2010a). These textures are seen to consist of concentric rings or a rough ‘knobbly’ 
mesh (Turner et al., 2014) (Figure 1.12). The ring structure is associated with newly 
synthesised PG originating from the most recent division cycle, which over time is 
processed by PG hydrolases to the mature ‘knobbles’ (Turner et al., 2014). The ring and 
mature structures are separated by a thick band of PG resembling a ‘piecrust’ (Chapter 
1.4.5), which are thought to be the initial sites of septation, and play a role in 
establishing cell polarity (Turner et al., 2010a). Purified sacculi are often used to analyse 
the PG architecture, but studies have made use of living cells to observe PG structure 







Figure 1.12 Peptidoglycan architecture of S. aureus as determined by AFM 
(A) Diagram of S. aureus surface PG structure based on yellow box region in (B) direct AFM 
observations of PG architecture. Newly synthesised PG is seen as concentric rings, while mature 
PG adopts a mesh like structure with clear “knobbles”. There is a clearly defined transition 
structure between the rings and the mesh, known as the piecrust, named for its distinctive 
appearance, and is the first part of the PG synthesised during septation. Adapted from Turner et 




1.6.5 Electron Microscopy (EM) 
 
EM has a higher resolving power (around 0.2 nm) than light microscopy due to its use of 
electrons which have a shorter wavelength than light (Smith, 2008). In thin-section EM 
samples are chemically fixed, dehydrated and embedded in resin, the samples are thin-
sectioned and then stained with heavy metals to increase image contrast, which are 
then imaged with transmission EM (TEM) (Eltsov and Zuber, 2006). Thin-section EM has 
shown the basic processes of division in S. aureus (Giesbrecht et al., 1997; Sugai et al., 
1997), but the accuracy of standard thin-section EM is limited due to the structural 
artifacts produced due to the harsh chemicals required in sample preparation (Matias 
and Beveridge, 2007). Cryo-electron microscopy (CryoEM) utilises vitrification of 
specimens, which rapidly immobilises and preserves morphological structures in a 
matrix of ice. CryoEM of vitreous sections (CEMOVIS) utilises vitrified samples which are 
then cut into thin sections and observed by EM, without staining, preserving the 
structure of the sample (Al-Amoudi et al., 2004). Alternatively, freeze substitution may 
be utilised where samples are fixed by rapid freezing (cryofixation) preserving the 
sample’s structure. The ice crystals within the sample are then replaced with organic 
solvent (which may contain chemical fixatives) at low temperatures. The samples can 
then be thin-sectioned, stained and analysed by EM at room temperature (Matias and 
Beveridge, 2006). CryoEM has been used to study PG from purified sacculi for both 
Gram-positive and negative species (Gan et al., 2008; Beeby et al., 2013). CryoEM has 
shown that a single layer of glycans run parallel to the cell surface of E. coli (Gan et al., 
2008). Glycan strands run circumferentially around the cell, perpendicular to the long 
axis of the cell (Gan et al., 2008). This result has also been observed in rod-shaped Gram-
positive organisms such as Bacillus anthracis and Listeria monocytogenes (Beeby et al., 
2013). The use of freeze substitution has confirmed the existence of a periplasmic space 
in S. aureus (Matias and Beveridge, 2006), as well as providing further details of the PG 
architecture within the septa of dividing bacteria (Matias and Beveridge, 2007). Scanning 
EM (SEM), where electrons are fired at the surface of whole cells, has also been utilised 





1.6.6 Fluorescence microscopy 
 
While EM can provide high resolution images of the cell and the cell wall, it provides 
little information about the localisation of cellular components. The fluorescent labelling 
of proteins has allowed the determination of subcellular localisations, as well as 
fluorescent D-amino acids to study PG dynamics (Radkov et al., 2018). Standard 
microscopy techniques are limited by the resolution limit of light to around ~250 nm 
(Huang et al., 2010). So called super resolution microscopy has been developed to 
alleviate this limitation, with methods such as structured illumination microscopy (SIM) 
and stochastic optical reconstruction microscopy (STORM) being utilised to study PG 
(Huang et al., 2010; Wheeler et al., 2011). Using STORM, the coordination of S. aureus 
cell division has been researched in detail (Chapter 1.4.5) (Lund et al., 2018).  
 
1.7 Staphylococcus aureus 
 
S. aureus is a Gram-positive spheroid bacterium found as a commensal organism on 
around 30 % of the population, commonly colonising the skin and nostrils (Mainous et 
al., 2006). It is non-motile and a facultative anaerobe as well as being catalase-, 
coagulase- and phosphatase-positive (Reddy et al., 2017). While S. aureus has a 
commensal relationship with humans, it will adapt to a pathogenic lifestyle on entering 
host tissues (through injury or medical intervention) (Reddy et al., 2017). Upon entering 
a host, S. aureus can infect a wide repertoire of sites around the body, causing skin and 
soft tissue infection (SSTIs), sepsis, osteomyelitis, peritonitis, pneumonia and 
endocarditis (Kim et al., 2014). S. aureus can be a causative agent of toxic shock 
syndrome, predominantly by the production of toxic shock syndrome toxin-1 (TSST-1) 
(Ferry et al., 2005). S. aureus and its associated toxins can also cause gastrointestinal 
infections and food poisoning. The ingestion of one or more of the preformed S. aureus 
enterotoxins can cause the rapid onset of food poisoning 2 to 8 hours after consumption 





It has been suggested that S. aureus is the cause of around 40% of all nosocomial 
infections, demonstrating the importance of research into this organism (Hecker et al., 
2010). The biochemistry and microbiology of this organism must be fully understood so 
that effective treatments can be devised to treat the wide range of diseases that it can 
cause, with a vaccine not yet being available (Proctor, 2012, 2015). 
 
1.7.1 Antibiotic resistance  
 
Shortly after the introduction of penicillin in the 1940s it was reported that resistant 
strains of S. aureus emerged due to β-lactamase (Rammelkamp and Maxon, 1942; 
Foster, 2017). The β-lactamase, encoded by blaZ, cleaves the β-lactam ring in penicillin 
(Sabath, 1982). Methicillin-resistant S. aureus (MRSA) was first reported in 1961 (Jevons, 
1961) shortly after the introduction of methicillin into the clinic to counter the rise of 
penicillin resistance (Lowy, 2003). Although named for methicillin resistance, MRSA 
strains are resistant to all β-lactam antibiotics, due to the acquisition of the mecA gene 
(Berger-Bächi and Rohrer, 2002; Stryjewski and Corey, 2014). MRSA infections are 
associated with significantly high morbidity and mortality rates (Dantes et al., 2013). 
 
The cause of β-lactam resistance was determined to be due to the acquisition of the 
mecA gene on a mobile genetic element called the staphylococcal cassette chromosome 
(SCCmec) (Katayama et al., 2000). The mecA gene encodes for a homologue of PBP2 
called PBP2A, which is not bound by β-lactam antibiotics (Zapun et al., 2008a). PBP2A 
only possesses transpeptidase activity, so the transglycosylase activity of the native 
PBP2 is still required in the presence of β-lactam antibiotics to synthesise PG (Rajagopal 
and Walker, 2017). The PG produced by PBP2A is less crosslinked than native PG, but still 





S. aureus strains often acquire resistances to other antibiotics, including glycopeptides 
such as vancomycin, commonly known as the antibiotic of last resort. Vancomycin binds 
to the D-Ala-D-Ala dipeptide of lipid II, preventing crosslinking and proper synthesis of 
the cell wall (Howden et al., 2010). Vancomycin resistant S. aureus (VRSA) have obtained 
the vanA gene of Enterococci, causing D-Ala-D-Ala to be replaced with D-Ala-D-lactate 
(Foster, 2017). It is more common for strains to be vancomycin-intermediate (VISA), 
which have a higher minimum inhibitory concentration (MIC) for vancomycin than a 
sensitive strain. This resistance is often associated with an increase in cell wall thickness 
(Gardete and Tomasz, 2014). The change in cell wall structure in VISA can be associated 
with single nucleotide substitutions in the walK or walR genes (Chapter 1.4.4), changing 
cell wall metabolism (Howden et al., 2011). 
 
1.7.2 S. aureus virulence factors 
 
S. aureus possesses a wide range of virulence factors (Figure 1.13), both secreted and 
cell surface associated, required for disease in a diversity of pathologies (Ukpanah and 
Upla, 2017). The cell wall of S. aureus impacts on virulence, as the PG, WTA and LTA are 
capable of causing septic shock and multiple organ failure within a host (Kengatharan et 
al., 1998). 
 
S. aureus produces a range of adhesins that allow binding to the host extracellular 
matrix and plasma components (Ferry et al., 2005). Microbial surface components 
recognising adhesive matrix molecules (MSCRAMM) adhesins are commonly anchored 
to the PG via covalent bonds and allow binding to host tissues (Foster et al., 2014). 
Sortase is the enzyme responsible for attaching surface proteins to PG via the LPXTG 
sorting signal motif (Mazmanian et al., 2000). Precursor proteins containing the LPXTG 
motif are transported to the secretory pathway, whereby they are directed to the cell 
envelope, and sortase, a transpeptidase, cleaves the motif between the threonine and 




protein and the pentaglycine bridge of the PG (Mazmanian et al., 2000). MSCRAMMs in 
S. aureus recognise host fibronectin via fibronectin-binding proteins, such as FnBPA and 
FnBPB, and fibrinogen with clumping factors A and B (ClfA, ClfB) (Ferry et al., 2005; 
Foster et al., 2014). It has been shown that ClfB is a major determinant for nasal 
colonisation (Wertheim et al., 2008). 
 
Protein A (SpA), associated with the cell wall of S. aureus, is also an MSCRAMM due to 
its ability to bind the von Willebrand factor in blood, which is a glycoprotein required for 
platelet adhesion at the site of tissue damage, as well as binding to blood clotting factors 
(Cheung et al., 2002). Protein A has a wide variety of other functions in infection, most 
importantly binding IgG of the host, interfering with opsonisation and phagocytosis 
(Ukpanah and Upla, 2017). Protein A can activate type I human interferons (IFN), such as 
IFN-β, which in a mouse pneumonia model has been shown to be important for lung 









Figure 1.13 Representative S. aureus virulence factors 
S. aureus produces a wide range of virulence factors to permit pathogenesis once inside a host. 




S. aureus are attacked by professional phagocytes during infection and must withstand 
killing for infection to progress. During infection, S. aureus is subjected to the 
complement system of the innate immune system. The complement system is a cascade 
of proteins that assists the immune response by opsonising bacteria to enhance 
phagocytosis, generating inflammatory signals for phagocyte recruitment and killing 
bacteria through the formation of the membrane attack complex (MAC) (Serruto et al., 
2010) (Figure 1.14). There are three complement pathways: classical, alternative and 
lectin, each consisting of proenzymes that sequentially cleave subsequent proteins, 
activating them in turn (Buchan et al., 2019). The three complement pathways converge 
with the cleavage of C3 by the C3 convertase (despite differences in the initial signal) 
producing C3a, a chemoattractant, and C3b which binds to the pathogen surface and 
opsonises it (Serruto et al., 2010). C3b binds more C3b molecules and C3 convertases, 
forming C5 convertases, producing C5a (essential for recruiting and activating 
phagocytes) and C5b. C5b deposits on the cell surface and binds molecules of C6, C7, C8 
and C9, eventually forming a pore known as the membrane attack complex (MAC), 
killing the bacterium (Merle et al., 2015). As Gram-positives have a thick layer of 
peptidoglycan covering their cell membrane, they are not affected by the MAC as it 
cannot reach the cell membrane. Gram-positive bacteria therefore have virulence 
factors that inhibit C3 and C5 convertases, preventing the production of C3a and C5a 
(Serruto et al., 2010). S. aureus produces the staphylococcal complement inhibitor 
(SCIN), which acts by binding to the host C3 convertase, halting the complement system 








Figure 1.14 The three pathways of the human complement system 
The classical, alternative and lectin pathways of the human complement. Representative bacterial 




S. aureus has 14 staphylococcal superantigen-like proteins (SSLs), a family of proteins 
involved in immune evasion (Koymans et al., 2018). Both SSL1 and SSL5 have been found 
to inhibit matrix metalloproteinases, which are involved in the recruitment of migratory 
inflammatory cells to the site of bacterial infection (Koymans et al., 2016). Toll-like 
receptor 2 (TLR2, Chapter 1.8.3) recognises the LTA and PG of S. aureus and is important 
for the activation of pathways leading to S. aureus clearance (Fournier and Philpott, 
2005). SSL3 has been shown to bind to the extracellular domain of TLR2, inhibiting its 
binding to S. aureus LTA and PG, preventing the production of inflammatory cytokines 
that would lead to bacterial clearance (Yokoyama et al., 2012). The secreted 
extracellular adherence protein (Eap) prevents neutrophil recruitment to the site of 
infection by blocking the interaction between host ICAM-1 and LFA-1, reducing 
neutrophil transmigration through endothelial cells (Foster, 2009). Phagocyte 
recruitment is also inhibited by the chemotaxis inhibitory protein of staphylococci 
(CHIPS) (Ukpanah and Upla, 2017). CHIPS binds to the C5a and formylated peptide 
receptors on the neutrophil surface, preventing the binding of C5a and formylated 
peptides, preventing chemotaxis of neutrophils towards C5a and the site of infection (de 
Haas et al., 2004). 
 
The secretion of enzymes that destroy host structures are important in the spread and 
dissemination of S. aureus throughout the host. The secretion of fibrinolysin, which 
degrades fibrin, allows the spread of S. aureus to surrounding tissues (Ukpanah and 
Upla, 2017). Hyaluronidases, which degrade the hyaluronic acid in the extracellular 
matrix, and may also play a role in dissemination and invasive infection tissue (Ukpanah 





S. aureus also produces toxins for tissue invasion and nutrient acquisition, as well as to 
escape immune killing. Alpha toxin (Hla) is a well characterised haemolysin of S. aureus 
that forms β-barrel pores in the membranes of host cells, resulting in host cell lysis 
(Berube and Bubeck Wardenburg, 2013). Hla binds to host cells via the ADAM10 
proteins in the host cell membrane which is expressed on a wide variety of cell types 
(Berube and Bubeck Wardenburg, 2013). The leukocidins are a group of pore-forming 
toxins produced by S. aureus (Alonzo and Torres, 2014). Leukocidins consist of two 
subunits, an S-subunit and an F-subunit, which, when secreted, oligomerise into a 
heptamer which subsequently forms a pore in the host membrane (Alonzo and Torres, 
2014). However, LukAB, which targets neutrophils via the CD11b cellular receptor (which 
binds C3b), is produced as a single heterodimer (DuMont et al., 2013). Panton-Valentine 
leukocidin (PVL) plays a key role in severe necrotising disease caused by S. aureus. PVL 
induces rapid death of human and rabbit, but not murine or simian, neutrophils (Löffler 
et al., 2010). Phenol soluble modulins (PSMs) are a group of seven toxins that target 
erythrocytes and leukocytes (Cheung et al., 2012) and are associated with invasive 
MRSA infections (Wang et al., 2007). PSMs are receptor independent pore-forming 
toxins that can target a wide variety of cell types, forming α-helical pores in membranes, 
resulting in host cell lysis (Buchan et al., 2019). It has been suggested that PSMs can 
release staphylococcal lipoproteins from the cytoplasmic membrane, resulting in TLR2 
signalling, leading to inflammation and sepsis (Chapter 1.7.3) (Buchan et al., 2019).  
 
S. aureus is known to produce abscesses during infection, which is common in the 
murine sepsis model of infection, where kidney abscesses are a key pathology (Pollitt et 
al., 2018). An abscess is an aggregation of bacterial cells surrounded by host immune 
cells, notably macrophages and neutrophils (Figure 1.15) (Kobayashi et al., 2015). Using 
immune evasion factors as previously discussed, S. aureus survives in the bloodstream 
and disseminates to organ tissues, such as the kidney (Cheng et al., 2011). It has been 
found that ClfA is important for the formation of an abscess in a rabbit model of skin 
infection (Malachowa et al., 2016). While in an organ such as the kidney, the iron 
limiting conditions must be overcome to allow replication to occur. S. aureus can 




haemoglobin, allowing S. aureus to utilise the iron containing haem group (Mazmanian 
et al., 2003; Torres et al., 2006). The replicating S. aureus cause migration of neutrophils 
and other immune cells to the site of infection (Cheng et al., 2011). Coagulase and von 
Willebrand factor binding protein (vWbp) are needed to form the fibrous pseudo-
capsule surrounding the S. aureus within the abscess (Kobayashi et al., 2015). This is 
surrounded by a layer of necrotic neutrophils and macrophages and also contains tissue 
debris and fibrin (Cheng et al., 2011; Kobayashi et al., 2015). As the abscess matures, 
fibroblasts proliferate, resulting in the production of a fibrous capsule encapsulating the 







Figure 1.15 Structure of a mature abscess formed by S. aureus 
S. aureus is found within the centre of the abscess protected by a fibrous pseudo-capsule. The bacteria are 
surrounded by DNA released from neutrophils. Within the abscess are dead macrophages and neutrophils, as well 
as some living. The entire abscess is encapsulated with a fibrous capsule of host origin, to isolate the bacteria 
from the other host tissues. Macrophages and neutrophils can pass through this in order to control the infection. 




When phagocytosed by host neutrophils and macrophages, S. aureus is subjected to 
further killing mechanisms. After phagocytosis, S. aureus is held within a phagosome 
that fuses with a lysosome filled with antimicrobial compounds and enzymes which 
degrade PG, proteins and DNA and produce an oxidative burst to kill pathogens (Buchan 
et al., 2019). During the oxidative burst (Figure 1.16), superoxide radicals (O2-) are 
produced by NADPH oxidase. Superoxide radicals do not directly contribute much to cell 
damage or death as S. aureus SodA and SodM, superoxide dismutases, convert 
superoxide radicals to hydrogen peroxide (H2O2) and O2, using manganese as a co-factor 
(Karavolos et al., 2003). S. aureus also produces the membrane-bound carotenoid 
staphyloxanthin, which gives S. aureus its distinctive colour. Staphyloxanthin acts as an 
anti-oxidant, containing abundant conjugated double bonds, allowing it to quench 
superoxide without damage to the cell (Clauditz et al., 2006; Buchan et al., 2019). 
Hydrogen peroxide, a product of both host and S. aureus superoxide dismutases, is 
converted to water and oxygen by S. aureus catalase (KatA) (Park et al., 2008). AhpC and 
AhpF, forming two subunits of S. aureus alkyl hydroperoxide reductase, also convert 
hydrogen peroxide to water and molecular oxygen, or convert alkyl peroxides to water 
and the corresponding alcohol, neutralising them (Cosgrove et al., 2007; Buchan et al., 
2019). Host myeloperoxidase can convert hydrogen peroxide, with a chloride ion, to 
hypochlorous acid (HOCl), which is the most antimicrobial chemical within the 
phagolysosome (Buchan et al., 2019). To prevent the function of hypochlorous acid, S. 
aureus inhibits the action of host myeloperoxidase by expressing staphylococcal 
peroxidase inhibitor (SPIN) (Buchan et al., 2019). SPIN inhibits the active site of 







Figure 1.16 Evasion of the oxidative burst by S. aureus 
The oxidative burst of neutrophils produced superoxide, hydrogen peroxide and hypochlorous acid 
in order to kill S. aureus. In turn S. aureus has mechanism to halt the production of and neutralise 




1.7.3 Host recognition of S. aureus 
 
PG is a pathogen associated molecular pattern (PAMP) recognised by the innate immune 
system via pattern recognition receptors (PRRs) resulting in the transcription of immune 
modulators, such as pro- or anti-inflammatory chemokines and cytokines (Bourhis and 
Werts, 2007). Nucleotide-binding oligomerisation domain protein (NOD) 1 and NOD2 are 
involved in the intracellular recognition of PG within host cells. NOD1 recognises PG, 
specifically a muropeptide of GlcNAc-MurNAc with a tripeptide stem containing 
diaminopimelic acid, resulting in the secretion of cytokines such as interleukin (IL) 6 and 
TNF-α (Chamaillard et al., 2003). NOD2 recognises the PG from both Gram-positive and 
negative bacteria, specifically detecting MurNAc with a dipeptide of L-Ala-D-iGlx 
(muramyl dipeptide), common to all PG (Girardin et al., 2003). The detection of PG by 
NOD2 results in the activation of the NF-κB pro-inflammatory cascade (Girardin et al., 
2003), causing the transcription of pro-inflammatory cytokines and leukocyte 
recruitment to help to clear bacterial infection (Lawrence, 2009). IL-1β and IL-6 are 
examples of pro-inflammatory cytokines that activate T and B cells respectively, 
stimulating the adaptive immune system after S. aureus is detected via innate immunity 
(Fournier and Philpott, 2005).The secretion of IL-8 results in the migration of neutrophils 
to the site of infection, which is important during abscess formation (Fournier and 
Philpott, 2005; Cheng et al., 2011). S. aureus is commonly phagocytosed by professional 
phagocytes during infection, but S. aureus can escape from the phagosome and grow 
and divide within the host cytoplasm (Kubica et al., 2008; Horn et al., 2018). S. aureus 
has been found to be able to survive within macrophages for days without a change in 
viability, and it has been suggested that these infected phagocytes may aid in S. aureus 
dissemination during an infection (Kubica et al., 2008; Pollitt et al., 2018). 
 
Toll-like receptor (TLR) 2 has been implicated in resistance to S. aureus infection in 
mouse models (Takeuchi et al., 2000; Hoebe et al., 2005). TLRs are structurally related to 
Drosophila Toll proteins (Medzhitov et al., 1997) and 10 have been found in mammals 




the MyD88 adaptor (Fournier and Philpott, 2005). TLR2 can detect the PG, lipoprotein 
and LTA (Chapter 1.3.2) of S. aureus. Detection of these PAMPs is known to cause the 
release of the cytokines TNF-α, IL-1β, IL-10, IL-12, IL-8 and the chemoattractant 
complement factor 5a (Fournier and Philpott, 2005). TLR2 can cooperate with TLR6 and 
TLR1 to increase the number of bacterial ligands that can be detected, and the 
formation of a heterodimer with these TLRs, and not a homodimer of TLR2, is required 
for TNF-α secretion (Ozinsky et al., 2000). The association with TLR1 and TLR6 also 
allows the discrete recognition of a wide range of PAMPs (Takeda et al., 2003). The α-, β- 
and γ- haemolysins of S. aureus target and cause the lysis of red blood cells in the host, 
producing an available iron source required for the proliferation of bacteria (Ukpanah 
and Upla, 2017). The haemolysins, in the presence of S. aureus LTA, activate the host 
NLRP3 inflammasome and the subsequent activation of caspase-1 (Muñoz-Planillo et al., 
2009). Caspase-1 cleaves the transcribed pro-IL-1β to the active IL-1β, activating the 
inflammatory response (Franchi et al., 2009). 
 
1.7.4 Augmentation of S. aureus infection by peptidoglycan 
 
S. aureus is present on the skin as part of a mixed microbiome of mostly commensal 
organisms (Grice et al., 2009). S. aureus is subjected to a phagocyte associated immune 
bottleneck during an infection (McVicker et al., 2014; Pollitt et al., 2018), where only a 
small proportion of the starting inoculum contributes to the infection (Boldock et al., 
2018). As S. aureus exists on the skin with other organisms, infection, potentially caused 
by hospital treatment, can result in a mixed inoculum infecting a patient. It is already 
known that the CAMP factor secreted by Propionibacterium acnes, a near ubiquitous 
skin bacterium (Brook and Frazier, 1991), enhances the haemolysis of S. aureus β-
haemolysin, increasing S. aureus virulence (Lo et al., 2011). The virulence of S. aureus is 
also augmented in a murine infection model when the inoculum also contains 
commensal organisms, without proliferation of the commensal bacteria (Boldock et al., 
2018). The augmentation could be achieved with purified PG, reducing the infectious 




a role for the resident skin microbiome, and potentially explaining the need for a large 
initial inoculum in mammalian models of S. aureus disease. The augmentation in mouse 
sepsis has been shown to be dependent on liver Kupffer cells phagocytosing both the S. 
aureus and augmenting material, resulting in a reduction in the production of reactive 
oxygen species, and the increased survival of S. aureus (Boldock et al., 2018). A murine 
augmentation model of infection has a unique phenotype whereby multiple liver 
abscesses form during the infection (Boldock et al., 2018). 
 
1.8 Animal models of S. aureus disease 
 
Animal models of disease are required to mimic complex host-pathogen interactions 
that occur during human interactions. No animal model is perfect to study human 
disease, with each model presenting advantages and disadvantages (Coulter et al., 
1998). 
 
A wide variety of animal models have been developed for studying different S. aureus 
diseases, including: Galleria mellonella (Pollitt et al., 2014), Drosophila melanogaster 
(Needham et al., 2004), Zebrafish (Danio rerio; Prajsnar et al., 2008) and mammals such 
as mice and rabbits (Salgado-Pabón and Schlievert, 2014). While mouse models are 
often considered the ‘gold standard’ for pre-clinical vaccine studies, many S. aureus 
virulence factors are human specific, and a high starting inoculum is required to initiate 





Invertebrate models have the advantage of providing high-throughput analysis at a 




immune characteristics with humans and do not have a complex collection of organ 
systems, meaning disease progression may not be relevant to human infection. 
 
1.8.1.1 Caenorhabditis elegans 
 
C. elegans is a soil dwelling nematode roughly 1mm long that has a short life cycle 
allowing it to be utilised in large quantities (Kenyon, 1988). In this model, C. elegans is 
fed S. aureus, and the primary read out of virulence is mortality of the nematodes (Sifri 
et al., 2003). S. aureus with knockouts in agr were shown to be less able to cause 
mortality in C. elegans, demonstrating reduced virulence (Sifri et al., 2003). Using 
transposon insertion mutants of S. aureus, high-throughput virulence screens can be 
performed using the C. elegans model, allowing rapid detection of virulence factors 
important for pathogenesis in this model (Begun et al., 2005). C. elegans is cultivated 
and maintained at 25 °C, which is below the optimum growth temperature for S. aureus. 
 
1.8.1.2 Galleria mellonella 
 
G. mellonella, the greater wax moth, are a commercially available model organism that 
are used to study a variety of pathogens, showing correlation in results with mice 
models (Cotter et al., 2000; Jander et al., 2000). For infection studies, the larvae are 
used. G. mellonella are not as well characterised as Drosophila (Chapter 1.8.1.3) but are 
known to have a circulatory system and immune system reminiscent of mammals, 
including superoxide producing phagocytes, and the production of antimicrobial 
peptides (Kemp and Massey, 2007). G. mellonella larvae have been used to study the 
virulence of S. aureus, including the involvement of agr in virulence and the relative 






1.8.1.3 Drosophila melanogaster 
 
D. melanogaster, a fruit fly, is commonly known as Drosophila and is widely used as a 
host to model disease (Kemp and Massey, 2007). Due to its wide usage, Drosophila are 
well characterised with mutants available for study, as well as being easy to breed and 
maintain (Kemp and Massey, 2007). Drosophila are not a natural host of S. aureus, but 
they have been used as a model organism to study S. aureus infection (Needham et al., 
2004). The dorsal thorax of Drosophila is infected with a needle coated in S. aureus 
culture, with fly death overtime a readout of virulence (Needham et al., 2004). Infection 
of the fly in this manner results in a systemic S. aureus infection and allowed the 
identification of genes important in virulence (Needham et al., 2004). Bacterial gene 
expression could be monitored via GFP production. The model also allowed the 
administration of antibiotics via the fly’s food, avoiding the need for further injections 
(Needham et al., 2004).  
 
1.8.2 Zebrafish  
 
Zebrafish (Danio rerio) have historically been utilised to study development due to being 
transparent, allowing simple imaging. Zebrafish are now commonly used to study 
infection due to the similarity to the human innate immune system, with both having 
orthologs of phagocytes and cytokines (van der Vaart et al., 2012). The zebrafish innate 
immune system is present at one day post fertilisation, with macrophages detectable at 
25 hours post fertilisation (hpf) and neutrophils at 18 hpf (Herbomel et al., 1999; 
Crowhurst et al., 2002). Later in the development, at around 4 – 6 weeks post 
fertilisation, zebrafish develop a full adaptive immune system (Trede et al., 2004), 
meaning that the importance of the innate immune system in infection can be 
investigated separately from that of the adaptive. With adequate infrastructure it is 
simple to breed and maintain fish allowing the generation of embryos that can be used 
in studies. Zebrafish are amenable to genetic modification to produce mutants, including 




oligonucleotides (morpholinos) are commonly used in zebrafish models to study 
immune components required to control infection (Corey and Abrams, 2001; Bill et al., 
2009). The pu.1 morpholino, injected at the one- to four- cell embryo stage, results in 
the depletion of myeloid cells (Su et al., 2007), the absence of neutrophils until 36 hpf 
and macrophages until 48 hpf (Klemsz et al., 1990). The use of the CRISPR/cas9 system 
has allowed the development of zebrafish mutants to be generated that can be used to 
study host-pathogen interactions without the need for chemicals and morpholinos 
(Kimura et al., 2014; Ma and Liu, 2015). 
 
The zebrafish model of infectious disease has been used to study the host-pathogen 
interactions of a variety of bacterial species, including Mycobacterium marinum (Swaim 
et al., 2006), S. aureus (Prajsnar et al., 2008), S. pneumoniae (Saralahti et al., 2014; Jim 
et al., 2016) and Enterococcus faecalis (Prajsnar et al., 2013). Injection of 1500 colony 
forming units of S. aureus into the circulation valley of zebrafish embryos (Figure 1.17) 
results in a systemic infection (Prajsnar et al., 2008), with the innate immune system 
being the primary defence against infection (Prajsnar et al., 2012). The phagocytes act as 
an immunological bottleneck for S. aureus infection, resulting in a small number of 
infected phagocytes acting as reservoirs of infection, leading to a clonal dissemination of 
infection (Prajsnar et al., 2012; McVicker et al., 2014). While the zebrafish model is high 
throughput, it is maintained at 28.5 °C where important virulence factors may not be 
expressed, meaning not all aspects of host-pathogen interaction can be investigated 




Mice have been used to develop a wide range of infection models where the routes of 
bacterial administration differ, to mimic the different pathologies bacteria can cause. S. 
aureus can cause a wide range of diseases, including sepsis, arthritis, skin infection, and 




routes, these pathologies have been modelled by murine infection (Table 1.3). Whilst 
mouse models are common, there have been many failed human clinical trials based on 
their use, raising questions as to their suitability to investigate human disease (Proctor, 
2012). S. aureus naturally colonises mice (Schulz et al., 2017), but most isolates used in 
research are human specific (Pollitt et al., 2018). A large negative of murine models is a 
high starting inoculum of bacteria is required to initiate infection, and doses may vary up 
to 100-fold depending on the S. aureus strain and route of administration (Table 1.3) 
(von Köckritz-Blickwede et al., 2008). This high inoculum requirement may be a 
consequence of several S. aureus virulence factors being human specific. To counter this 
and improve sensitivity, humanised mice are being developed (Knop et al., 2015; Prince 




Rabbits are commonly used to study bone (osteomyelitis) and joint infections caused by 
S. aureus (Reizner et al., 2014). Staphylococci are the most common cause of 
orthopaedic infections, with S. aureus and S. epidermidis able to form a biofilm on the 
materials used in prosthetics and implants, resulting in a difficult to treat and potentially 
recurring infection (Montanaro et al., 2011; Arciola et al., 2015). The large size of a 
rabbit allows implant-based infection models of osteomyelitis to be studied (Zhang et 
al., 2017). Rabbit models have also been associated with endocarditis (heart) infection 
models of S. aureus, due to the similarity to human endocarditis disease progression 
(Coulter et al., 1998). Using the rabbit endocarditis model, it was shown that WTA is 
required for the attachment of S. aureus to heart endothelial cells, and a lack of WTA 







Figure 1.17 Zebrafish embryo 30 hpf 
Bright field microscopy image of zebrafish embryo 30 hpf. Scale bar 100 µm. The site of injection is 








Disease Model Infection Route Infectious 
dose (CFU) 
Phenotype References 
Skin infection Subcutaneous 1 × 107–
1 × 109 
Dermonecrosis 
caused by secreted 
toxins 
(Kennedy et al., 
2010; Malachowa 
et al., 2013) 
Sepsis Intravenous 1 × 106–
1 × 107 




(Cheng et al., 
2009; McVicker et 
al., 2014; Boldock 
et al., 2018; Pollitt 
et al., 2018) 
Survival Intravenous 5 × 107–
5 × 108 
Acute lethal disease 
within 48 hours of 
infection; formation 
of multiple lesions in 
heart 
(Cheng et al., 
2010; McAdow et 
al., 2011; Pollitt et 
al., 2018) 
Peritonitis Intraperitoneal 5 × 108 (LD50) 
6 × 109 (LD90) 
Acute lethal disease 
within 12 hours of 
infection; formation 
of abscess lesions on 
peritoneal surfaces 






Local- 2 × 102 
-2 × 106 
 
Septic- 
1 × 107 
Swelling and 
erythema of joints 
with increased levels 
of TNF-α, IL-1β, IL-6 
and NF-κB in knee 
joint over 28 days. 
(Liu et al., 2001; 
Mohammad et al., 
2016; Baranwal et 
al., 2017) 
Pneumonia Intranasal 2–4 × 108 Acute lethal disease 
within 72 hours of 
infection; infiltration 
of inflammatory cells 
into alveolar air 
space 
(Kiser et al., 1999; 
Bubeck 










maintain S. aureus in 
the gut for 3 weeks 
post infection  
(Misawa et al., 
2015) 
Table 1.3 Summary of representative mouse models of S. aureus infection 




1.9 Project Aims 
 
Previous work has determined the structure of the S. aureus cell wall and PG when 
cultured in vitro. The aim of this study was to further the knowledge of S. aureus 
morphology and cell wall architecture during an infection. A further aim was to 






Chapter 2  




Media was prepared using distilled water (dH2O) and sterilised by autoclaving solutions 
at 121 °C and 15 psi for 20 minutes.  
 
2.1.1 Tryptic Soy Broth (TSB)  
 
Tryptic soy broth (Oxoid)       30 g/l 
Bacteriological Agar (VWR) was added at 1.5 % (w/v) to produce Tryptic Soy Agar (TSA). 
 
2.1.2 Chemically Defined Media (CDM) 
 
All glassware was rinsed with dH2O before being used for CDM preparation to remove all 





2.1.2.1 Solution 1 
 
Sodium phosphate dibasic (Na2HPO4.2H2O)     7 g/l 
Potassium phosphate monobasic (KH2PO4)     3 g/l 
ʟ-Aspartic Acid        0.15 g/l 
ʟ-Alanine         0.1 g/l 
ʟ-Arginine         0.1 g/l 
ʟ-Cysteine         0.05 g/l 
Glycine         0.1 g/l 
ʟ-Glutamic Acid        0.15 g/l 
ʟ-Histidine         0.1 g/l 
ʟ-Isoleucine         0.15 g/l 
ʟ-Lysine         0.1 g/l 
ʟ-Leucine         0.15 g/l 
ʟ-Methionine         0.1 g/l 
ʟ-Phenylalanine        0.1 g/l 
ʟ-Proline         0.15 g/l 
ʟ-Serine         0.1 g/l 
ʟ-Threonine         0.15 g/l 
ʟ-Tryptophan         0.1 g/l 
ʟ-Tyrosine         0.1 g/l 
ʟ-Valine         0.15 g/l 
The pH of solution 1 was measured before mixing and autoclaving and adjusted to 7.2 




2.1.2.2 Solution 2 (1000 x) 
 
Biotin          0.02 g 
Nicotinic Acid         0.4 g 
ᴅ-Pantothenic Acid        0.4 g 
Thiamine HCl         0.4 g 
Pyridoxal HCl         0.8 g 
Pyridoxamine di-HCl        0.8 g 
Riboflavin         0.4 g 
Chemicals for solution 2 were dissolved in 140 ml of dH2O and filter sterilised using a 
Stericup filter unit (milipore) with a 0.1 µm filter. Solution that was diluted to 1x using 
dH2O before mixing with other solutions. 
 
2.1.2.3 Solution 3 
 
Adenine Sulphate        0.4 g/l 
Guanine HCl         0.4 g/l 
Chemicals for solution 3 were dissolved in 0.1 M HCl. 
 
2.1.2.4 Solution 4 
 
Calcium Chloride Hexahydrate (CaCl2.6H2O)     1 g/l 
Ferrous Ammonium Sulphate ((NH4)2Fe(SO4)2.H2O)    0.6 g/l 





2.1.2.5 Solution 5 
 
Glucose         100 g/l 
Magnesium sulphate Heptahydrate (MgSO4.7H2O)    5 g/l 
Solution 5 was made using dH2O and was autoclaved separately to the other solutions 
used for the preparation of CDM. 
 
2.1.2.6 Preparation of CDM 
 
Solution 1         700 ml 
Solution 3         50 ml 
Solution 4         10 ml 
 
The three solutions were mixed and autoclaved under standard conditions. Once the mix 
had reached below 50 °C, 100 ml of solution 2 (at 1x concentration) and 100 ml of 
solution 5 (also below 50 °C) were added. CDM was stored at 4 °C. 
 
2.1.3 LK Broth  
 
Tryptone         10 g/l 
Yeast Extract         5 g/l 
KCl          7 g/l 





2.1.4 Brain Heart Infusion (BHI) 
 
Brain Heart Infusion (Oxoid)       37 g/l 
 
2.1.5 Porcine Serum 
 
Porcine Serum (Gibco – Thermofisher)     500 ml 
Serum was left to defrost overnight at 4 °C. After defrosting the serum was used 




All buffers were prepared using dH2O, sterilised by autoclaving (when required), and 
stored at room temperature or 4 °C as required. 
 
2.2.1 Phosphate Buffered Saline (PBS) 
 
Phosphate Buffered Saline Tablets (Sigma)     2 Tablets /l 
 
2.2.2 50 mM Tris-HCl  
 
Tris base         6.06 g/l 
The pH was adjusted to pH 7 or 7.5 with HCl, corrected to the final volume with dH2O 





2.2.3 50 mM Tris-HCl pH 7.5, SDS, 50 mM DTT, 1.25 mM EDTA 
 
SDS          3 g/l 
EDTA          372 mg/l 
DTT          7.71 g/l  
 
2.2.4 TAE (50x) 
 
Tris base          242 g/l 
Glacial acetic acid         0.57 % (v/v) 
EDTA pH 8.0          0.05 mM 
 
A 1x TAE working solution was made by diluting the 50x stock solution with dH2O. 
 
2.2.5 Tris/EDTA/NaCl buffer (TES) 
 
Tris base          2.42 g/l 
EDTA           1.86 g/l 
NaCl           5.84 g/l 
 





2.2.6 Phage buffer 
 
MgSO4          1 mM 
CaCl2           4 mM 
Tris-HCl pH 7.8         50 mM 
NaCl           100 mM 
Gelatin          0.1 % (w/v) 
 
2.2.7 Sodium Phosphate Buffer – 200 mM, pH5.5 (10x) 
 
Sodium phosphate monobasic (200 mM) and sodium phosphate dibasic (200 mM) were 
mixed to produce a solution of pH 5.5. 
 
2.2.8 Sodium Borate Buffer – 250 mM, pH 9 
 
Boric acid (H3BO3) was dissolved in dH2O and adjusted to pH 9 using NaOH before 
autoclaving. 
 
2.2.8 0.5M Ammonium Buffer, pH9 
 
Ammonium Hydroxide        0.5 M 
 





2.2.10 HPLC buffers 
 
All HPLC buffers were made with Milli-Q filtered water and filtered (0.2 µm pore size, 
Merck) prior to use. All chemicals used in HPLC analysis were of HPLC grade. 
 
2.2.10.1 Buffer A – Ultra Pure Milli-Q water with formic acid 
 
1 ml of formic acid (98+ % pure) was added to 1 l of ultra-pure Milli-Q water. Buffer was 
made fresh for each use. 
 
2.2.10.2  Buffer B – Acetonitrile with formic acid 
 
250 µl of formic acid (98+ % pure) was added to 250 ml of acetonitrile. Buffer was made 








The antibiotics that were used in this study are listed in Table 2.1. Antibiotics stock 
solutions were filter sterilised using a 0.2 µm pore filter and then stored at -20 °C. If 
added to media, antibiotics were added once media had reached a temperature of 50 °C 
or below. 
 
2.4 Chemicals and Enzymes 
 
All the chemicals and enzymes used in this study were of analytical grade quality and 
were purchased from Fisher Scientific, MP biomedicals or Merck (Sigma-Aldrich) unless 
otherwise stated). DNA polymerase and the appropriate buffers were purchased from 
New England Biolabs. Concentrations, storage conditions and solvents used are shown in 
Table 2.2.  
 
2.5 Bacterial Strains 
2.5.1  Staphylococcus aureus strains 
 
The strains of Staphylococcus aureus used in this study are listed in Table 2.3. All strains 
were plated out onto TSA containing the appropriate antibiotic concentrations (Table 
2.1) where required for selection, and stored at 4 °C. Each strain was stored as a stock at 
-80 °C using Microbank Beads which was used to produce the colonies on TSA plates.  
 
2.5.2  Other bacterial strains used 
 
Other bacterial strains used in this study are listed in Table 2.4. Strains were grown and 












Erythromycin (Ery) 5 5 100% (v/v) Ethanol 
Kanamycin (Kan) 50 50 dH2O 
Lincomycin (Lin) 25 25 50% (v/v) ethanol 
Minocycline (Mino) 2 2 dH2O 
Neomycin (Neo) 50 50 dH2O 
Spectinomycin 
(Spec) 
50 100 dH2O 
Tetracycline 
(Tet) 
5 5 50% (v/v) ethanol 
 





Stock Solution Concentration Solvent Storage 
Mutanolysin 1 mg/ml 
200 mM sodium 
phosphate 
-20 °C 
Pronase 20 mg/ml TES pH 8.0 -20 °C 
Lysostaphin 5 mg/ml 
20 mM sodium acetate 
(pH 5.2) 
-20 °C 
Bovine Serum Albumin 
(BSA) 
 
10% (w/v) PBS 4 °C 
Gentamycin 
(Sanofi-Aventis) 
40 mg/ml dH2O 4 °C 
Paraformaldehyde 4% (w/v) 
100 mM sodium 
phosphate buffer (pH 
7.0) 
4 °C 
Saponin 10% (w/v) dH2O 4 °C 
Cellosyl 0.5 mg/ml 
5 mM ammonium 
formate, 10 mM 









Strain Genotype Source 
SH1000 (SJF 682) Functional rsbU+ derivative of 8325-4 (Horsburgh et al., 2002) 
SH1000 atl (SJF 1367) SH1000 atl::eryR (Foster, 1995) 
SH1000 scaH (SJF 2109) SH1000 scaH::kanR (Wheeler et al., 2015) 
SH1000 kanR (SJF 3674) SH1000 lysA::kanR lysA+ (McVicker et al., 2014) 
SH1000 pbp3 (SJF 4422) SH1000 pbp3::specR 
Constructed by Dr K. 
Wacnik (University of 
Sheffield) 
SH1000 pbp3 pbp4 (SJF 
4423) 
SH1000 pbp3::specR pbp4::eryR 
Constructed by Dr K. 
Wacnik (University of 
Sheffield) 
SH1000 pbp4 (SJF 4425) SH1000 pbp4::eryR 
Constructed by Dr K. 
Wacnik (University of 
Sheffield) 
SH1000 sagA (SJF 4606) SH1000 sagA::tetR (Wheeler et al., 2015) 
SH1000 scaH (SJF4607) SH1000 scaH::tetMR (Wheeler et al., 2015) 
SH1000 sagB (SJF 4608)  SH1000 sagB::kanR (Wheeler et al., 2015) 
SH1000 atl sagA sagB 
(SJF 4610) 
SH1000 atl::eryR sagA::tetR sagB::kanR (Wheeler et al., 2015) 
SH1000 atl sagA scaH 
(SJF 4611) 
SH1000 atl::specR sagA::tetR 
scaH::tetMR 
(Wheeler et al., 2015) 
SH1000 sagA sagB scaH 
(SJF 4612) 
SH1000 sagA::tetR sagB::kanR 
scaH::tetMR 
(Wheeler et al., 2015) 
SH1000 atl sagB scaH 
(SJF 4613) 
SH1000 atl::eryR sagB::kanR 
scaH::tetMR 
(Wheeler et al., 2015) 
SH1000 atl sagB (SJF 
4972) 
SH1000 atl::eryR sagB::kanR (Wheeler et al., 2015) 
SH1000 sagB scaH (SJF 
4973) 
SH1000 sagB::kanR (Wheeler et al., 2015) 
SH1000 sagA sagB (SJF 
4974) 




SH1000 sagA scaH (SJF 
5217) 
SH1000 sagA::tetR scaH::kanR This study 
SH1000 atl (SJF 5255) SH1000 atl::kanR 
Constructed by Dr B. 
Salamaga (University of 
Sheffield) 
SH1000 atl sagA (SJF 
5261) 
SH1000 atl::kanR sagA::tetR This study 
SH1000 atl scaH (SJF 
5262) 
SH1000 atl::kanR scaH::tetMR This study 
NewHG (SJF 3663) 
S. aureus Newman with saeSL allele 
from strain RN1 
(Mainiero et al., 2010) 
NewHG kanR (SJF 3680) NewHG lysA::kanR lysA+ (McVicker et al., 2014) 
NewHG tetR (SJF 3681) NewHG lysA::tetR lysA+ (McVicker et al., 2014) 
NewHG sagB (SJF 4912) NewHG sagB::kanR This study 
NewHG pbp4 (SJF 5103) NewHG pbp4::eryR This study 
NewHG tetR pbp4 (SJF 
5135) 
NewHG lysA::tetR lysA+ This study  
NewHG kanR pbp4 (SJF 
5136) 
NewHG lysA::kanR lysA+ pbp4::eryR This study 
NewHG sagB pbp4 (SJF 
5147) 
NewHG sagB::kanR pbp4::eryR This study 
Table 2.3 The strains of Staphylococcus aureus used within this study  
 eryR, erythromycin resistance; kanR, kanamycin resistance; specR, spectinomycin 




Species Strain Genotype Source 
Enterococcus 
faecalis 
OG1RF Wildtype background (Bourgogne et al., 2008) 




2.6 Growth Conditions 
 
Standard conditions for growth conditions used TSB. Media was inoculated using an 
overnight culture produced by adding a single colony to 10 ml TSB in a 50 ml Falcon 
tube, which was left overnight in a water bath (Julabo) at 37 °C with shaking at 200 rpm. 
The overnight culture was used to inoculate 50 ml fresh media in a 250 ml conical flask 
to produce an optical density (OD600) of 0.05. Flasks were left in a water bath at 37 °C 
with shaking at 200 rpm to produce a culture at mid-exponential phase (OD600 0.4-0.8), 
unless otherwise stated.  
 
2.7 Determination of bacterial density 
2.7.1 Optical density measurements  
 
Optical density measurements of liquid culture were taken using a Biochrom WPA 
Biowave DNA spectrophotometer at a wavelength of 600 nm (OD600), determining the 
bacterial load of a culture. If required, a 1:10 dilution was made using sterile culture 
media. 
 
2.7.2 Direct cell counts (CFU/ml) 
 
Direct cell counts were performed to quantify viable bacterial numbers. Bacterial 
suspensions were serially diluted 1:10 in sterile PBS. 10 µl of each dilution was spotted 
onto TSA plates, allowed to dry and incubated at 37 °C overnight. The number of colony 





2.8 Growth Curves  
 
Strains were streaked from Microbank bead frozen stocks (stored at -80 °C) onto TSA 
containing the appropriate concentration of antibiotic (Chapter 2.3) if required to select 
for the strain. An overnight culture was made as in Chapter 2.6, which was used to 
inoculate 50 ml of pre-warmed TSB in 250 ml conical flask to an OD600 of 0.01. Cultures 
were grown in triplicate as in Chapter 2.6, and growth was measured hourly by OD600 
measurements (Chapter 2.7.1) and/or direct cell counts (Chapter 2.7.2) until stationary 
phase was reached. 
 
2.9 Centrifugation  
  
The following centrifuges were used to harvest samples: 
 Eppendorf microcentrifuge 5418 with a capacity of up to 18 x 1.5- or 2-ml 
microfuge tubes, maximum speed 16873 x g (14000 rpm).  
 Sigma centrifuge 4K15C with a capacity of 16 x 50 ml falcon tubes, maximum 
speed 5525 x g (5100 rpm). 
 Avanti High Speed J25I centrifuge, Beckman Coulter: 
o JA-25.50 rotor with a capacity of up to 6 x 50 ml, maximum speed 75000 x 
g (25000 rpm). 
 Avanti High Speed J-26XP centrifuge, Beckman Coulter: 
o JLA 8.1000 rotor with a capacity of 6 x 1000 ml, maximum speed of 15970 




Samples were sonicated using a Soniprep 150 Plus bench-top ultrasonic disintegrator 
(MSE) with an exponential microprobe (tip diameter of 3 mm). Unless otherwise stated, 




2.11 DNA techniques 
2.11.1 Genomic DNA extraction 
 
1 ml of an overnight culture (Chapter 2.6) was centrifuged at 14000 rpm for 5 min to 
harvest cells. The pellet was resuspended in 190 µl of dH2O to which 10 µl stock 
Lysostaphin was added and then incubated at 37 °C for 1 hour. Genomic DNA was then 
purified using a Qiagen DNeasy Blood and Tissue kit according to manufacturer’s 
instructions. 
 
2.11.2 Primer design 
 
Primers for PCR amplification, 20 - 30 nucleotides in length, were synthesised by 
Eurofins MWG Operon. Primers were designed based on the genomic DNA sequence of 
S. aureus 8325. Primers were resuspended in nuclease-free water (New England Biolabs) 
to 100 and 10 µM stock and working solutions respectively and stored at -20 °C. The 







Primer Sequence (5’-3’) Application Source 
Atl_TnINS_F ACATTTACAGGTGATTTAG
CTGTGTTG 
Amplifies a region of 
the atl gene. 
Forward primer. 







Amplifies a region of 
the atl gene. 
Reverse primer. 

















Amplifies the sagB 
gene. 
Forward primer. 




Amplifies the sagB 
gene. 
Reverse primer. 




Amplifies a region of 





Amplifies a region of 





Amplifies a region of 
the pbp4 gene. 
Forward primer. 





Amplifies a region of 
the pbp4 gene. 
Reverse primer. 
Dr K. Wacnik 
(University of 
Sheffield) 




2.11.3 Taq polymerase 
 
PCR amplifications were performed using DreamTaq Green Master Mix (Thermo 
Scientific), as accurate amplification was not needed in this study. Individual reaction 
volumes were as follows: 
DreamTaq Green master Mix (2x)      25 µl 
Forward primer (10 µM)       2.5 µl 
Reverse primer (10 µM)       2.5 µl 
Template DNA         50-100 ng 
Nuclease free water         Up to 50 µl  
PCR amplification was performed in a Veriti Thermal Cycler (Applied Biosystems). The lid 
was pre-heated to 105 °C with the following cycling conditions: 
1x Initial denaturation 95 °C 1 min 
30x Denaturation 95 °C 30 s 
 Annealing 55-62 °C 30 s 
 Extension 72 °C 1 min/kb 
1x Final extension 72 °C 5 min 
 
2.11.4 Agarose gel electrophoresis 
 
A 1% (w/v) agarose gel containing 0.5 µg/ml ethidium bromide was used to separate 
PCR DNA products in 1 x TAE buffer. Gels had 120 V applied for around 30 min at room 
temperature. DNA bands were visualised using a UV transilluminator and a photograph 
was taken using a UVi Tec Digital camera and UVi Doc Gel documentation system. PCR 





 Marker DNA fragment size (kb) 
















Quick load purple 2-log  



























2.12 Phage techniques 
2.12.1 Bacteriophage 
 
Phage transduction of S. aureus was performed using bacteriophage ϕ11 (Mani et al., 
1993). 
 
2.12.2 Preparation of phage lysate 
 
The donor strain of S. aureus was grown overnight as in Chapter 2.6. 200 µl of the 
overnight culture was then mixed with 5 ml of TSB, 5 ml of phage buffer (Chapter 2.2.6) 
and 100 µl of a ϕ11 phage lysate stock in a sterile 25 ml Universal tube. This was 
incubated at 25 °C overnight until the mixture had cleared. The lysate was then filter-
sterilised with a 0.2 µm pore filter (Merck) and stored at 4 °C until required. 
 
2.12.3 Phage transduction 
 
A single colony of the recipient S. aureus strain was inoculated into a 250 ml conical flask 
containing 50 ml LK which was incubated overnight in a water bath at 37 °C with shaking 
at 200 rpm. The resulting overnight culture was harvested by centrifugation at 5000 x g 
for 10 min at room temperature and resuspended in 3 ml of fresh LK. 500 µl of the 
recipient strain was then combined with 1 ml fresh LK, 10 µl 1 M CaCl2 and 500 µl donor 
phage lysate in a 25 ml Universal tube. The tubes were incubated at 37 °C for 25 mins 
without shaking, and then a further 15 mins with shaking. 1 ml ice cold 0.02 M sodium 
citrate was added to the mixture, which was then incubated for 5 min on ice. The cells 
were harvested by centrifugation at 5000 rpm at 4 °C for 10 min and the supernatant 
was discarded. The pellet was resuspended in 1 ml ice cold 0.02 M sodium citrate and 
incubated on ice for 45 to 90 min. 100 µl of cells were spread on LK agar plated 




Plates were incubated at 37 °C for 24 to 48 hours until single colonies were visible. These 
were picked and streaked onto TSA plates containing the selective antibiotics. 
 
2.13 Purification of Sacculi 
 
An overnight culture (made as in Chapter 2.6) was used to inoculate 50 ml of media 
(normally TSB) in a 250 ml conical flask to an OD600 of 0.05. This was incubated at 37 °C, 
200 rpm until the desired OD600 was reached (generally OD600 ~0.6). Cultures were 
centrifuged to harvest cells and resuspended in Tris HCl pH 7.5 containing 2 % SDS (w/v) 
and boiled for 10 min to kill cells and inactivate enzymes before being harvested by 
centrifugation and washed once with dH2O. Thick suspensions of boiled cells were added 
to lysing matrix tubes containing 0.1 mm silica beads (Lysing Matrix B, MP Biomedicals). 
The cells were sheared 10 times at 6.0 m/s for 30 sec using an MP Biomedicals FastPrep 
24 Homogeniser, with samples being kept on ice between cycles to prevent overheating. 
Sacculi were separated from the lysing matrix by centrifuging for 30 sec at 100 x g and 
collecting the supernatant. The sacculi were harvested from the supernatant and 
resuspended in 4 % (w/v) SDS and boiled for 30 mins to remove non-covalently bound 
cell wall components. Cells were harvested again and resuspended in Tris pH 7.5 with 
SDS/EDTA/DTT (Chapter 2.2.3) and boiled for 30 mins to remove remaining non-
covalently bound proteins. Remaining SDS was removed by washing the pellet six times 
in dH2O and pellet collected by centrifugation, removing the supernatant each time. 
Pellets were resuspended in 50 mM Tris HCl pH 7.5 containing 2 mg/ml pronase (Table 
2.2) to remove any covalently bound proteins. Wall teichoic acids and any other 
remaining cell wall polymers were removed by incubating the sacculi in 250 µl 48 % 
(w/v) hydrofluoric acid (HF) at 4 °C for 48 hours. The purified sacculi were washed in 
alternating 50 mM Tris HCl pH 7.5 and dH2O until the pH was raised to at least 5.0, 
ending on a dH2O wash to remove Tris HCl residue. Purified sacculi were pelleted and 






2.14 Digestion of peptidoglycan to produce soluble muropeptides 
 
Purified PG (~2 mg) was resuspended in 10 µl sodium phosphate buffer (Chapter 2.2.7), 
90 μl dH2O and 50 μg mutanolysin. This was incubated overnight (~16 hours) at 37 °C 
and the reaction was stopped by boiling for 5 minutes. Muropeptides were collected by 
centrifugation at 16873 x g and reservation of the supernatant.  
 
2.15 Reduction of samples by sodium borohydride 
 
Soluble muropeptides were mixed with an equal volume of sodium borate buffer 
(Chapter 2.2.8) to raise the pH to at least pH 9. Sodium borohydride was added, and the 
reaction was left for 15 minutes at room temperature. The reaction was stopped by 
destruction of excess borohydride by the addition of phosphoric acid to a pH of at least 
4. The pH was then raised to ~5.6 using NaOH and then filtered (0.2 μm, Merck) to 
remove any insoluble contaminants from the sample. 
 
2.16 HPLC analysis of muropeptides using the ammonium phosphate buffer system 
 
Samples were analysed using a Thermo Scientific Hypersil GOLD aQ column (200 x 2.1 
mm, 1.9 µm particle size), which was pre-equilibrated with Buffer A (Chapter 2.2.4.1) in 
a Waters HPLC system. S. aureus muropeptides were eluted from the 200 x 2.1 mm 
column using a flow rate of 0.3 ml/min, using a multi-step convex gradient over 63 
minutes for S. aureus (Table 2.7), and 45 minutes for E. faecalis (Table 2.8). Eluted 
muropeptides were detected by measuring absorbance at 202 nm and analysed using 





Time (min) % Buffer A % Buffer B 
0 100 0 
5 95 5 
23 90 10 
42 85 15 
47 70 30 
47.1 0 100 
55 0 100 
55.1 100 0 
63 100 0 
 
Table 2.7 RP-HPLC elution gradient for S. aureus muropeptides analysis 
 
 
Time (min) % Buffer A % Buffer B 
0 100 0 
30 70 30 
30.1 10 90 
35 10 90 
35.1 100 0 
45 100 0 
 





2.17 Phosphate free muropeptide digestion and mass spectrometry analysis 
 
When muropeptides were to be analysed by mass spectrometry (MS) a phosphate free 
buffer was used to remove the need to desalt samples. Purified PG (~2 mg) was 
resuspended in 90 µl MilliQ water and 10 µl 50 mM ammonium formate buffer pH 4.8 
was added, along with 20 µl cellosyl (Table 2.2). This was incubated overnight at 37 °C, 
900 rpm in a thermal shaker (Eppendorf). Cellosyl was inactivated at 100 °C for 10 min, 
and samples were centrifuged at 16873 x g for 10 min, reserving the supernatant. The 
supernatant was dried using a speed vac vacuum concentrator (Thermofisher) and 
resuspended in 25 µl of MilliQ water and 25 µl of 0.5 M Ammonium buffer pH 9.0 
(Chapter 2.2.8). Samples were reduced at room temperature for 30 min by the addition 
of tetra methyl ammonium borohydride. Samples were then acidified using 5 % (v/v) 
formic acid to pH 4.0 – 4.5. Samples were then reduced to around 30 µl using a speed 
vac, and 15 µl to the HPLC system (Agilent 1100, with an ACE3 C-18AQ column (1 × 150 
mm). RP-HPLC conditions were as follows: buffer A (Chapter 2.2.10.1) to a maximum of 
50% buffer B (Chapter 2.2.10.2) over 128 min at a flow rate of 0.05 ml/min (Table 2.9). 
Muropeptides were detected by UV at 205 nm. 
 
MS analysis was performed using a modified protocol of previously published methods 
(Dembek et al., 2018). Muropeptides were analysed by infusion MS by directing RP-HPLC 
eluate to the ion source on an LTQ mass spectrometer (Thermo). The spray voltage was 
set at 3.6 kV and the transfer capillary temperature at 200 °C. Mass spectra were 
collected over the range m/z = 300–2000 with MS/MS fragmentation spectra triggered 
for all ion signals >5 × 103 intensity. Analysis was performed using Xcalibur QualBrowser 
v2.0 (Thermo). Relative quantities of muropeptides were calculated by the normalised 
percentage area under each peak from which the chemical structure had been 
determined. Peak identity was assigned based on the greatest abundance of an ion 
within the peak. MS/MS fragmentation spectra confirmed the identity of monomeric 
and dimeric muropeptide species. Higher crosslinked species were assigned based on 




Time (min) % Buffer A % Buffer B 
0 100 0 
5 100 0 
10 98 2 
30 94 6 
58 93 7 
100 92 8 
110 50 50 
112 15 85 
117 15 85 
118 100 0 
128 100 0 
 






2.18 Animal models of infection 
2.18.1 Zebrafish embryo model of infection 
2.18.1.1 Zebrafish strains and husbandry 
 
London Wild Type (LWT) strains were used for all zebrafish experiments in this study. 
Adult zebrafish were maintained by staff at the University of Sheffield Bateson Centre 
Zebrafish Facility. Adult fish were kept in a continuous re-circulating closed system 
aquarium with a light/dark cycle of 14/10 hours at 28 °C. LWT zebrafish embryos were 
kept in E3 medium at 28.5 °C. 
 
2.18.1.2 Zebrafish E3 medium (x 10) 
 
NaCl           50 mM 
KCl           1.7 mM 
CaCl2           3.3 mM 
MgSO4          3.3 mM 
 
A 1 x working stock was made by diluting the 10 x with dH2O. A final concentration of 
0.0005 % methylene blue (Nusslein-Volhard and Dahm, 2002) was added to prevent 




A 3.0 % (w/v) solution of methylcellulose was prepared in E3 medium. The solution was 
stirred, frozen and defrosted multiple times to ensure complete solubilisation (Nusslein-
Volhard and Dahm, 2002). The solution was drawn up into 20 ml syringes and stored at -




2.18.1.4 Zebrafish anaesthesia  
 
Zebrafish embryos were anaesthetised in 0.02 % (w/v) 3-amino benzoic acid ester 
(tricaine, Sigma) prior to injection. The working stock consisted of 0.4 % (w/v) tricaine in 
20 mM Tris-HCl pH 7 (prepared by the staff at the University of Sheffield Bateson Centre 
Zebrafish Facility). The working stock was kept at 4 °C in the dark. 
 
2.18.1.5 Microinjections of S. aureus into zebrafish embryos 
 
S. aureus strains were grown from an overnight culture (Chapter 2.6) used to inoculate 
50 ml TSB in a 250 ml conical flask at 37 °C, 200 rpm, until OD600 reached approximately 
1. 40 ml of the culture was centrifuged in a 50 ml falcon tube at 5100 rpm (Sigma 
centrifuge 4K15C) for 10 min at 4 °C. The supernatant was discarded, the pellet washed 
in sterile PBS, centrifuged as before and resuspended in sterile PBS to a known 
concentration. This known concentration was determined based on the OD600 of each 
culture, with bacterial quantification performed before and after a microinjection 
experiment. To do this, four injections were performed into 1 ml of sterile PBS, vortexed 
and, in duplicate, 100 µl was spread onto TSA. After incubation overnight at 37 °C the 
number of CFU was directly counted from the plate. 
 
Zebrafish embryos were dechorionated manually at roughly 28 hpf, before being 
injected at roughly 30 hpf with 1 nl of bacterial suspension from a calibrated glass 
needle. The fine bore glass needles for microinjection were made by heating non-
filament glass capillary tubes (World Precision Instruments, WPI) in an electrode puller. 
Bacterial inoculum was loaded into the microinjection needles using microcapillary 
pipettes (Fisher Scientific Ltd) and injection volume was calibrated using a graticule slide 
to 1 nl. Before injection embryos were briefly immersed in 0.02 % (w/v) buffered tricaine 
anaesthetic solution in E3 before being immobilised onto a glass slide covered with 3.0 
% (w/v) methylcellulose. Injections into the zebrafish embryo circulation valley were 




a dissecting light microscope (Leica). After injection, embryos were removed from the 
methylcellulose to Petri dishes containing sterile E3 medium and left for 1 – 2 hours at 
28.5 °C to allow any remaining methylcellulose to dissolve. Embryos were placed into 
fresh E3 medium and then placed individually into 96-well plates with 250 µl of E3 per 
well. 
 
2.18.1.6 Determination of zebrafish embryo mortality 
 
For each experiment, at least 20 fish were injected with S. aureus for each strain 
investigated. Zebrafish embryos were inspected twice a day for the presence of a 
heartbeat, absence of which was confirmation of death, using a dissecting light 
microscope (Leica). 
 
2.18.1.7 Determination of S. aureus growth within zebrafish embryos 
 
To quantify the bacterial growth within the zebrafish embryos single embryos were 
collected with 100 µl E3 medium into 2 ml cap containers (Peqlab). Embryos were 
individually homogenised using a PreCellys 24-dual (Peqlab) and the resulting 
homogenates were serially diluted in sterile PBS and plated onto TSA as 10 µl spots. The 
limit of detection for this experiment was 10 CFU/embryo. Clearance was defined as 
being below the limit of detection. 
  
2.18.2 Murine Sepsis Model 
 
6-7-week-old female BALB/c mice were purchased from Charles River (Margate, UK) and 
maintained at the University of Sheffield’s Biological Services Unit using standard 
husbandry protocols. Bacteria for inoculum were grown to stationary phase in TSB and 
washed 3 times in sterile endotoxin free PBS and finally resuspended in PBS containing 
10% (w/v) BSA and stored at -80 °C until required. Dilutions were made to the bacterial 




– 1 x 107 CFU per mouse. Purified PG required for injections was centrifuged for 2 
minutes at 14000 rpm and then suspended in sterile endotoxin free PBS, before being 
sonicated (Chapter 2.10) at an amplitude of 10 microns for 30 seconds. PG was injected 
at a dose of 250 µg per mouse and was injected at the same time as the bacteria. 
 
Mice were kept at 37 °C for 10 mins prior to injections to dilate veins. Mice were 
intravenously injected in the tail vein, with 100 µl of culture being injected. Viable 
bacteria in the inoculum were quantified by serial dilution and plating onto TSA, and 
leaving overnight at 37 °C, before directly counting the CFU to determine injected dose. 
 
Mice were screened for health and wellbeing twice daily throughout the experiment, 
with weights being recorded daily. At the end of the experiment (normally 72 hpi), or if 
mice were found to have exceeded severity limits, mice were sacrificed under Schedule 
1 using concussion of the brain by striking the cranium with death being confirmed by 
cervical dislocation. Livers and kidneys (and where possible spleens, lungs and hearts) 
were then harvested and stored at -20 °C until processing. Sterile PBS (3 ml to livers, 2 
ml to other organs) was added and organs were homogenised using a Precellys 24 
homogeniser (for 20 seconds). CFU per organ were determined by plating 10 µl spots of 
serial dilutions of the homogenate onto TSA plates and incubating at 37 °C overnight. 
The limit of detection within livers was 600 CFU and for all other organs sampled 400 
CFU. 
 
2.18.3 Use of clodronate for macrophage depletion 
 
Clodronate liposomes and empty control PBS liposomes (Liposoma research, the 
Netherlands, clodronateliposomes.com) were ordered and injected as per 
manufacturer’s instructions. For mice, clodronate and control liposomes were injected 
at a dose of 100 µL of suspension per 10 grams (stock 5 mg clodronate/mL) 




bacteria as in Chapter 2.18.2. For zebrafish, 1 nl of clodronate or control liposomes were 
injected into the circulation valley of zebrafish embryos at 24 hpf, before being infected 
with a dose of around 150 CFU of bacteria at 30 hpf as in Chapter 2.18.1.5. 
 
2.19 Collection of peptidoglycan from murine organs 
 
Organs of one type (n = 10) were pooled from a single mouse experiment that shared 
the initial starting inoculum. Cells were recovered by centrifugation at 18000 rpm 
(Avanti centrifuge, JA 25.50 rotor, Chapter 2.9) and resuspended in Tris HCl (50 mM, pH 
7.5) containing 2% SDS (w/v) and boiled for 10 min to kill cells. Cells were washed twice 
in dH2O, and the pellet resuspended in 10 ml 50 mM Tris HCl pH 7.5. The mixture was 
transferred to a Braun Homogeniser bottle containing 50 g of sterile, acid-washed glass 
beads and placed on ice. The contents of the bottle were disrupted using a Braun 
homogeniser (Braun, Germany). Each bottle was homogenised for 10 x 30 sec, with 5 
min on ice in-between each homogenisation. The beads were separated from the 
broken cells with a vacuum sintered glass filter, and the resulting filtrate centrifuged 
(18000 rpm, 10 min, 4 °C, Avanti centrifuge, JA 25.50 rotor, Chapter 2.9) to pellet the 
sacculi. The resulting pellet was then purified in the same way as Chapter 2.13. 
 
2.20 Human cell work 
2.20.1 Monocyte derived macrophages (MDMs) 
 
Monocytes were isolated from peripheral blood mononuclear cells (PBMCs) from 
healthy donors, as previously described (Boldock et al., 2018). Ficoll Plaque (GE 
Healthcare) density centrifugation was used to isolate PBMCs from donor blood, which 
were seeded into 24 well plates (Corning) at 2 x 106 cells/ml in RPMI 1640 medium with 
the addition of 2 mM/l L-glutamine (Lonza) which was further supplemented with 10 % 
(v/v) new-born foetal calf serum (Gibco). This set up resulted in wells containing 
approximately 2 x 105 MDM/ml. After incubating for 24 hours at 37 °C with 5 % (v/v) 




10 % (v/v) low endotoxin heat inactivated foetal calf serum (Biosera) to remove non-
adherent cells. Cells had supernatant removed twice a week which was replaced with 
fresh supplemented RPMI 1640. Differentiated MDM were used at 14 days.  
 
All media and reagents were warmed to 37 °C before being used with MDMs unless 
otherwise stated. Differentiated MDMs were challenged with S. aureus strains at a MOI 
of 5 (i.e. 1 x 106 CFU per well of 2 x 105 MDMs), which were added to the MDMs in fresh 
RPMI 1640. The MDMs were challenged with S. aureus for 4 hours at 37 °C, 5 % (v/v) 
CO2, after which infected media was removed and MDMs were washed with ice cold 
PBS. Any remaining extracellular bacteria were killed by the addition of 100 μg/ml 
gentamicin in fresh RPMI 1640 media and incubation for 30 min. After this the wells 
were washed with PBS and the MDM were maintained in fresh RPMI 1640 
supplemented with 4 μg/ml gentamycin and 0.8 μg/ml lysostaphin until the desired time 
point.  
 
At the desired time points MDM were washed with PBS and incubated with 250 μl 2 % 
(w/v) saponin at 37 °C, 5 % (v/v) CO2 for 12 min. PBS was added to make well volume 1 
ml and cells were further lysed by vigorous pipetting. Cell lysis was confirmed by light 
microscopy. Viable intracellular CFU was determined by serial dilution, and spotting 10 
μl onto TSA plates, which were left at 37 °C overnight. Extracellular bacteria killing by 
gentamycin and lysostaphin was confirmed by fixing control MDM with 2 % (v/v) 
paraformaldehyde before bacterial challenge, and then exposing to gentamycin and 
lysostaphin then lysed as described, showing absence of bacteria in lysates. Other MDM 
were not infected with S. aureus and treated as above, to confirm that all bacteria 
recovered came from the initial inoculum. All MDM experiments had two biological 







Neutrophil work was carried out by Ms Natalia Hajdamowicz (University of Sheffield), 
following a modified protocol described (Boldock et al., 2018). Neutrophils were purified 
from anti-coagulated human blood and kept at 37 °C with 5 % CO2 (v/v) in RPMI 1640 
medium. To 96 well Tissue Culture Corning plate containing 90 µl of approximately 
2.5 x 106 cells/ml (around 225000 neutrophils per well) 10 µl of bacterial stock culture 
was added to produce a MOI of 5. After 30 minutes, gentamycin was added to 40 mg/ml 
and a sample was taken without gentamycin treatment to calculate phagocytosed 
bacteria numbers. After 60 and 120 min of co-culture, 100 µl of sample was transferred 
to a 1.5 ml Eppendorf tube and centrifuged for 3 min at 400 x g to recover neutrophils. 
Neutrophils were washed with 1 ml ice cold sterile PBS, and then lysed with 1 ml room 
temperature alkali water (6 M NaOH added to dH2O until pH 11 and filtered) and 
vigorous pipetting. Intracellular CFU were determined by serially diluting in sterile PBS 
and plating 10 µl spots onto TSA, which were left overnight at 37 °C, and CFU calculated 
the next day by directly counting. 
 
2.21 Transmission electron microscopy (TEM) 
 
After organ CFU had been determined (Chapter 2.18.2) 1 ml of homogenate was 
centrifuged (16873 x g, 10 min, room temperature) to produce a pellet. The resulting 
pellet was mixed with 2.5 % (w/v) glutaraldehyde and left overnight at 4 °C to fix 
samples. Glutaraldehyde was removed from the pellet and washed with PBS. Two 
further PBS washes were performed, with PBS being left on the sample for 20 min at 4 
°C before being removed and discarded. Samples were then mixed with 2 % (w/v) 
aqueous osmium tetroxide for 2 hours (room temperature) for secondary fixation. 
Excess osmium tetroxide was removed using two PBS washes, with PBS being left on the 
sample for 10 min before being discarded. Samples were dehydrated by the addition of 
incremental concentrations of ethanol (75 % (v/v), 95 % (v/v) and 100 % (v/v) ethanol) 




were then incubated twice with propylene oxide to complete dehydration, each time for 
15 min. 
 
Samples were mixed with a 50 % (w/v) propylene oxide to 50 % Epon resin (v/v) mixture 
and left overnight at room temperature to allow infiltration of the sample. The resin was 
removed, and any remaining propylene oxide was removed by evaporation over 1 hour. 
Pure Epon resin was added to the sample, which was left for 4 hours, after which the 
resin was removed and replaced with fresh pure Epon resin for another 4 hours. Epon 
resin was removed and the samples were imbedded in fresh resin. Resin polymerisation 
was performed at 60 °C for 48 – 72 hours. 80 nm thin sections of the samples were 
produced using an Ultracut E Ultramicrotome (Reichert-Jung) at room temperature. The 
thin sections were mounted onto 200-square mesh copper TEM grids (Agar Scientific) 
already treated with a 1.5 % Pyroxylin (w/v, in amyl acetate) film. Mounted sections 
were stained in 3 % (w/v) aqueous uranyl acetate for 30 min and washed with dH2O. 
Sections were then stained with Reynold’s lead citrate (Reynolds, 1963) for 5 min and 
washed with dH2O. 
 
Sections were imaged using a FEI Tecnai T12 Spirit Transmission Electron Microscope 
operating at 80 kV. Images were recorded using a Gatan Orius™ SC1000B bottom-
mounted CCD camera. TEM images were analysed using Fiji software (Schindelin et al., 
2012). Cell area was calculated using adapted methodology (Zhou et al., 2015). Two 
perpendicular measurements were made along the long and short axis the cell, from the 
edge of the cell wall to the edge of the cell wall. The measured radii were then used to 
calculate the estimated cell area. For cell wall measurements, four equidistant cell wall 
measurements were made around the cell where the cell wall was clearly defined 






2.22 Flow cytometry 
 
Analysis of S. aureus particle size was analysed by measuring the forward scatter (FSC) of 
particles. Overnight cultures of S. aureus strains were grown in Chapter 2.6. These were 
used to inoculate 1 ml of TSB in a well of a 24 well plate to an OD600 of 0.05. The 24 well 
plate was left at 37 °C and 200 rpm until an OD600 of 0.6 (exponential phase) was 
achieved. Bacteria were diluted 1:100 in PBS filtered through a 0.2 µm syringe filter to 
remove salt crystals that could interfere with the measurements. FSC was analysed by 
flow cytometry using a Millipore Guava EasyCyte system. Light scatter data were 
obtained with logarithmic amplifiers for 2500 events, and each strain was measured in 
triplicate, from three independent overnight cultures. 
 
2.23 Ethics statement 
 
Murine work was carried out according to UK law in the Animals (Scientific Procedures) 
Act 1986, under Project License PPL 40/3699 and Project License P3BFD6DB9 
(Staphylococcus aureus and other pathogens, pathogenesis to therapy). Personal license 
PIL IF5CD6EC4 (Categories A, B and C). 
 
All zebrafish work was carried out according to the stipulations set out in Project License 
PPL 40/3574. However, it is important to note that zebrafish embryos fewer than 5 days 
post fertilization (dpf) are not protected under the Animals (Scientific Procedures) Act 
1986 as they are not capable of independent feeding.  
 
Human blood was obtained from healthy volunteers, with informed consent, in 








All statistical analysis was performed using Prism version 8.3.0 (GraphPad). Doubling 
times from growth curves was determined by fitting a curve with non-linear regression 
(Malthusian growth) using Prism. This was fitted to the most exponential part of the 
graph. 
 
Zebrafish experiments are representative of at least n = 2 unless otherwise stated. 
Figures of zebrafish experiments show combined results of replicate experiments. In 
zebrafish embryo survival experiments, the Kaplan-Meier method was employed. 
Comparison between survival curves was made using the log-rank (Mantel Cox) test.  
 
For bacterial count and weight change comparison in murine experiments the Mann-
Whitney U test was used. For comparison of two or more independent samples 
simultaneously the Kruskal Wallis test was applied with Dunn’s multiple comparison 
test. For clonality experiments, and.  Shannon’s diversity index was calculated using the 
equation 𝐻 = − ∑ 𝑝𝑖 ln(𝑝𝑖), (where H = Shannon diversity index and pi = the 
proportion of species i relative to the total number of species present).  Species 
evenness was derived from the Shannon diversity index using the equation 𝐸𝐻 = 𝐻/ln𝑆 
(where EH = species evenness, H = Shannon diversity index and S = the total number of 
species within the community (species richeness)). Species evenness within an organ 
over time was then analysed using mean linear regression analysis. For relative fitness 
experiments, the equation 𝑤 = ( )
( )
 was used and analysed using a one sample 
Wilcoxon signed rank test (w = relative fitness, X1 = starting mutant proportion and X2 = 





2.25 Collaborative work 
Chapter 3 – TEM samples were given to Ms Lucia Lafage (University of Sheffield), who 
fixed, stained and sectioned samples. Lucia also assisted me in collecting the images for 
analysis. Digestion of samples for LC-MS was performed with assistance from Dr Jacob 
Biboy (University of Newcastle), while samples were analysed by LC-MS with assistance 
by Dr Joe Gray (University of Newcastle), but all results were analysed by me. E. faecalis 
strain and infected murine kidneys were provided by Dr Josie Gibson (University of 
Sheffield; Figure 3.10).  
 
Chapter 4 – Ms Simone Tazoll (University of Lübeck, a master’s level student) assisted 
me in producing some repeats of survival curves for some glucosaminidase mutants, 
including figures 4.1ABC, 4.2BC and 4.3AB. Flow cytometry was performed with the 
assistance and expertise of Dr Bartłomiej Salamaga (University of Sheffield). 
 
Chapter 5 – Neutrophil experiments were performed by Ms Natalia Hajdamowicz 
(University of Sheffield), I provided intellectual input into experiment design and analysis 
of results. Mr William Turnbull was an undergraduate student at the University of 
Sheffield working on a Harry Smith vacation studentship. William assisted me to produce 
survival and OD600 growth curves for SH1000 pbp3, pbp4 and pbp3 pbp4. Dr Eric Pollitt 
(University of Sheffield) gave advice on statistical analysis for relative fitness and 
population dynamics experiments.  
 
All murine experiments were conducted in collaboration with Mr Oliver Carnell, Dr Josie 
Gibson, Dr Grace Pidwill or Dr Daria Shamarina (University of Sheffield). For all 
experiments in this study, I wrote the Individual Study Plans (ISPs), prepared the 
inoculum, infected and culled mice and managed the overall experimental procedures 
and performed data analysis. Collaborators assisted me in loading needles, writing down 
weight and wellbeing measurements and the dissection of mice. I also collaborated in 




Chapter 3  





PG structure is discussed in depth in Chapter 1.2. Briefly, almost all bacteria are 
surrounded by an essential layer of PG (murein) (Vollmer et al., 2008a). PG consists of 
repeating units of N-acetylglucosamine and N-acetylmuramic acid linked by β-1-4 
glycosidic bonds forming the glycan backbone (de Pedro and Cava, 2015). Peptide side 
chains are linked to the N-acetylmuramic acid residue, which, in S. aureus, consist of L-
Ala, D-iGlx (Gln or Glu), L-Lys, D-Ala, D-Ala (Vollmer et al., 2008a; Kühner et al., 2014). 
Stem peptides allow crosslinking of PG. In S. aureus these crosslinks consist of an 
interpeptide bridge consisting of five glycine residues. This interpeptide bridge is known 
as a 3-4 crosslink, linking the L-Lys of one chain to the D-Ala in position 4 of the other 
chain (Vollmer et al., 2008a). This single macromolecule maintains cell integrity by 
withstanding turgor pressure, determines and sustains cell shape as well as providing an 
anchor for other cell wall components (Vollmer et al., 2008a). These anchored cell wall 
components include surface proteins which are covalently bonded to the terminal 
glycine residue of non-crosslinked pentaglycine bridges (Navarre and Schneewind, 
1999). Wall teichoic acids (WTA) are anchored to the PG of the cell wall via a linkage unit 
to carbon-6 of N-acetylmuramic acid residues of the glycan backbone (Neuhaus and 
Baddiley, 2003). 
 
PG is commonly analysed using reverse-phase high performance liquid chromatography 
(RP-HPLC), methodology originally proposed by Bernd Glauner (Glauner, 1988). PG is 
purified using proteases, removing covalently bound proteins, and surfactants such as 
SDS to remove non-covalently bound proteins (Glauner, 1988). The PG is then treated 
with hydrofluoric acid (HF), removing phosphate linked molecules such as WTA (Jonge et 




production of soluble disaccharide peptides termed muropeptides (Glauner, 1988, 
Figure 3.1A). The digestion targets the glycan backbone of PG, leaving pentaglycine 
crosslinks intact, allowing multimeric muropeptides to be detected and analysed (Figure 
3.1B). Muropeptides are then reduced, and analysed by RP-HPLC, and a trace measured 
by UV-absorbance (Glauner, 1988). 
 
To identify UV-absorbance peaks, individual muropeptide containing fractions are 
collected, desalted by HPLC and analysed by mass spectrometry (MS) sometimes 
coupled to MS/MS (Jonge et al., 1992b). This is a time consuming process, and it is now 
common for muropeptides to be analysed by MS or MS/MS coupled with RP-HPLC (LC-
MS), meaning that an ion spectra is produced in tandem to the UV-absorbance trace, 
reducing the time needed for data collection (Bern et al., 2017), as has been done in my 
study. This methodology still requires the manual analysis and identification of major 
ions to identify UV-absorbance peak identity, but work has been published to automate 
this process (Bern et al., 2017). 
 
Muropeptide traces are often complex, with multiple different species being present on 
a single trace, due to multimeric muropeptides and modifications (Jonge et al., 1992b; 
de Jonge and Tomasz, 1993). MRSA strains grown in the presence of methicillin show a 
greatly changed muropeptide composition, with a large reduction in oligomeric 
muropeptide species and a shift to monomeric and dimeric species (de Jonge and 
Tomasz, 1993; Müller et al., 2015). The presence of the mecA gene with no antibiotic 
stimulation results in the same muropeptide composition as a wildtype not containing 
mecA (Jonge et al., 1992b). S. aureus PG structure is also influenced by nutrient 
availability. As cells reach stationary phase, glycine in the medium becomes depleted, 






Figure 3.1 Schematic representation of S. aureus muropeptides 
(A) A S. aureus monomeric muropeptide consists of a of an N-acetylglucosamine and N-
acetylmuramic acid residue, with a L-Ala,D-iGlx (Gln or Glu), L-Lys, D-Ala, D-Ala peptide side chain. 
Bonded to the L-Lys residue is a pentaglycine bridge that can form crosslinks between peptide 
stems. (B) Multimeric monopeptides are formed by crosslinking peptide stems via a pentaglycine 




Several cell wall structural homeostasis mechanisms have also been identified. O-
acetylation of N-acetylmuramic acid by oatA has been shown to render S. aureus PG 
resistant to digestion by lysozyme (Bera et al., 2005), with only pathogenic strains 
showing this modification (Bera et al., 2006). This modification has been directly shown 
to contribute to pathogenesis in a murine septic arthritis model of infection (Baranwal et 
al., 2017). Penicillin binding protein 4 (PBP4) is responsible for the highly crosslinked PG 
found in S. aureus (Wyke et al., 1981a), with around 85% of all muropeptides containing 
at least one crosslink (Sobral and Tomasz, 2019). Abnormal muropeptide traces have 
also been produced by inactivating femA (de Jonge et al., 1993), a gene required to 
insert the first and second glycine residues in the pentaglycine bridge (Sobral and 
Tomasz, 2019). This resulted in an increase of serine containing and mono-glycine 
crosslinks, as well as being involved in methicillin resistance (de Jonge et al., 1993). 
 
Bacteria live within dynamic and hostile environments, such as a host, which present a 
variety of different threats to survival. To permit survival within such environments, 
bacteria may modify their dynamic cell wall to resist environmental conditions. This is 
described as PG plasticity, with modifications made to PG in response to environmental 
stimuli, whether that be nutritional status, host interaction or induced by factors such as 
temperature or oxygen limitation (Cava and de Pedro, 2014; Fang et al., 2016). As S. 
aureus has known cell wall adaptations involved in infection, it can be hypothesised that 







The aim of this chapter was to determine the structure of S. aureus PG during infection, 
using the murine sepsis model. The specific aims were to: 
i. Determine the structure of S. aureus PG during infection 
ii. Investigate any unique muropeptides of S. aureus during infection 






3.3.1 Method development 
3.3.1.1 Purification optimisation of peptidoglycan from S. aureus NewHG 
 
During each purification step for PG isolation (Chapter 2.13) material is lost, reducing the 
yield of purified material. The number of bacteria recovered from an organ during 
infection are known (Pollitt et al., 2018) and are likely to be limiting in terms of PG 
amounts for analysis. For this reason, each purification step was scrutinised to ensure 
that it was required to produce a high quality muropeptide trace (Figure 3.2). Cells 
grown in TSB that were only boiled and then treated with mutanolysin showed low 
levels of muropeptides (Figure 3.2A, all UV absorbance peaks below 400 mAU), whereas 
treating boiled cells with hydrofluoric acid (HF) increased the yield of muropeptides, 
with the absorbance reaching 1000 mAU for some UV-absorbance peaks (Figure 3.2B). 
Boiling cells twice in the presence of SDS (Figure 3.2C,) gave an increased yield 
compared to boiling the cells in dH2O (Figure 3.2A), with most UV absorbance peaks 
having an absorbance of over 500 mAU. However, with a RP-HPLC time of around 30 
mins, there is a sharp increase in absorbance (Figure 3.2C) that is not seen in the 
samples boiled in the presence of SDS and HF treated (Figure 3.2D). This is likely caused 
by wall teichoic acids (WTA) eluting from the column. As WTA alter the trace, HF 
treatment will be necessary to purify PG from in vivo derived samples. Cells killed by 
boiling and then treated with pronase (Figure 3.2E, most UV absorbance peaks 500 
mAU) show a small increase in yield compared to cells only heat inactivated (Figure 
3.2A), but also gives an abnormal increase in absorbance at 30 min, suggesting WTA. 
This increase abnormality is lost when pronase treated PG is reacted with HF (Figure 
3.2F). Treating cells with pronase and boiling cells once in the presence of SDS (Figure 
3.2G) also shows increased muropeptide abundance compared to heat inactivating cells 
(Figure 3.2A), but this also shows the increase in absorbance caused by WTA not seen in 
the HF treated equivalent (Figure 3.2H). The results suggest that treatment with HF is 
the most important purification step, improving both the yield and the muropeptide 







Figure 3.2 Role of purification steps in muropeptide profile determination of S. aureus NewHG 
peptidoglycan by RP-HPLC 
Muropeptide profiles of NewHG (SJF 3663) grown in TSB using different purification methods prior to 
mutanolysin digestion. (A) Boiled cells, (B) boiled and HF treatment, (C) boiled and SDS treated, (D) boiled, SDS 
and HF treated, (E) boiled and pronase treated, (F) boiled, pronase and HF treated, (G) boiled, SDS and pronase 




3.3.1.2 Sensitivity analysis of RP-HPLC muropeptide analysis 
 
A muropeptide trace of PG from in vivo grown bacteria has not been reported before. To 
ensure that this is feasible, the sensitivity of RP-HPLC was scrutinised to determine the 
fewest number of bacteria possible to produce a muropeptide trace of suitable quality 
(Figure 3.3). Different volumes of a culture of known CFU/ml were individually purified 
(Chapter 2.13), digested (Chapter 2.14) and analysed (Chapters 2.15, 2.16). All starting 
CFU gave recognisable muropeptide profiles. However, the number and UV-absorbance 
of distinct muropeptides decreased with lower amounts of starting material. A starting 






Figure 3.3 Analysis of the effect of initial CFU on muropeptide profile of S. aureus NewHG by RP-HPLC 
Representative muropeptide profiles of NewHG (SJF 3663) grown in TSB using different starting CFU. Muropeptide 




3.3.2 Mass spectrometry analysis of S. aureus muropeptides grown to exponential and 
stationary phase 
 
For all UV-absorbance peak identification of muropeptides by mass spectrometry (MS), 
the ion of greatest abundance within a peak was used for the peak designation. For 
monomeric and dimeric muropeptide species, MS/MS was used to confirm the identity 
of the most abundant observed ion (Appendix 1). For muropeptide species with greater 
crosslinking (oligomers), the mass of the most abundant ion found by MS was used to 
identify the UV-absorbance peak. 
 
S. aureus NewHG kanR (SJF 3680) was chosen to produce a reference muropeptide trace, 
as this strain is used to infect mice (Chapter 2.18.2). NewHG kanR was cultured using 
standard growth conditions (Chapter 2.6), to exponential phase (OD600 of 0.6) or 
stationary phase (8 hours of growth, OD600 of around 9 - 10) in three independent 
repeats. For MS analysis, samples were digested using a phosphate free methodology to 
remove the need for desalting, as well as in the absence of sodium to reduce the 
formation of sodium adducts in the MS ion spectra (Chapter 2.17). Three UV-absorbance 
muropeptide profiles (with ion spectra) were produced for NewHG kanR cultured in TSB 
to exponential phase (Figure 3.4A). The representative trace shows the identification of 
monomeric muropeptide species (3, 4, 5 and 14), dimeric muropeptide species (17 and 
24) and higher crosslinked trimeric (28), tetrameric (29) and pentameric (33) 
muropeptide species. Three independent cultures of NewHG kanR cultured in TSB to 
stationary phase were used to produce muropeptide profiles (Figure 3.4B). As for 
exponential phase PG, monomeric species were identified, and crosslinked species (up 
to pentameric) were also observed in all samples. 
 
The area under each identified UV-absorbance peak was measured and expressed as a 
percentage of the total area of all identified peaks for each trace (Appendix 2 Tables 1 
and 2). These were then grouped based on the level of crosslinking, with monomers 




a higher level of crosslinking. The extent of crosslinking between exponential and 
stationary phase cultures was then compared (Figure 3.4C). Stationary phase cells show 
significantly more monomeric muropeptide species than that of exponential phase cells 
(p = 0.0059). No significant difference could be seen in the abundance of dimeric 
muropeptides (p > 0.9999) between stationary and exponential phase cells. Stationary 
phase cells show significantly fewer oligomeric (highly crosslinked) muropeptide species 
compared to exponential phase cells (p = 0.0055), suggesting a reduction in PG 






Figure 3.4 Analysis of muropeptide profiles of S. aureus NewHG kanR by RP-HPLC and MS 
Representative muropeptide profiles of NewHG kanR (SJF 3680) cultured in TSB in (A) exponential phase (OD600 
~0.6) or (B) stationary phase (OD600 ~9). Muropeptides have been labelled after being identified by MS, using 
muropeptide numbers from Table 3.1. (C) Area of eluted identified UV-absorbing peaks, corresponding to 
different muropeptides, was quantified and is shown as a percentage of the total of all identified peaks 
grouped based on cross-linking (exponential phase - black bars, stationary phase – blue bars, n = 3, error bars 
represent the standard deviation of the mean). A two-way ANOVA with Sidak’s multiple comparison post-test 











Table 3.1 S. aureus NewHG muropeptide database 
 
Muropeptide database derived from material from Figures 3.4; 3.6 and 3.9 and from Appendix 2 
Tables 1, 2, 3, 4 and 5. Each muropeptide has been given a muropeptide number for this study. 





3.3.2 Analysis of S. aureus muropeptide profile after culture in porcine serum 
3.3.2.1 Growth of S. aureus in porcine serum 
 
The growth of S. aureus NewHG kanR (SJF 3680) in porcine serum was determined under 
standard conditions (Chapter 2.6, Figure 3.5).  
 
NewHG kanR has a reduced growth rate in porcine serum (doubling time 34.6 min) 
compared to TSB (doubling time 28.7 min). The yield was 5.9 x 1012 and 4.4 X 109 CFU/ml 
for TSB and serum respectively after 10 hours (Figure 3.5B). Mid-exponential and 
stationary phase growth in serum were defined as 3 and 8 hours after inoculation 
respectively.  
 
3.3.2.2 Analysis of muropeptides of S. aureus cultured in porcine serum 
 
Muropeptides from purified PG of NewHG kanR (SJF 3680) cultured, in triplicate, to 
exponential phase and stationary phase in porcine serum were analysed by MS (Figure 
3.6A and B) as in Chapter 3.3.2.1. In both stationary and exponential phase samples, 
monomeric, dimeric, trimeric, tetrameric and pentameric species were observed. In all 
serum samples, the most abundant pentameric muropeptide species found was a 
structure lacking two acetyl groups (muropeptide 31, Table 3.1). 
 
Each identified muropeptide was integrated and expressed as a percentage of the total 
area of all identified peaks for a single trace (Appendix 2 Tables 3 and 4) and grouped 
based on crosslinking (Figure 3.6C). No significant differences could be found between 
the abundance of monomers (p = 0.99), dimers (p = 0.27) or oligomers (p = 0.11) from 
exponential phase cells grown in TSB or porcine serum. Comparing stationary phase 
serum to stationary TSB grown muropeptides, there were significantly fewer monomeric 
(p = 0.0004) and significantly more dimeric (p = 0.0338) muropeptides in the serum 
sample, but no significant difference between oligomeric muropeptides (p = 0.40) 












Figure 3.5 Analysis of S. aureus NewHG growth in porcine serum 
Growth (37 °C) of NewHG kanR (SJF 3680) in TSB (black circles) compared to NewHG kanR in porcine 
serum (orange squares) measured by (A) absorbance and (B) CFU/ml. Bacterial cultures were 
prepared in triplicate and error bars represent the standard deviation of the mean. were prepared in 





Figure 3.6 Analysis of muropeptide profiles of S. aureus NewHG kanR grown in serum by 
RP-HPLC and MS 
Representative muropeptide profiles of NewHG kanR (SJF 3680) cultured in porcine serum in (A) 
exponential phase or (B) stationary phase. Muropeptides have been labelled after being identified 
by MS, using muropeptide numbers from Table 3.1. (C) Area of eluted identified UV-absorbing 
peaks, corresponding to different muropeptides, was quantified and is shown as a percentage of the 
total of all identified peaks grouped based on cross-linking (exponential phase TSB - black bars, 
stationary phase TSB – blue bars, exponential phase serum – red bars, stationary phase serum – 
purple bars, n = 3, error bars represent the standard deviation of the mean). A two-way ANOVA with 
Sidak’s multiple comparison post-test was used to compare abundance of each muropeptide species 





3.3.3 Analysis of S. aureus cultured in chemically defined media (CDM) 
3.3.3.1 Growth of S. aureus in CDM 
 
S. aureus NewHG kanR (SJF 3680) was grown in TSB and CDM under standard conditions 
(Chapter 2.7.1, Figure 3.7). When cultured in CDM, NewHG kanR shows a reduced 
optimal growth rate (doubling time 35.7 mins) and increased lag time compared to TSB 
(doubling time 30.9 mins). An OD600 of around 0.4, was defined as mid-exponential 







Figure 3.7 Analysis of S. aureus NewHG growth in CDM 
Growth (37 °C) of NewHG kanR (SJF 3680) in TSB (black circles) and CDM (red squares). Bacterial 





3.3.3.2 Analysis of muropeptides of S. aureus cultured in CDM and modified CDM 
 
A single exponential CDM derived sample of NewHG kanR (SJF 3680) PG was purified and 
analysed by MS (Chapters 2.13 and 2.17) (Figure 3.8A), as well as a single stationary 
phase sample cultured in CDM (Figure 3.8B). In both the exponential and stationary 
phase samples, monomeric, dimeric, trimeric, tetrameric and pentameric species were 
observed. A trace of NewHG kanR cultured in CDM containing 125 mM of glycine was 
also produced (Figure 3.8C), but only species up to tetrameric could be identified. This 
experiment is a repeat of work already published (de Jonge et al., 1996). Three unique 
muropeptides were also found to be present in this sample, muropeptides: 1, 13 and 22 
(Table 3.1), as previously described (de Jonge et al., 1996). These muropeptides show 
the terminal alanine of the stem peptide substituted with a glycine, unique to this trace. 
NewHG kanR were also cultured in CDM without glucose, the PG purified and a 
muropeptide trace produced. In this trace monomeric, dimeric, trimeric and tetrameric 
muropeptide species were observed. 
 
3.3.3.3 Peptidoglycan crosslinking of S. aureus cultured in CDM  
 
All identified peaks were integrated and expressed as a percentage of the total area of 
all identified peaks (Appendix 2 Table 5) and grouped together based on crosslinking 
(Figure 3.9). All data sets in this figure consist of one repeat, so serve as preliminary 
results with no statistical analysis. As seen previously (Figure 3.4C), preliminary results 
suggest that stationary phase cells grown in CDM have fewer highly crosslinked 
muropeptides and more monomeric species. Cells grown in CDM containing 125 mM 
glycine show a drastic reduction in the level of highly crosslinked muropeptides, and a 
greater amount of monomeric muropeptides. Cells grown in CDM without glucose show 
an increase in the proportion of dimeric muropeptide species and decrease in oligomeric 







Figure 3.8 Analysis of muropeptide profiles of S. aureus NewHG kanR grown in CDM 
and modified CDM by RP-HPLC and MS 
Muropeptide profiles of NewHG kanR (SJF 3680) cultured in CDM to (A) exponential phase or (B) 
stationary phase or cultured in (C) CDM containing 125 mM glycine to exponential phase or (D) 
CDM lacking glucose to exponential phase. Muropeptides have been labelled after being 





   
Figure 3.9 Analysis of muropeptide cross-linking of S. aureus NewHG kanR grown in CDM or 
modified CDM 
Area of identified UV-absorbing peaks from Figure 3.8, corresponding to different muropeptides, 
was quantified and shown as a percentage of the total area of all identified peaks grouped based on 
cross-linking (exponential phase CDM - black bars, stationary phase CDM – blue bars, CDM 

















3.3.4 S. aureus muropeptide database 
 
The identified muropeptides from Figures 3.4, 3.6, 3.8 and Appendix 2 Tables 1, 2, 3, 4 
and 5 were combined to produce a database of muropeptides (Table 3.1). Each 
muropeptide has been allocated a muropeptide number (specific to this study) based on 
molecular mass. For each muropeptide the structure, the range of retention times and 
the range of observed masses are recorded. If a muropeptide was observed in different 
charge states during MS, both ions have been recorded with the same muropeptide 
number. 
 
3.3.5 Analysis of S. aureus peptidoglycan from a murine infection  
 
The murine sepsis model was used as a source of in vivo grown bacteria. In this model 
kidney abscesses are the characteristic pathology (Pollitt et al., 2018). S. aureus NewHG 
kanR (SJF 3680), at a dose of 1 x 107 CFU, was used to inject groups of 10 mice. 72 hpi, 
mice were culled, and kidneys were harvested, homogenised and CFU determined 
(Chapter 2.18.2). Kidney homogenates (all from mice from a single experiment, totalling 
20 kidneys) were combined and PG was collected (Chapter 2.19) and purified (Chapter 
2.13). After purification, the remaining pellet appeared a grey colour rather than the 
white colour expected of purified PG, which could not be removed with further SDS 
washes or pronase treatments. To produce a muropeptide trace, 2 mg of this material 
was digested and analysed by MS (Chapter 2.17). 
 
Two muropeptide traces of NewHG kanR (SJF 3680) purified from murine kidneys, 72 hpi, 
were produced and analysed (Figure 3.10A). Monomeric, dimeric, trimeric and 
tetrameric muropeptide species were detectable in this trace. All muropeptides 
identified in the trace were also found in the TSB grown samples, with no unique species 
found (Table 3.1, Appendix 2 Table 6). This may be due to the lower concentration of 
muropeptides meaning that satellite peaks are not at a concentration where they can be 




The extent of crosslinking in PG from NewHG kanR (SJF 3680) recovered from murine 
kidneys was determined as previously described (Chapter 2.17). The area of each 
identified UV-absorbance peak was calculated and expressed as a percentage of the 
total area of all identified peaks (Appendix 2 Table 6) and expressed based on the level 
of crosslinking (Figure 3.10B). Significantly more monomeric muropeptides are found in 
stationary phase TSB samples (p = 0.0180) and kidney samples (p = 0.0081) than 
exponential phase TSB samples. No significant difference was observed between 
monomeric muropeptide abundance in stationary TSB PG or kidney PG (p = 0.8734). No 
significant differences could be found between the abundance of dimeric muropeptides, 
with no differences found between exponential and stationary phase TSB samples (p = 
0.9994), exponential phase TSB and kidney PG (p = 0.1580) or stationary phase TSB and 
kidney PG (p = 0. 1656). Significantly fewer highly crosslinked muropeptide species were 
found in stationary phase TSB PG than exponential phase PG (p = 0.0101). It was found 
that kidney PG contains significantly reduced levels of highly crosslinked muropeptides 
compared to exponential phase TSB material (p = 0.0002). No significant difference in 
oligomer abundance in kidney material and stationary phase TSB PG (p = 0.0691) was 
found. Also, no significant differences could be found between stationary phase TSB PG 







Figure 3.10 Analysis of muropeptide profiles of S. aureus NewHG kanR recovered from murine 
kidneys by RP-HPLC and MS 
(A) Representative muropeptide profile of NewHG kanR (SJF 3680) recovered from murine kidneys 72 hpi. 
Muropeptides have been labelled after being identified by MS, using muropeptide numbers from Table 
3.1. (B) Area of eluted identified UV-absorbing peaks, corresponding to different muropeptides, was 
quantified and is shown as a percentage of the total of all identified peaks grouped based on cross-linking 
(exponential phase TSB - black bars, stationary phase TSB – blue bars, n = 2 NewHG kanR recovered from 
murine kidney– red bars, n = 3, error bars represent the standard deviation of the mean). A two-way 
ANOVA with Sidak’s multiple comparison post-test was used to compare abundance of each muropeptide 




3.3.6 Production of Enterococcus faecalis peptidoglycan from a murine infection  
 
To determine the wider applicability of the approach, using the established protocols 
(Chapter 2.18.2), kidneys from 10 mice infected intravenously with E. faecalis (72 hpi) 
were harvested and the PG purified (Chapter 2.19). The sample was then digested 
(Chapter 2.14), reduced (Chapter 2.15) and analysed by RP-HPLC (Chapter 2.16). The 
gradient used to analyse E. faecalis PG was provided by Dr Stéphane Mesnage (personal 
communication) using standard HPLC buffers (Chapters 2.2.10.1, Chapter 2.16). To serve 
as a control, E. faecalis PG was purified from bacteria cultured in TSB to exponential 
phase (Figure 3.11B). Figure 3.11B shows the muropeptide trace produced from murine 
kidneys infected with E. faecalis. Although a low level of muropeptides (absorbance of 
less than 500 mAu) were recovered using this technique, it suggests that this 
methodology could be used to investigate the PG structure of other bacterial species 






Figure 3.11 Muropeptide profiles of E. faecalis recovered from TSB and murine kidneys by 
RP-HPLC 





3.3.7 Transmission electron microscopy (TEM) analysis of S. aureus from an infection 
 
To determine the morphology of in vivo S. aureus, TEM was used to visualise cells 
recovered from a murine kidney infection (Chapter 2.21). 
 
3.3.7.1 TEM images of exponential phase S. aureus cultured in TSB 
 
Three independent cultures of S. aureus NewHG kanR (SJF 3680) were grown using 
standard growth conditions (Chapter 2.6) to mid-exponential phase (OD600 ~0.6). 1 ml of 
each culture was centrifuged to harvest cells and fixed and stained as previously 
described (Chapter 2.21). Sections were then imaged, with representative images shown 
(Figures 3.12 and 3.13). Background staining seen in some of these images is caused by 








Figure 3.12 Low magnification TEM image of S. aureus NewHG in the exponential growth 
phase 
Thin section of chemically fixed S. aureus NewHG kanR (SJF 3680) cultured in TSB to exponential 





Figure 3.13 TEM images of S. aureus NewHG in the exponential growth phase 
Thin sections of chemically fixed S. aureus NewHG kanR (SJF 3680) cultured in TSB to exponential phase at 




3.3.7.2 TEM images of stationary phase S. aureus cultured in TSB 
 
Using standard growth conditions (Chapter 2.6), three independent cultures S. aureus 
NewHG kanR (SJF 3680) to stationary phase (8 hours after inoculation, OD600 9 – 10). 250 
μl of each sample was centrifuged to harvest cells, which were then fixed and stained 
(Chapter 2.21). Thin sections of each culture were then obtained, with representative 
images shown (Figures 3.14 and 3.15). White sections within cells are areas of low 
electron absorption caused by poor infiltration of the stain and did not impact upon 
image analysis.  
 
3.3.7.3 TEM images of uninfected murine kidney homogenate 
 
Uninfected murine kidney homogenate (1 ml) was centrifuged to harvest insoluble 
material. This material was fixed, stained and thin sections imaged (Chapter 2.21). These 
images (Figure 3.16) provide information on what the background stain looks like for 








Figure 3.14 Low magnification TEM image of S. aureus NewHG in the stationary growth 
phase 
Thin section of chemically fixed S. aureus NewHG kanR (SJF 3680) cultured in TSB to stationary 






Figure 3.15 TEM images of S. aureus NewHG in the stationary growth phase 
Thin sections of chemically fixed S. aureus NewHG kanR (SJF 3680) cultured in TSB to stationary phase 
at high magnification. Scale bars (black lines) represent 500nm. Scale bar (blue line) shows 500 nm. 






Figure 3.16 TEM images of homogenised uninfected murine kidney 





3.3.7.4 TEM images of S. aureus recovered from murine kidneys 
 
Mice were infected with 1 x 107 CFU NewHG kanR (SJF 3680). 72 hpi, mice were culled, 
and kidneys were collected, homogenised, and CFU determined (Chapter 2.18.2). After 
calculating CFU, 1 ml of kidney homogenate was centrifuged to harvest insoluble kidney 
material and S. aureus cells. Pellets were then fixed, stained, thin sectioned and imaged 
(Chapter 2.21), with representative images shown (Figures 3.17 and 3.18). The high level 
of background staining is consistent with that seen from uninfected murine kidneys 
(Figure 3.16). In all images of S. aureus isolated from kidneys, a complete or partial zone 
of low electron density can be seen, which is distinct from the surrounding kidney 
material (Figures 3.17 and 3.18). S. aureus cells were difficult to locate and image when 
isolated from kidneys, with generally only one being visible in a field of view (Figure 








Figure 3.17 TEM images of S. aureus NewHG recovered from murine kidneys 
Thin sections of chemically fixed S. aureus NewHG kanR (SJF 3680) recovered from murine kidney 
homogenate at low magnification. Scale bars (black lines) represent 500 nm. S. aureus cells were 





  Figure 3.18 TEM images of S. aureus NewHG recovered from murine kidneys 
Thin sections of chemically fixed S. aureus NewHG kanR (SJF 3680) recovered from murine kidney 





3.3.7.5 Analysis of TEM images of S. aureus  
 
All images collected for S. aureus NewHG kanR (SJF 3680) cultured to exponential phase 
in TSB, cultured to stationary phase in TSB or isolated from infected murine kidneys 
were analysed for morphological changes (Figure 3.19). As TEM images thin sections, no 
Z-axis is available. As such, it cannot be confirmed that cell volume is being measured 
from the centre of the cell. To counter this, S. aureus images were analysed for their cell 
area (Figure 3.19A). S. aureus cells grown to exponential phase have a significantly 
greater cell area than those cultured to stationary phase in TSB (p < 0.0001). S. aureus 
cells recovered from murine kidneys 72 hpi also show a significant reduction in area 
compared to exponential phase cells (p < 0.0001). Cells recovered from infected kidneys 
were also found to have a significantly smaller area than cells in stationary phase 
cultured in TSB (p = 0.0364). The cell wall of imaged cells was also measured (Figure 
3.19B). Exponential phase cells have a significantly thinner cell wall than that of 
stationary phase cells (p < 0.0001) and those recovered from kidneys (p < 0.0001). No 
significant difference between cell wall thickness of stationary phase cells or cells 
recovered from kidneys could be detected (p = 0.9611). Finally, the absence or presence 
of an incomplete or complete septum in S. aureus cells was counted and expressed as 
the percentage of all cells measured from that growth condition (Figure 3.19C). A 
significantly greater proportion of stationary phase cells have no septa when compared 
to exponential phase cells (p < 0.0001) and cells recovered from kidneys (p = 0.0001). No 
significant difference could be found between exponential phase cells and cells 
recovered from kidneys in the proportion of cells with no visible septa (p = 0.5429). S. 
aureus cells in exponential phase have a significantly greater proportion of cells 
possessing an incomplete septum than both stationary phase cells (p < 0.0001) and 
kidney derived cells (p = 0.0007). Stationary phase cells and kidney derived cells show no 
significant difference in the proportion of cells that have an incomplete septum (p = 
0.2617). Infected kidneys cells have a significantly greater proportion with a complete 
septum (with daughter cells remaining unseparated) than exponential phase cells (p = 
0.0057) and stationary phase cells (p = 0.0034). No significant difference could be found 
between the proportion of exponential and stationary phase cells that showed a 





Figure 3.19 Analysis of cell area, cell wall thickness and septa formation in NewHG recovered 
from murine kidneys 
TEM images (Figures 3.10 – 3.17) were analysed to determine the (A) cell area, (B) cell wall thickness and (C) presence 
of a septum in NewHG kanR (SJF 3680) in different growth conditions. (A) The cell area of NewHG kanR (SJF 3680) 
cultured in TSB to exponential phase (black lines, 3 independent repeats totalling 411 cells), in TSB to stationary phase 
(blue lines, 3 independent repeats totalling 320 cells) or recovered from murine kidneys 72 hpi (red lines, 2 
independent repeats totalling 180 cells). Results analysed using a one-way ANOVA with multiple comparisons (* p = 
0.0364, **** p < 0.0001). (B) Average cell wall thickness of NewHG kanR (SJF 3680) cultured in TSB to exponential 
phase (black lines, 3 independent repeats totalling 367 cells), in TSB to stationary phase (blue lines, 3 independent 
repeats totalling 256 cells) or recovered from murine kidneys 72 hpi (red lines, 2 independent repeats totalling 104 
cells). Results analysed using a one-way ANOVA with multiple comparisons (**** p < 0.0001). Box and whiskers for (A) 
and (B) represent mean, range and lower and upper quartiles. (C) Normalised percentage of NewHG kanR (SJF 3680) 
that show no septum, an incomplete or completed septa (exponential phase cultured in TSB – black bars, stationary 
phase cultured in TSB – blue bars, cells recovered from murine kidney homogenate – red bars). Normalised 
proportions were compared using a two-way ANOVA with multiple comparisons with Tukey’s correction (no septa *** 
p = 0.0001, **** p < 0.0001; incomplete septa *** p = 0.0007, **** p < 0.0001; complete septa ** p = 0.0034 and 






My work has determined the first peptidoglycan structure from bacteria grown within a 
host (in vivo). During an infection, S. aureus NewHG kanR (SJF 3680) has significantly 
reduced PG crosslinking than S. aureus cultured in TSB to exponential phase. 
Muropeptide profiles of S. aureus purified from infected kidneys 72 hpi resemble that of 
cells cultured in TSB to stationary phase in terms of crosslinking (Figure 3.10B). TEM 
analysis also shows that S. aureus recovered from murine kidneys 72 hpi have a smaller 
cell area than stationary and exponential phase cells (Figure 3.19A), as well as a thicker 
cell wall than exponential phase cells (Figure 3.19B). S. aureus also has an increased 
number of cells with a complete septum visible when analysed by TEM compared to 
exponential phase cells (Figure 3.19C) but show the same number of cells without a 
septum. These key findings are summarised overleaf (Table 3.2). 
 
Starvation of S. aureus in glucose depleted media for a period of 25 days at 21 °C is 
associated with a reduction in cell size compared to exponential phase cells (Watson et 
al., 1998), matching the results of S. aureus cells recovered from an infection (Chapter 
3.3.7.5). A proportion of glucose starved cells were also found to possess septa when 
observed by TEM, suggesting that the population is not static, and PG synthesis is 
occurring, albeit at a reduced rate (Watson et al., 1998). The results shown for S. aureus 
recovered from a murine infection (Figure 3.19C) also show incomplete and complete 
septa (with the daughter cells remaining attached). This suggests that the cells 
recovered from an infection are also in a state of starvation, and are not a static 
population, with PG synthesis and cell division occurring, but at a reduced rate. A 
reduction in PG crosslinking has also been described in stationary phase S. aureus cells 
when grown in a minimal media, which was hypothesised to be due to the depletion of 









Table 3.2 Summary of key results presented in Chapter 3 
The structure and morphology of NewHG kanR (SJF 3680) in different growth conditions as 
determined by RP-HPLC, MS and TEM analysis. * indicates a result significantly different from 




No other study has ever determined PG structure from bacteria during an infection. 
However, several studies have used conditions that mimic this complex environment. 
Staphylococcus epidermidis PG isolated from an in vitro biofilm show substitutions in the 
pentaglycine bridge, with glycine residues being substituted for serine or alanine 
residues, providing resistance to PG digestion by lysostaphin (Loza-Correa et al., 2019). 
An increase in O-acetylated N-acetylmuramic acid residues was also observed within 
biofilms, which is vital for resistance to lysozyme based degradation (Bera et al., 2006; 
Loza-Correa et al., 2019). Using my methodology (Chapter 2.13), the extent of O-
acetylation of muropeptides cannot be measured. This is due to the reduction of 
muropeptides occurring at a basic pH, as well as HF treatment, both of which remove O-
acetylation from the cell wall. S. epidermidis PG recovered from biofilms cultured in 
platelet concentrates showed a reduced muropeptide species diversity compared to 
cells grown in TSB (Loza-Correa et al., 2019). This reduced diversity mirrors my results 
(Chapter 3.3.5), suggesting that PG from S. aureus has reduced complexity and 
crosslinking during an infection. It has been hypothesised that in S. epidermidis PG 
synthesis is reduced, creating a less complex PG structure. This allows energy to be used 
in other processes, allowing proliferation of bacteria in a harsh, restrictive environment 
(Loza-Correa et al., 2019).  
 
Listeria monocytogenes is an intracellular pathogen that encounters a variety of 
environments during its lifecycle (Quereda et al., 2016). Once within a host cell, the PG 
structure and proteins associated with the cell wall (including the way they are 
associated to the PG) are modified, facilitating an intracellular lifecycle (Portillo and 
Pucciarelli, 2012). In a mouse model of infection, L. monocytogenes up regulates two 
major virulence regulators, PrfA and VirR, which have effects such as remodelling the 
cell wall surface and release of muropeptides (Camejo et al., 2009). For example, VirR 
upregulates the expression of dlt, which reduces the overall negative charge on WTA 
and LTA, increasing resistance to cationic antimicrobial peptides. PrfA has been shown 
to upregulate inlA and inlB, both essential for entry into host cells to initiate the 




sugar transporter which facilitates rapid proliferation of L. monocytogenes when 
intracellular (Chico-Calero et al., 2002).  
  
Salmonella enterica can colonise the gut and gall bladder due to its bile resistance, which 
is in part due to changes in the PG structure (Hernández et al., 2015). When the bile salt 
sodium deoxycholate is introduced to a S. enterica culture there is a reduction in the 
number of muropeptides bound to Braun’s lipoprotein and a reduction in the number of 
L(meso)-diaminopimelyl-D(meso)-diaminopimelic acid peptide bridges, increasing 
resistance to bile salts (Hernández et al., 2015). S. enterica serovar Typhimurium has the 
capacity for intracellular survival and has been found to remodel PG using the enzyme 
EcgA, which becomes activated in the nutrient limited environment inside eukaryotic 
cells (Rico-Pérez et al., 2016). EcgA is a D, L-endopeptidase that cleaves the γ-D-glutamyl-
meso-diaminopimelic acid bond in the stem peptide of non-crosslinked muropeptides. It 
has been hypothesised that this cleavage is also used to avoid recognition of muramyl 
peptides by the NOD1 receptor, preventing an immune response, allowing persistence 
and systemic infection in mice (Rico-Pérez et al., 2016). Also when S. enterica serovar 
Typhimurium is cultured within human epithelial cells its PG contains unique 
muropeptides, a reduction in glycine containing muropeptides and a decrease in 
crosslinking (Quintela et al., 1997). 
 
The PG of S. aureus is known to be influenced by nutrient availability during growth. As 
cells reach stationary phase glycine depletes as it is used for protein and cell wall 
production. This results in a thickening of the cell wall and the production of irregular 
septa with an increased number of non-crosslinked pentaglycine side chains (Zhou and 
Cegelski, 2012). These changes occur in the newly synthesised PG rather than a 
modification to existing PG (Zhou and Cegelski, 2012). In a S. aureus biofilm, non-
crosslinked pentaglycine bridges are used as attachment sites for proteins which is not 
seen in planktonic culture (Kim et al., 2018). Many surface proteins are required in 
abscess formation (Cheng et al., 2009, 2011), which are bound to the terminal glycine in 




reduction in crosslinking in PG recovered from infected kidneys (Figure 3.10B) could be 
due to the glycine bridges being used to anchor proteins required for abscess formation, 
permitting survival and pathogenesis in the host, rather than crosslinking PG.  
 
A decrease in crosslinking can also be explained by the substitution of D-Ala for glycine in 
the terminal position of the peptide stem. This was observed in cells cultured with 
exogenous glycine, which is associated with a decrease in methicillin resistance, 
demonstrating the effect on nutritional status on PG structure (de Jonge et al., 1996) 
(Figure 3.8C). However, no muropeptides peak with stem peptides terminating with a 
glycine residue were detected in S. aureus recovered from murine kidneys (Appendix 2 
Table 6). Alterations in crosslinking in response to environmental and nutritional factors 
is carried out by S. aureus components. PBP4 is known to result in a high level of 
crosslinked PG in S. aureus (Wyke et al., 1981a). If the expression of pbp4 (encoding 
PBP4) is downregulated, it would be expected that the PG would show a reduction in 
crosslinking, as observed in kidney derived cells (Figure 3.10B). This leads to the 
hypothesis that PG synthases, such as PBP4, could play a role in S. aureus pathogenesis.  
 
S. aureus recovered from murine kidneys shows reduced cell area, increased cell wall 
thickness and an increase in complete septa while remaining unseparated (Table 3.2). 
The separation of daughter cells, and therefore the resolution of complete septa, 
requires PG hydrolases such as Atl (Oshida et al., 1995). An increased number of 
observed cells with complete septa, but daughter cells remaining joined, could suggest a 
downregulation of hydrolases, potentially due to a lack of nutrients, resulting in reduced 
division. PG hydrolases modify PG allowing cellular enlargement (Wheeler et al., 2015). 
If hydrolases are downregulated in later stages of infection, the reduced cell area could 
therefore be explained by a more rigid cell wall, a result of reduced hydrolysis, 
potentially resulting in a reduction in the cell’s ability to increase in volume. As 
previously described (Chapter 1.4.4), the WalKR two-component system upregulates the 
expression of PG hydrolases such as Atl. WalKR is inactive during stationary phase 




activity. A lack of hydrolytic PG processing would also explain an increased cell wall 
thickness, as less PG is cleaved from the cell wall. It has been shown that the host can 
influence that transcriptional profile of S. aureus during an infection (Thänert et al., 
2017). Some strains of mice, such as BALB/c and A/J, have been shown to be highly 
susceptible to S. aureus, whereas C57BL/6 are highly resistant to such infection (von 
Köckritz-Blickwede et al., 2008), and these differences in resistance influence the 
bacterial transcription of genes (Thänert et al., 2017). During infection in the resistant 
C57BL/6, S. aureus was shown to upregulate the expression of the hydrolase lytM 
compared to infection in the S. aureus susceptible A/J mouse strain (Thänert et al., 
2017). In S. aureus susceptible A/J mice, no change in PG hydrolase transcription was 
reported compared to C57BL/6 mice (Thänert et al., 2017). While this suggests that 
there may be no change in transcription of PG hydrolases during infection of S. aureus 
susceptible BALB/c mice, transcription of genes does not always correlate linearly to 
translation to a function protein product. These observations lead to the hypothesis that 






Chapter 4  





Peptidoglycan hydrolases cleave bonds in the bacterial peptidoglycan sacculus, allowing; 
the regulation of cell growth, the separation of cells during division and the expansion of 
the cell wall, amongst other roles (Vollmer et al., 2008b). The turnover of peptidoglycan 
due to hydrolysis also releases muropeptides into the bacteria’s environment. These 
soluble muropeptides can be detected by the host immune system by proteins such as 
nucleotide binding and oligomerization domain proteins (NODs) and NOD-like receptors 
(NLRs) (Martinon and Tschopp, 2005). NOD2 recognises the MurNAc-D-Ala-D-Glu unit 
released from the peptidoglycan, present in Gram-positive bacteria such as S. aureus, 
resulting in the activation of signalling cascades activating the nuclear factor-κB (NF-κB) 
response. NF-κB causes the upregulation of inflammatory responses, and therefore host 
antimicrobial activity (Irazoki et al., 2019). It has also been shown that insoluble 
peptidoglycan, in the form of purified sacculi, can augment an S. aureus infection in a 
murine model of infection (Boldock et al., 2018). This insoluble peptidoglycan could 
potentially be cleaved by the action of peptidoglycan hydrolases and contribute to 
virulence. The turnover products produced by peptidoglycan hydrolases can therefore 
interact with the host, and play a role in host-pathogen interactions, specifically within 
pathogenesis, so warrant investigation. 
 
Peptidoglycan glucosaminidases have been discussed previously (Chapter 1.4.3.2). The 
genomes of SH1000 and NewHG contain four putative glucosaminidases which were 
identified using the well characterised Atl glucosaminidase domain as a BLAST template. 
Four bacterial chromosome encoded glucosaminidases were identified: atl, sagA, sagB 
and scaH. The genes lytP2 and lytP4 were also identified (Chan et al., 2016b), and both 




respectively (Bae et al., 2006). Bacteriophages are not present, or are differentially 
present, in the genomes of all strains (Horsburgh et al., 2002), and so to understand the 
role of the glucosaminidases, the core genome encoded enzymes are key. 
 
S. aureus causes a wide range of pathologies using a diversity of virulence factors 
(Chapter 1.7.2). Study of the requirements for S. aureus pathogenesis may reveal new 
potential therapeutic targets that will help to combat infections, which is especially 
relevant in the ever-approaching post-antibiotic era. Due to the medical importance of 
S. aureus as a pathogen, it is common for genetic screens to be used to rapidly detect 
genes important for pathogenesis. This can be done by using transposon mutagenesis to 
produce strains with different single gene knockouts that can be studied in a high 
throughput way (Fey et al., 2013). Transposon mutagenesis studies have not yet 
reported a role for glucosaminidases in infection (Coulter et al., 1998; Bae et al., 2004; 
Valentino et al., 2014; Wang et al., 2015). However, other putative peptidoglycan 
hydrolases have been implicated (Coulter et al., 1998). As well as these studies, targeted 
studies have been used to directly observe the importance of specific proteins in 
virulence. The loss of Sle1 activity, a N-acetylmuramyl-L-alanine amidase, results in cell 
clustering and attenuation in a murine model of infection (Kajimura et al., 2005). 
Conversely, the loss of Atl does not impact virulence in a murine device-related infection 
model (McCarthy et al., 2016). A major limitation of these studies, however, is the high 
degree of redundancy seen with PG hydrolases, meaning that the inactivation of one 
hydrolase may not result in a phenotype, as other hydrolases compensate for its activity. 
Other S. aureus PG metabolism components are known to contribute to virulence (Reed 
et al., 2015), suggesting that PG homeostasis, by the action of synthases and hydrolases, 
could be important for virulence. It  
 
As previously discussed (Chapter 1.8), there are a wide range of animal models available 
to study S. aureus infections. Each model has a set of advantages and disadvantages, and 
by using models in combination more meaningful results can be obtained. For example, 




screen of strains, which can then be confirmed in a more immunologically relevant 
murine model. Zebrafish are bred and maintained very easily, with a pair being able to 
produce 100-200 eggs per mating (Prajsnar et al., 2008). Zebrafish possess TLRs that 
have a high homology to those of humans (Jault et al., 2004), as well as having 
circulating macrophages by 25 hpf (Herbomel et al., 1999), and neutrophils by 30 hpf 
(Prajsnar et al., 2008). In this model, 1500 CFU of S. aureus are injected into the 
zebrafish circulation valley, a dose which does not override the fish’s immune system 
and results in approximately 50 % host mortality (McVicker et al., 2014). The injected 
inoculum is phagocytosed by macrophages and neutrophils, from which a small subset 
of S. aureus escape, founding a lesion that leads to fish death (McVicker et al., 2014; 
Pollitt et al., 2018). Likely a single bacterium founds the lesion, meaning that the 
macrophages and neutrophils act as an immunological bottleneck, resulting in clonal 
expansion during infection (McVicker et al., 2014; Pollitt et al., 2018). 
 
The well-established murine sepsis model of infection was also chosen in this study to 
analyse the virulence of S. aureus strains. This model has been highly studied, and the 
dynamics of the infection are well understood (Pollitt et al., 2018) (Figure 4.1). Around 1 
x 107 CFU of S. aureus are injected intravenously into the blood stream of the mice. The 
majority of the free bacteria are phagocytosed by host macrophages within the liver, 
with a small minority taken up by neutrophils (Pollitt et al., 2018). There are two 
possible outcomes once within a phagocyte: the bacteria can be contained, potentially 
killed and the infection is eventually cleared, or the bacteria can overwhelm the 
phagocyte and escape into the surrounding environment (Pollitt et al., 2018). Even if 
bacteria escape the phagocyte, many are then phagocytosed by another immune cell, 
with only a small proportion escaping this cycle. Free bacteria can potentially form 
micro-abscesses within the liver, with each micro-abscess being founded by a single 
bacterium, resulting in clonal expansion (Pollitt et al., 2018). The free bacteria, and those 
within the micro-abscesses, are in a constant dynamic with phagocytes, and can be 
further phagocytosed, resulting in their clearance or subsequent escape. The 
phagocytosis of these bacteria has also been linked to the dissemination of the bacteria 




populations of bacteria can form abscesses (Pollitt et al., 2018). The CFUs recovered 
from the kidney abscesses, and to a lesser extent the liver, are a major output of the 








Figure 4.1 Schematic of S. aureus infection dynamics in the murine sepsis model of 
infection 
An intravenous infection releases free bacteria into the blood stream, which can be 
phagocytosed by host neutrophils and macrophages. Most bacteria are taken up by the 
resident macrophages of the liver; the Kupffer cells. Whatever the phagocyte that captures 
the S. aureus, the bacteria are either killed and cleared from the host, or the bacteria can 
escape the phagocyte, becoming free bacteria again. After escaping, bacteria can seed the 
formation of micro-abscesses from which bacteria can be further phagocytosed. It is 
proposed that neutrophils can facilitate the dissemination of bacteria to other sites in the 
body, including kidneys, where S. aureus can establish abscesses, a major output of the 
murine sepsis model of infection. The thickness of the arrows represents the proportion of 




4.2 Aims of this chapter 
 
The aim of this chapter was to characterise the role of the glucosaminidases of S. aureus 
in infection. Using in vivo models, the role the glucosaminidases play in virulence will be 
established. The specific aims of this chapter were to: 
 
i. Investigate the impact of the S. aureus glucosaminidases on virulence 






4.3.1 Role of the glucosaminidases (SagB, Atl, SagA and ScaH) in growth 
 
Previous, preliminary studies have shown that a sagB mutant in the SH1000 (Wheeler et 
al., 2015) and Newman (Chan et al., 2016b) genetic backgrounds have a growth defect in 
liquid medium (BHI and TSB respectively).  
 
Using the S. aureus SH1000 genetic background (Wheeler et al., 2015) every single, 
double and triple mutant lacking an active sagB gene in combination with atl, sagA and 
scaH was tested for growth in liquid TSB (Figure 4.2). As expected, SH1000 sagB (SJF 
4608, doubling time 37 min) shows a defect when compared to the wild type SH1000 
(SJF 682, doubling time 31 min), taking a longer time to reach a similar OD600 over the 
eight-hour period (Figure 4.2A). The double mutants SH1000 atl sagB (SJF 4972, Figure 
4.2B, doubling time 41 min) and SH1000 sagA sagB (SJF 4974, doubling time 38 min) and 
SH1000 sagB scaH (SJF 4973, Figure 4.2C, doubling time 36 min) all showing a similar 
growth defect to the single mutant SH1000 sagB compared to parental SH1000. Triple 
mutants containing an inactive sagB gene; SH1000 atl sagA sagB (SJF 4610, doubling 
time 47 min), SH1000 sagA sagB scaH (SJF 4612, doubling time 51 min) and SH1000 atl 
sagB scaH (SJF 4613, doubling time 48 min) show a slower rate of growth, but still reach 








Figure 4.2 Role of glucosaminidases in growth of S. aureus SH1000 
Strains were grown in TSB at 37 °C with shaking and OD600 was measured. Growth of SH1000 (SJF 682, black 
circles) in TSB compared to (A) SH1000 sagB (SJF 4608, red squares), (B) SH1000 atl sagB (SJF 4972, red 
squares), (C) SH1000 sagA sagB (SJF 4974, red squares) and SH1000 sagB scaH (SJF 4973, blue triangles) or 
(D) SH1000 atl sagA sagB (SJF 4610, red squares), SH1000 sagA sagB scaH (SJF 4612, blue triangles) and 
SH1000 atl sagB scaH (SJF 4613, green diamonds). Bacterial cultures were prepared in triplicate and error 




4.3.2 Role of glucosaminidases in S. aureus virulence in the zebrafish model 
 
Zebrafish embryos at 30 hpf were injected into the circulation valley with 1500 CFU of 
bacteria in a volume of 1 nl (Prajsnar et al., 2008). SH1000 sagB was found to be 
significantly attenuated (p < 0.0001) compared to the wildtype SH1000 (SJF 682) (Figure 
4.3A). SH1000 atl sagB (SJF 4972, p < 0.0001), SH1000 sagA sagB (SJF 4974, p < 0.0001) 
and SH1000 sagB scaH (SJF 4973, p < 0.0001) were also found to be significantly 
attenuated when compared to the wildtype (Figure 4.3B). SH1000 atl sagB caused no 
mortality when injected at a dose of 1500 CFU, whereas SH1000 sagA sagB had a 
survival rate of 88% and SH1000 sagB scaH a survival rate of 85%. Finally, triple 
glucosaminidase mutants with an inactive sagB gene were analysed using the model. 
SH1000 atl sagA sagB (SJF 4610), SH1000 sagA sagB scaH (SJF 4612) and SH1000 atl 
sagB scaH (SJF 4613) were all significantly attenuated when compared to the wild type 
SH1000 (Figure 4.3C). The data in Figure 4.3 shows that a lack of a functional sagB gene 






Figure 4.3 Role of the glucosaminidases in S. aureus virulence in the zebrafish infection model 
(A) Survival curves showing the attenuation of SH1000 sagB (SJF 4608, red line) compared to parental SH1000 
(SJF 682, black lines) (3 repeats, n>20, **** p < 0.0001). (B) Survival curves demonstrating that SH1000 atl sagB 
(SJF 4972, yellow line), SH1000 sagA sagB (SJF 4974, blue line) and SH1000 sagB scaH (SJF 4973, red line) are all 
attenuated compared to the parental SH1000 (SJF 682, black lines) (2 repeats, n>20, **** p < 0.0001). (C) 
Survival curves showing the attenuation of SH1000 atl sagA sagB (SJF 4610, red line), SH1000 sagA sagB scaH 
(SJF 4612, blue line) and SH1000 atl sagB scaH (SJF 4613, green line) are all attenuated compared to the 
parental SH1000 (SJF 682, black lines) (2 repeats, n>20,**** p < 0.0001). There is no significant difference 
between SH1000 atl sagA sagB and SH1000 atl sagB scaH, but both are significantly more attenuated than 




4.3.3 Growth of SH1000 sagB in vivo  
 
The observed virulence attenuation could be attributed to an inability of SH1000 sagB 
(SJF 4608) to grow in vivo. To test this the zebrafish embryo model, as described in 
Chapter 2.18.1.7 (McVicker et al., 2014), was used. At specified time points after 
inoculation, five infected living zebrafish embryos (and all dead embryos) were collected 
and homogenised, after which they were plated out to determine bacterial CFU. When 
wildtype SH1000 (SJF 682) is injected into zebrafish embryos (1500 CFU) bacterial CFU 
either remain similar to the injected CFU, or increase associated with host death (104 – 
105 CFU) (Figure 4.4A). In contrast, embryos injected with the same dose of SH1000 sagB 
(SJF 4608) show a decrease in the number of CFU over time, with some embryos 
containing bacterial numbers below the limit of detection (10 CFU/embryo), suggesting 
bacterial clearance (Figure 4.4B). SH1000 was observed to cause mortality in 23 % of 





Figure 4.4 Growth of a S. aureus sagB strain within the zebrafish infection model 
Bacterial CFU were recovered from zebrafish embryos infected with (A) SH1000 (SJF 682) or (B) 
SH1000 sagB (SJF 4608) (n= 50-60) at times shown. Open black circles are live embryos and red 




4.3.4 Construction of a S. aureus NewHG sagB strain 
 
It is important to verify the attenuation of a sagB mutation in another S. aureus genomic 
background, to ensure that the phenotype is not specific to SH1000. The NewHG 
background is derived from the clinical isolate Newman, isolated in 1952 (Duthie and 
Lorenz, 1952). For murine studies of S. aureus infection, Newman is commonly used as 
the genomic background for studying virulence. However, a single nucleotide change in 
the saeS gene (a global virulence regulator) results in a higher level of toxin expression 
than that of other S. aureus strains (Mainiero et al., 2010). The saeS gene of NewHG has 
been repaired, resulting in toxin gene expression equivalent to levels in other S. aureus 
strains. 
 
The sagB mutation was transduced into the NewHG parental background (SJF 3663) 
using bacteriophage ϕ11 to produce NewHG sagB (SJF 4912). This was confirmed using 
PCR, where amplification of the sagB gene produced the expected mutant band in the 
transduced strain (Figure 4.5A; Wheeler et al., 2015). 
 
4.3.5 Virulence of NewHG sagB in the zebrafish embryo model of infection 
4.3.5.1 NewHG sagB virulence phenotype 
 
The NewHG sagB strain (SJF 4912) was investigated for its virulence in the zebrafish 
model of infection compared to the parental strain (SJF 3663). NewHG sagB was 
significantly attenuated (70% survival, p = 0.0043) compared to the same dose (1500 
CFU) wildtype (46% survival) (Figure 4.5B). This confirms that the sagB mutant virulence 





4.3.5.2 NewHG sagB in vivo growth kinetics 
 
The in vivo growth kinetics of NewHG sagB were also studied using the zebrafish 
infection model. The CFU recovered from embryos infected with parental NewHG were 
found to be equal to those of the starting inoculum (103 CFU) or higher (up to 106 CFU), 
showing the growth of NewHG within the embryo. Dead embryos infected with NewHG 
had ~1 x 103-6 recovered CFU, demonstrating that bacteria multiplied within the embryo 
(Figure 4.5C). However, as some fish were found dead containing ~103 CFU, this would 
imply that low numbers of bacteria (the same as the starting inoculum) can cause 
mortality in the zebrafish embryo. NewHG sagB infected fish also showed a 
maintenance or increase in recovered CFU over time, suggesting that NewHG sagB can 
grow in the zebrafish host (Figure 4.5D). Embryos infected with NewHG sagB can also 
clear infection, which was not seen in embryos infected with parental NewHG (Figure 
4.5C and D, limit of detection 10 CFU/embryo), indicating that NewHG sagB has a 
growth defect in vivo in this model. Dead embryos infected with NewHG sagB have CFU 





  Figure 4.5 The role of SagB in virulence in the S. aureus NewHG background in the zebrafish model of 
infection 
(A) 1% (w/v) TAE agarose gel showing PCR amplification of the sagB gene from wildtype NewHG (lane 2), positive 
control SH1000 sagB (lane 3) and NewHG sagB (SJF4912) (lane 4) using primers psagB_F (forwards) and psagB_R 
(reverse). The wildtype band of 761 bp can be seen in lane 2. The expected mutant band of 1700 bp, shown in 
lane 3 and indicated with a black arrow, is also seen in lane 4. Relevant sizes of DNA ladder (GeneRuler 1 kb DNA 
ladder, Thermo Scientific) are shown in kb (lane 1). (B) Survival curves showing the attenuation of NewHG sagB 
(SJF 4912, red line) compared to parental NewHG (SJF 3663, black lines) (2 repeats, n>20, ** p = 0.0043). (C, D) 
Bacterial CFU were recovered from zebrafish embryos infected with approximately 1500 CFU (C) NewHG (SJF 
3663) or (D) NewHG sagB (SJF 4912) (n= 70-85) at times shown. Open black circles are live embryos and red 




4.3.6 Analysis of sagB virulence in murine models of infection 
4.3.6.1 The murine sepsis model of infection 
 
The well-established mouse sepsis model of infection was used (Chapter 2.18.2) to 
investigate NewHG sagB (SJF 4912) (Jonsson et al., 2004; Kim et al., 2014; Pollitt et al., 
2018). In murine experiments, NewHG kanR (SJF 3680) was used as the parental type S. 
aureus strain. NewHG (SJF 3663) and NewHG kanR have been shown to have the same 
virulence in both the zebrafish embryo model and murine sepsis models of infection 
(McVicker et al., 2014), so can be used interchangeably and NewHG kanR can be selected 
for using kanamycin from organ homogenates.  
 
To investigate the virulence of sagB in the murine sepsis model of infection, groups of 10 
mice were injected with 1 x 107 CFU of NewHG kanR or NewHG sagB (Figure 4.6). Weight 
loss after infection is a measure of general sickness. Mice infected with NewHG sagB (SJF 
4912) show significantly reduced weight loss that those infected with NewHG kanR, with 
most mice infected with NewHG sagB maintaining their weight over the 72-hour 
infection period (Figure 4.6A, p = 0.0005). Significantly fewer S. aureus were recovered 
from the livers (p = 0.0178) and kidneys (p = 0.0178) of mice infected with NewHG sagB 







Figure 4.6 The role of SagB in virulence in the murine sepsis model of infection 
Approximately 1 x 10
7 
CFU of S. aureus NewHG kan
R
 (SJF 3680) or NewHG sagB (SJF 4912) were injected 
intravenously into mice (n=10). Weight loss 72 hpi (A, *** p = 0.0005), liver CFU (B, * p = 0.0178) and 
kidney CFU (C, * p = 0.0368). Groups were compared using a Mann-Whitney U test (NewHG kan
R
 – black 




4.3.6.2 Augmentation of sagB in the murine sepsis model of infection 
 
Augmentation in S. aureus infection has been described in detail in chapter 1.7.4. Briefly, 
insoluble purified peptidoglycan co-injected with S. aureus enhances pathogenicity 
(Boldock et al., 2018). In the mouse sepsis model of infection, augmentation depends on 
co-internalisation of both the bacteria and the peptidoglycan by the resident 
macrophages of the liver, Kupffer cells (Boldock et al., 2018). Augmentation with 
peptidoglycan was shown to reduce the reactive oxygen species burst and acidification 
of S. aureus containing phagolysosomes in Kupffer cells. The addition of peptidoglycan in 
infection allows S. aureus to survive more within macrophages, and therefore more S. 
aureus can seed abscesses, and worsen infection (Boldock et al., 2018). Augmentation 
results in a large CFU of S. aureus within the livers of mice. 
 
NewHG kanR (SJF 3680) or NewHG sagB (SJF 4912), at a low dose (around 1 x 106 CFU) 
were injected intravenously either with or without 250 µg of purified PGN (NewHG kanR, 
SJF 3680). When injected with low dose NewHG kanR or NewHG sagB alone, mice either 
maintained or gained weight over the infection period. When NewHG kanR was co-
injected with peptidoglycan, mice lost significantly more weight than mice receiving 
NewHG kanR alone (p = 0.0079). Mice infected with NewHG sagB and peptidoglycan also 
lose significantly more weight than those mice infected with NewHG sagB alone (Figure 
4.7A, p = 0.0159). The positive control of NewHG kanR shows a significant increase of 
CFU in the livers of mice when peptidoglycan is co-injected with NewHG kanR (p = 
0.0079), demonstrating augmentation has occurred (Figure 4.7B). NewHG sagB, 
however, does not appear to be augmented when co-injected with peptidoglycan, as 
there is no significant increase in CFU recovered from the livers, although the median is 
higher (Figure 4.7B, p = 0.0952). While there are no significant differences in the kidneys 
between low dose bacteria and co-injection groups (Figure 4.7C), there is a clear trend 
for higher CFU recovered from mice infected with NewHG kanR with peptidoglycan than 
NewHG kanR alone, whereas for NewHG sagB this trend is less apparent. There were no 
significant differences found between the bacteria only and co-injection groups in the 




The results of this experiment suggest that NewHG sagB cannot be augmented using 
NewHG kanR purified peptidoglycan, as there are no significant differences in CFU 










 CFU S. aureus NewHG kan
R
 (WT, SJF 3680) or NewHG sagB (SJF 4912) with or without 
250 μg WT S. aureus PGN was injected intravenously into mice (n=5). Weight loss 72 hpi (A) and CFUs 
recovered from livers (B), kidneys (C) and spleen (D) were recorded to determine if the sagB mutant could be 
augmented. Groups were compared using Mann-Whitney U tests (NewHG kan
R
 – black circles, NewHG sagB- 





4.3.6.3 Augmentation using purified peptidoglycan from NewHG sagB 
 
As NewHG sagB (SJF 4912) cannot be augmented by wildtype NewHG (SJF 3663) 
peptidoglycan, it was investigated if purified NewHG sagB peptidoglycan can augment a 
NewHG infection.  
 
To investigate if sagB peptidoglycan could augment a wild type infection in the murine 
model, mice were injected with either: low-dose (1 x 106 CFU) NewHG kanR, low-dose 
NewHG kanR with 250 µg NewHG peptidoglycan or low-dose NewHG kanR with 250 µg 
NewHG sagB peptidoglycan. Mice co-injected with low-dose NewHG kanR and NewHG 
sagB peptidoglycan show a significant weight loss than mice injected with NewHG kanR 
alone (Figure 4.8A, p = 0.0029). The bacterial CFU recovered from the livers of mice co-
infected with low-dose NewHG kanR with 250 µg NewHG peptidoglycan or infected with 
low-dose NewHG kanR and 250 µg NewHG sagB peptidoglycan where both significantly 
higher than those infected with low-dose NewHG kanR alone (Figure 4.8B, p = 0.0079). 
From the numbers of bacteria recovered from the kidneys, it is clear there is a trend for 
more bacteria being recovered from mice receiving NewHG kanR with NewHG 
peptidoglycan than NewHG kanR alone, despite the lack of significance (p = 0.1667). Co-
injecting with NewHG sagB peptidoglycan significantly increases the number of bacteria 
recovered from the kidney, further confirming that augmentation has occurred using 
sagB mutant peptidoglycan (Figure 4.8C, p = 0.0317). No significant differences in CFU 
could be found in the spleens, lungs or hearts of any group (Figure 4.8D, E and F 
respectively). The conclusion from this experiment is that sagB peptidoglycan can be 





Figure 4.8 Augmentation of S. aureus NewHG using peptidoglycan from wildtype and sagB S. aureus 
strains 
Mice (n=5) were injected with approximately 1x10
6
 CFU S. aureus NewHG kan
R
 (WT, SJF 3680) alone, or with 
250 µg NewHG kan
R
 PGN or 250 µg NewHG sagB PGN. Weight loss 72 hpi (A, p= 0.0029) and CFUs recovered 
from livers (B, p = 0.0079), kidneys (C), spleen (D), lungs (E) and heart (F) were determined. Groups were 
compared using a Mann-Whitney U test (NewHG kan
R
 only – black circles, NewHG kan
R
 with wild type PGN - 
blue squares and NewHG kan
R




4.3.7 S. aureus sagB survival in human macrophages 
 
While murine models share similarities to human infection the differences between the 
systems means that results may not translate through to be relevant in a clinical setting 
(Jonsson et al., 2004). Research has shown that during the mouse sepsis model of 
infection, bacteria move through the blood to the liver, where they are phagocytosed by 
the resident macrophages Kupffer cells (Pollitt et al., 2018). As macrophages may play a 
role in the attenuation of sagB, and to ensure that the attenuation results translate to a 
clinically relevant model, the ability of NewHG sagB (SJF 4912) to survive in human 
macrophages compared to NewHG kanR (SJF 3680) was investigated using monocyte 
derived macrophages (MDMs) (chapter 2.20.1). 
 
Approximately 2 x 105 MDMs were infected with either NewHG kanR (SJF 3680) or 
NewHG sagB (SJF 4912) at a multiplicity of infection (MOI) of 5 for a period of 4 hours. 
Extracellular bacteria were removed by gentamycin, and MDMs were lysed at specified 
time points to determine intracellular CFU (Boldock et al., 2018). When NewHG kanR is 
used to infect MDMs, a significant (~10 fold) drop in intracellular CFU was seen in the 
first 30 min after gentamycin treatment (Figure 4.9). After this, the number of 
intracellular CFU remains roughly stable (5 – 6.5 hpi). This could be due to MDMs being 
unable to kill anymore bacterial cells, or because the remaining S. aureus are able to 
withstand killing by MDMs. Intracellular numbers of NewHG sagB recovered also show 
roughly a 10-fold drop in the first 30 min after gentamycin treatment. However, at time 
points past 5 hpi, the intracellular recovered CFU continue to drop, suggesting killing of 
NewHG sagB by the MDMs (Figure 4.9). The intracellular NewHG sagB CFU recovered 5 
(p = 0.0250), 5.5 (p = 0.0075) and 6 hpi (p = 0.0003) are all significantly lower than those 
recovered for NewHG kanR, demonstrating NewHG sagB is less able to survive within 







Figure 4.9 The role of SagB in intracellular killing of S. aureus by human MDMs  
 
MDMs were incubated with S. aureus NewHG kan
R
 (SJF 3680, black circles) or NewHG sagB (SJF 
4912) at a MOI of 5 (1 x 10
6 
CFU) for 4 hours before being treated with gentamycin for 0.5 hours to 
kill extracellular bacteria. MDMs were lysed at specific time points and intracellular bacterial 
numbers were determined. A two-way ANOVA with Tukey’s multiple comparison post-test was used 
to compare the first two time points for each strain, while paired two-tailed t-tests were used to 
compare between the strain CFU at subsequent time points. (* p = 0.0250, ** p = 0.0075, *** p = 




4.3.8 The interrelationship between SagB and macrophages within infection models 
 
The sagB mutant is less able to survive within human MDMs. If SagB has an important 
role in macrophage interaction, then depletion of these phagocytes may restore 
virulence of the sagB mutant. This can be achieved by injecting animal hosts with 
liposomes containing clodronate before infection with S. aureus. Clodronate itself is 
non-toxic, as are liposomes (Rooijen and Sanders, 1994). However when delivered in 
liposomes, which are selectively taken up by macrophages, clodronate accumulates 
within the macrophages, resulting in their death and depletion (Rooijen and Sanders, 
1994). 
 
4.3.8.1 Role of macrophages in the zebrafish embryo model of infection 
 
Macrophages can be depleted from the zebrafish model using the methods in chapters 
2.18.3 and 2.18.1.5. The injection of clodronate liposomes into the circulation valley of 
zebrafish embryos 24 hpf depletes the macrophages without killing the zebrafish 
embryo (Shwartz et al., 2019).  
 
At 24 hpf, zebrafish embryos were injected with either clodronate containing liposomes 
or liposomes only containing PBS (control liposomes). At 30 hpf, both groups were 
injected with either 150 CFU SH1000 (SJF 682) or SH1000 sagB (SJF 4608) (Figure 4.10). A 
low dose of bacteria (150 CFU) was used as it has been previously shown that removal of 
macrophages renders the host more pathogen susceptible (Prajsnar et al., 2020). 
Embryos injected with control liposomes show a significant difference in survival 
between those injected with 150 CFU of SH1000 or SH1000 sagB, showing that at this 
dose a sagB mutant is also attenuated (p = 0.0254). Embryos that had been treated with 
clodronate liposomes, to deplete macrophages, saw no significant difference in survival 
in embryos injected with either SH1000 or SH1000 sagB (Figure 4.10, p = 0.2733). 
Embryos injected with clodronate liposomes show significantly higher mortality than 




(p < 0.0001). Without macrophages in the infection model, SH1000 sagB, which is 
otherwise attenuated, has a virulence equivalent to the wildtype SH1000. This suggests 
that in the zebrafish model of infection, macrophage interaction is the cause for the 





Figure 4.10 The role of macrophages in the attenuation of S. aureus sagB in the zebrafish 
infection model 
 
At around 24 hpf, zebrafish embryos were injected with either empty liposomes or clodronate 
containing liposomes. At 30 hpf, around 150 CFU of SH1000 (SJF 682) or SH1000 sagB (SJF 4608) 
were injected. (Black lines – SH1000, red lines – SH1000 sagB, solid lines – empty liposome, broken 






















4.3.8.2 Role of macrophages in the murine sepsis model 
 
The methods used to deplete macrophages are described in Chapters 2.18.2 and 2.18.3. 
Clodronate containing liposomes are injected into the tail vein of mice 24 hours before 
S. aureus infection (Verdrengh and Tarkowski, 2000; Boldock et al., 2018; Pollitt et al., 
2018).  
 
Mice were injected with either clodronate or control liposomes 24 hours before being 
injected intravenously with 1 x 105 CFU NewHG kanR (SJF 3680) or NewHG sagB (SJF 
4912) (Figure 4.11). For mice injected with control liposomes and NewHG kanR or 
NewHG sagB, no significant difference could be found between the weight loss, liver 
CFU, kidney CFU or spleen CFU recovered from infected mice (Figure 4.11A, B, C and D 
respectively). Despite the lack of significance, there is a trend for fewer recovered CFU 
and greater clearance in mice infected with NewHG sagB. The lack of significance may 
be due to the low inoculum. Concomitantly, low numbers of bacteria were recovered 
from the organs of infected mice (Figure 4.11). Clodronate treatment led to a dramatic 
increase in recovered CFU for both strains (Figure 4.11). This allowed the two bacterial 
strains to be compared. 
 
Clodronate treated mice injected with NewHG sagB lost significantly less weight over a 
period of 72 hpi compared to mice injected with NewHG kanR (Figure 4.11A). 
Interestingly the CFU recovered from the liver, kidneys and spleen of clodronate treated 
mice infected with NewHG sagB were consistently and significantly lower than those 
recovered from mice infected with NewHG kanR (Figure 4.11 B, C and D). Thus, although 
macrophages are important in the control of both the wildtype and sagB strains, they 





Figure 4.11 The role of macrophages in the murine sepsis model in the attenuation of S. aureus sagB 
mutants 
 
Mice (n=10) were injected with approximately 1 x 10
5 
CFU of NewHG kan
R
 (SJF 3680) or NewHG sagB (SJF 4912) 
24 hours post treatment with empty liposomes or clodronate containing liposomes. 72 hpi, mice were 
sacrificed and the weight change (A, * p = 0.0254) and liver (B, * p = 0.0243), kidney (C, ** p = 0.0030) and 
spleen (D, * p = 0.0196) CFU were determined. Groups were compared using Mann-Whitney U tests (NewHG 
kan
R
 – black circles, NewHG sagB- red squares). One mouse in the NewHG kan
R
 clodronate treated group was 




4.3.9 The role of multiple glucosaminidases in staphylococcal pathogenesis 
 
The results from Figure 4.3B and 4.3C suggest that all the glucosaminidases may play a 
role in virulence of S. aureus. The remaining glucosaminidases: Atl, SagA and ScaH were 
interrogated for their role and importance in the growth and virulence of S. aureus. 
 
4.3.9.1 Role of glucosaminidases in growth 
 
Existing glucosaminidase mutants in the SH1000 background were analysed for their 
growth as described in Chapter 2.8. At each hourly timepoint, the OD600 and the CFU per 
ml culture was determined for both the mutant and the control parental strain. It is 
already known that atl mutants form clusters of cells, due to an inability to properly 
divide daughter cells (Takahashi et al., 2002; Wheeler et al., 2015).  
 
SH1000 atl (SJF 1367) was grown at 37 °C, 200 rpm in 50 ml TSB in a 250 ml conical flask, 
with absorbance at 600 nm and CFU per ml being determined (Chapter 2.7.1, 2.7.2), 
compared to the parental SH1000 (SJF 682). As SH1000 atl forms particles consisting of 
many bacteria the CFU at each timepoint was determined for an unsonicated sample, 
the CFU of which represents the number of particles per ml, and a sonicated sample, the 
CFU of which represents the number of bacteria per ml (Chapter 2.10). The growth of 
SH1000 atl as determined by optical density shows the same growth kinetics as the 
parental SH1000 (Figure 4.12A). However, the CFU growth shows that, when 
unsonicated, the SH1000 atl mutant has fewer particles than SH1000 (Figure 4.12A). This 
can be explained as the atl mutant results in the formation of clusters. When sonicated, 
SH1000 atl follows the same growth kinetics as the sonicated SH1000 strain. This shows 
that SH1000 atl grows at the same rate as parental SH1000 but cannot complete 
division. Both SH1000 sagA (SJF 4606) and SH1000 scaH (SJF 4607) were also analysed 
(Figure 4.12B and C respectively). Both mutants showed the same growth kinetics as 
parental SH1000 (SJF 682) when analysed by optical density, and by CFU, with both 




4.12 show that SH1000 atl (SJF 1367), SH1000 sagA (SJF 4606) and SH1000 scaH (SJF 
4607) all have the same growth kinetics as the parental SH1000. The only exception is 





Figure 4.12 The role of S. aureus SH1000 glucosaminidases in growth in TSB 
 
Growth of parental SH1000 (SJF 682, black circles solid line) or parental SH1000 sonicated (open black circles and 
broken line) in TSB compared to: (A) SH1000 atl (SJF 1367, yellow squares) and sonicated SH1000 atl (yellow 
open squares, broken lines), (B) SH1000 sagA (SJF 4606, blue squares) and sonicated SH1000 sagA (blue open 
squares, broken lines) or (C) SH1000 scaH (SJF 4607, red squares) and sonicated SH1000 scaH (red open squares, 
broken lines). Bacterial cultures were prepared in triplicate and error bars represent the standard deviation of 





4.3.9.2 Virulence of glucosaminidase mutants in the zebrafish embryo model of infection 
 
To determine if the glucosaminidases play a role in virulence, 1500 CFU of each strain 
was injected into the circulation valley of zebrafish embryos. As SH1000 atl (SJF 1367) 
forms clusters during growth, defining the injected CFU was vital. Around 500 particles 
of SH1000 atl were injected into zebrafish embryos, which was the equivalent of roughly 
1500 bacteria. To ensure that the correct number of bacteria for each glucosaminidase 
strain was correct, the parental and mutant strains were plated on TSA unsonicated, to 
determine the number of particles injected, and sonicated, to determine the number of 
bacteria injected. 
 
Zebrafish infected with 500 CFU (particles) of unsonicated SH1000 atl were compared to 
a group injected with 1500 CFU of unsonicated parental SH1000 (Figure 4.13A). SH1000 
atl was shown to cause the same amount of mortality in zebrafish embryos as the wild 
type SH1000, suggesting that the clusters formed by SH1000 atl do not impact upon 
pathogenesis in the zebrafish model. This matches with data of a murine implant model, 
where a JE2 atl mutant was found to have no significant difference in virulence 
compared to the wild type JE2 (McCarthy et al., 2016). Zebrafish injected with 1500 CFU 
of unsonicated SH1000 sagA also showed no difference in virulence when compared to 
mortality of zebrafish injected with the same CFU of parental SH1000 (Figure 4.13B). 






Figure 4.13 Role of the glucosaminidases Atl, SagA and ScaH in S. aureus virulence in the 
zebrafish infection model 
 
Survival curves of zebrafish embryos injected with approximately 1500 CFU of S. aureus SH1000 (SJF 
682, black lines) or (A) approximately 500 CFU SH1000 atl (1500 CFU after sonication) (SJF 1367, 
yellow line) (B) approximately 1500 CFU SH1000 sagA (SJF 4606, blue line) or (C) approximately 1500 
CFU SH1000 scaH (SJF 4607, red line). (3 repeats, n>20), all groups are not significantly different 




4.3.9.3 Construction of double glucosaminidase mutant strains 
 
Double glucosaminidase mutants were constructed in the SH1000 genomic background 
using phage transduction (chapter 2.12.3). To produce SH1000 atl sagA (SJF 5261), a 
phage lysate was produced from SH1000 atl (SJF 5255), which was used to transfer the 
atl mutation into SH1000 sagA (SJF 4606). The PCR confirmation for this strain can be 
seen in Figure 4.14A, where mutant bands can be seen in lanes 4 and 8. SH1000 atl scaH 
(SJF 5262) was made in the same fashion, with the atl gene transduced into SH1000 
scaH (SJF 4607), confirmed by PCR amplification of the target genes (Figure 4.14B). 
Finally, SH1000 sagA scaH (SJF 5217) was constructed by transducing a scaH mutation 
(SJF 2109) into SH1000 sagA (SJF 4606). The success of this transduction was confirmed 
by PCR of the sagA and scaH genes to ensure both contained the marked insertion, 










Figure 4.14 Verification of double glucosaminidase mutants 
 
(A) 1% (w/v) TAE agarose gels showing PCR amplification of the atl and sagA genes from S. aureus. 
Lane 2 shows wild type atl band (777 bp) expected from the primer set (Atl_TnINS_F and 
Atl_TnINS_R). The expected mutant band (donor strain SH1000 atl mutant, SJF 5255, 2500 bp), 
shown in lane 3 and indicated with a black arrow, is also seen in lane 4 of the SH1000 atl sagA (SJF 
5261). Lane 6 shows the wild type sagA band (1835bp) expected from the primer set (psagA_F and 
psagA_R). The expected mutant band (3000 bp), indicated with an arrow, from SH1000 sagA (SJF 
4606) can be seen in lane 7, and in lane 8 for SH1000 atl sagA (SJF 5261). (B) 1% (w/v) TAE agarose 
gel showing PCR amplification of the atl and scaH genes from S. aureus. Lane 2 shows wild type atl 
band (777 bp) expected from the primer set (Atl_TnINS_F and Atl_TnINS_R). The expected mutant 
band (donor strain SH1000 atl mutant, SJF 5255, 2500 bp), shown in lane 3 and indicated with a 
black arrow, is also seen in lane 4 of SH1000 atl scaH (SJF 5262). Lane 6 shows the wild type scaH 
band (2074 bp) expected from the primer set (pscaH_F and pscaH_R). The expected mutant band 
(4000 bp), indicated with an arrow, from SH1000 scaH (SJF 4607) can be seen in lane 7. Lane 8, 
SH1000 atl scaH (SJF 5262), also shows the mutant band. (C) 1% (w/v) TAE agarose gel showing PCR 
amplification of the sagA and scaH genes from S. aureus. Lane 2 shows wild type sagA band 
(1835bp) expected from the primer set (psagA_F and psagA_R). The expected mutant band (donor 
strain SH1000 sagA mutant, SJF 4606, 3000 bp), shown in lane 3 and indicated with a black arrow, is 
also seen in lane 5 of SH1000 sagA scaH (SJF 5217). Lane 7 shows the wild type scaH band (2074 bp) 
expected from the primer set (pscaH_F and pscaH_R). The expected mutant band (4000 bp), 
indicated with an arrow, from SH1000 scaH (SJF 4607) can be seen in lane 8. Lane 10, SH1000 sagA 
scaH (SJF 5217), also shows the mutant band. Relevant sizes of DNA ladder (GeneRuler 1 kb DNA 




4.3.9.4 Growth kinetics of double glucosaminidase mutants 
 
The double glucosaminidase mutants constructed (Chapter 4.3.9.3) were analysed for 
growth kinetics compared to the parental SH1000 (SJF 682). As an atl mutant is known 
to form clusters (Chapter 4.3.9.1, Takahashi et al., 2002), all mutants were plated 
unsonicated, to measure number of particles, and sonicated, to measure the number of 
bacteria in the culture (chapter 2.10). 
 
SH1000 atl sagA (SJF 5261) showed the same growth kinetics as parental SH1000 (SHF 
682) when compared by measuring optical density (Figure 4.15A). Similarly, to SH1000 
atl (SJF 1367), SH1000 atl sagA shows clustering by CFU. The unsonicated CFU of SH1000 
atl sagA was consistently around 10-fold lower than the unsonicated wildtype SH1000. 
When sonicated, SH1000 atl sagA shows similar CFU to sonicated SH1000. SH1000 atl 
sagA had the same growth rate as SH1000, whilst forming clusters. 
 
SH1000 atl scaH (SJF 5262) shows the same phenotype as SH1000 atl sagA. SH1000 atl 
scaH shows the same growth pattern as parental SH1000 when optical density was 
measured. SH1000 atl scaH also showed clustering, with unsonicated CFU lower than 
unsonicated wildtype SH100, but sonicated CFU matching sonicated SH1000 CFU (Figure 
4.15B). 
 
The SH1000 sagA scaH (SJF 5217) mutant showed the same optical density growth as 
parental SH1000 (Figure 4.15C). Unsonicated and sonicated SH1000 sagA scaH CFU 
match the corresponding SH1000 CFU. This demonstrates that SH1000 sagA scaH has 
the same growth rate as parental SH1000 and does not form clusters during growth 





Figure 4.15 Role of glucosaminidases in growth of S. aureus 
 
Growth of parental SH1000 (SJF 682, black circles solid line) or parental SH1000 sonicated (open black circles 
and broken line) in TSB compared to: (A) SH1000 atl sagA (SJF 5261, green squares) and sonicated SH1000 
atl sagA (green open squares, broken lines). (B) SH1000 atl scaH (SJF 5262, orange squares) and sonicated 
SH1000 atl scaH (orange open squares, broken lines). (C) SH1000 sagA scaH (SJF 5217, purple squares) and 
sonicated SH1000 sagA scaH (purple open squares, broken lines). Bacterial cultures were prepared in 
triplicate and error bars represent the standard deviation of the mean. Sonicated strains were sonicated for 




4.3.9.5 Virulence phenotype of double glucosaminidase mutants 
 
To determine if the double glucosaminidase mutants had a different virulence 
phenotype than that of the parental SH1000 (SJF 682), strains were analysed in the 
zebrafish embryo model of infection (Chapter 2.18.1). To ensure the same number of 
bacteria were injected for each strain, CFU were determined from both sonicated and 
unsonicated samples of the inoculum used. Unsonicated mutant strains, and parental 
SH1000 (SJF 682) were injected into embryos. 400 particles of SH1000 atl sagA (SJF 
5261), 300 particles of SH1000 atl scaH (SJF 5262) and 1300 particles of SH1000 sagA 
scaH (SJF 5217), all consisting of around 1300 bacteria, were injected into embryos and 
compared to an injection of 1300 bacteria of parental SH1000 (SJF 682) (Figure 4.16A). 
SH1000 sagA scaH is as virulent as the parental SH1000 (p = 0.9189). Both SH1000 atl 
sagA and SH1000 atl scaH cause significantly lower mortality than the parental SH1000 
(both p < 0.0001). SH1000 atl scaH causes significantly reduced mortality than SH1000 
atl sagA (p = 0.0203). As SH1000 sagA scaH is not attenuated, and SH1000 atl scaH is 
significantly more attenuated than SH1000 atl sagA it can be inferred that Atl is the 
most important hydrolase with glucosaminidase activity for virulence (excluding SagB), 
followed by ScaH and then SagA. 
 
As atl mutants have been shown to form clusters that separate upon sonication (Figures 
4.12 and 4.15) the effect of sonicating the glucosaminidase mutants (Chapter 2.10) on 
virulence was investigated. For all strains, the equivalent of 1300 bacteria were injected 
into the embryos. 400 particles of unsonicated SH1000 atl sagA (1300 bacteria), 1300 
CFU of sonicated SH1000 atl sagA or 1300 CFU SH1000 (Figure 4.16B). Unsonicated 
SH1000 atl sagA is significantly attenuated compared to parental SH1000 (p < 0.0001). 
Sonicated SH1000 atl sagA has equivalent virulence to parental SH1000 (p = 0.9413). An 
injection of 300 particles of unsonicated SH1000 atl scaH (1300 bacteria) is significantly 
attenuated compared to the equivalent bacterial numbers of wildtype SH1000 (p < 
0.0001). Injecting 1300 CFU of sonicated SH1000 atl scaH causes the same mortality as 




SH1000 sagA scaH caused no change in virulence compared to an equivalent dose of 






Figure 4.16 Role of the glucosaminidases Atl, SagA and ScaH in S. aureus virulence in the zebrafish 
infection model in double mutant bacteria 
 
Survival curve of zebrafish embryos injected with approximately 1300 CFU of S. aureus SH1000 (SJF 682, black 
lines) or: (A) 400 particles of unsonicated SH1000 atl sagA (SJF 5261, solid green line) consisting of 1300 bacteria 
(when sonicated), 300 particles of unsonicated SH1000 atl scaH (SJF 5262, solid orange line) consisting of 1300 
bacteria (after sonication) or 1300 CFU unsonicated SH1000 sagA scaH (SJF 5217, solid purple line, sonication did 
not change CFU). (3 repeats, n>20, **** p < 0.0001). (B) 400 particles unsonicated SH1000 atl sagA (SJF 5261, solid 
green line) consisting of 1300 bacteria (when sonicated) or approximately 1300 CFU of sonicated SH1000 atl sagA 
(broken green line) (3 repeats, n>20, all stated CFU are approximate, **** p < 0.0001, * p = 0.0203). (C) 300 
particles of unsonicated SH1000 atl scaH (SJF 5262, solid orange line) consisting of 1300 bacteria (after sonication) 
or 1300 CFU sonicated SH1000 atl scaH (broken orange line). (3 repeats, n>20, all stated CFU are approximate, 
**** p < 0.0001). (D) 1300 CFU unsonicated SH1000 sagA scaH (SJF 5217, solid purple line, sonication did not 




4.3.9.6 Particle size of double glucosaminidase mutants 
 
The cause of attenuation of SH1000 atl sagA (SJF 5261) and SH1000 atl scaH (SJF 5262) 
is likely due to the bacteria being unable to separate and clustering, much like an atl 
mutant (Takahashi et al., 2002; Wheeler et al., 2015). To measure the change in particle 
size, flow cytometry was utilised to measure changes in the forward scatter (FSC) of light 
caused by different glucosaminidase mutants (Chapter 2.22). FSC values are comparable 
to the size of the particle being measured, allowing strains to be compared for particle 
size by their differing FSC values; the larger the FSC value, the larger the particle 
(Salamaga et al., 2017). It has previously been shown by light microscopy that S. aureus 
without functional Atl form clusters (Wheeler et al., 2015). An assumption of this 
experiment is when strains are sonicated, they are becoming single cells, i.e. individual 
bacteria not connected to other daughter cells. 
 
First, glucosaminidase mutants, both single and double, where analysed by flow 
cytometry to determine their relative particle size (Figure 4.17A). As previously 
described, SH1000 atl (SJF 1367) shows an increase in particle size compared to parental 
SH1000 (SJF 682) (p = 0.0013). Both SH1000 sagA (SJF 4606) and SH1000 scaH (SJF 4607) 
show no significant difference in particle size to the parental SH1000, indicating no 
clustering (p = 0.9996 and 0.9998 respectively). SH1000 atl sagA (SJF 5261) and SH1000 
atl scaH (SJF 5262) both show a significant increase in FSC value compared to parental 
SH1000, suggesting they have an increased particle size, and therefore are clustering (p 
< 0.0001 for both strains). This matches with previously described data, where 
sonication increased CFU on plating (Figures 4.15 and 4.16). SH1000 sagA scaH (SJF 
5217) shows no difference in FSC value to parental SH1000, so also does not show 
clustering (p = 0.9996). When sonicated, the FSC of both SH1000 atl sagA and SH1000 
atl scaH are seen to drop (Figure 4.17B), suggesting that the cells have gone from 
clusters to individual cells. When these values were compared to sonicated wildtype 
SH1000, the glucosaminidase mutants, including SH1000 sagA scaH, were found to have 




   
Figure 4.17 Analysis of glucosaminidase mutant particle size by flow cytometry 
 
(A) Comparison of the median forward scattered (FSC) light values of parental SH1000 (SJF 682, white bar), 
SH1000 atl (SJF 1367, yellow bar), SH1000 sagA (SJF 4606, blue bar), SH1000 scaH (SJF 4607, red bar), SH1000 
atl sagA (SJF 5261, green bar), SH1000 atl scaH (SJF 5262, orange bar) and SH1000 sagA scaH (SJF 5217, purple 
bar). (n = 3, **** p < 0.0001). (B) Comparison of the median FSC light values of parental SH1000 (unsonicated 
white bar, sonicated black and white bar), SH1000 atl sagA (unsonicated green bar, sonicated green and white 
bar), SH1000 atl scaH (unsonicated orange bar, sonicated orange and white bar) and SH1000 sagA scaH 
(unsonicated purple bar, sonicated purple and white bar). (n = 3, **** p < 0.0001). Error bars show ±SD, 
Median FSC values were compared using a one-way ANOVA with Dunnet’s multiple comparison test, strains 




4.3.9.7 Does sonication restore sagB virulence? 
 
It has been reported in the literature that sagB mutants also have a clustering 
phenotype (Wheeler et al., 2015; Chan et al., 2016b). As an atl mutant has a more 
pronounced clustering phenotype, and atl sagA/scaH double mutants regain virulence 
on being sonicated, it was examined if sonication could restore virulence to SH1000 
sagB (SJF 4608), using the zebrafish embryo model of infection. 
 
Figure 4.18 shows that the sonication of SH1000 (SJF 682) does not change the virulence 
when compared to the same CFU of unsonicated SH1000 (p = 0.8672). Unsonicated 
SH1000 sagB (SJF 4608) (1500 CFU) has no difference in mortality in zebrafish embryos 
than the same dose of sonicated SH1000 sagB (p = 0.4381). Unsonicated SH1000 sagB is 
significantly attenuated compared to unsonicated SH1000 (p = 0.0053) and sonicated 






Figure 4.18 The effect of sonication on the virulence of SH1000 sagB in the zebrafish model 
of infection 
 
At around 30 hpf, zebrafish embryos were injected with approximately 1500 CFU of SH1000 (SJF 
682) or SH1000 sagB (SJF 4608). These strains were either injected unsonicated or having been 
sonicated for 20 seconds at an amplitude of 5 microns (sonication of these strains did not change 
CFU, data not shown). (Black lines – SH1000, red lines – SH1000 sagB, solid lines – unsonicated 




4.3.9.8 Phenotypic analysis of a triple glucosaminidase mutant 
 
As the double glucosaminidase mutant analysis shows virulence phenotypes, strain 
SH1000 atl sagA scaH (SJF 4611) was used to determine the combined role of all three 
glucosaminidases in infection (Wheeler et al., 2015). 
 
 The growth of SH1000 atl sagA scaH (SJF 4611) was compared to the parental SH1000 
(SJF 682) using both direct CFU counts and optical density measurements (Figure 4.19A). 
The optical density measurements show a slower growth rate for SH1000 atl sagA scaH 
(doubling time 34.8 min) than the wildtype strain (25.9 min). However, at 7 hours, 
SH1000 atl sagA scaH reaches the same optical density as SH1000. The CFU counts are 
for sonicated and unsonicated mutant and wildtype. Unsonicated SH1000 atl sagA scaH 
shows around 10-fold lower CFU than unsonicated parental SH1000 and sonicated 
SH1000 atl sagA scaH, suggesting clustering and the inability for daughter cells to 
separate correctly. When comparing the sonicated SH1000 atl sagA scaH CFU (doubling 
time 44.8 min) to sonicated wildtype SH1000 CFU (doubling time 25.9 min), SH1000 atl 
sagA scaH CFU are consistently lower than SH1000, and do not reach the same numbers 
until 8 hours. This confirms that SH1000 atl sagA scaH has a reduced growth rate 
compared to wildtype SH1000, and forms clusters of cells during growth. 
 
To confirm the clustering, flow cytometry was used to measure the particle size of 
SH1000 atl sagA scaH by the FCS value compared to wildtype SH1000 (Chapter 2.22). 
SH1000 atl sagA scaH has a significantly higher FSC value than that of parental SH1000 
(Figure 4.19B, p < 0.0001), confirming clustering. Upon sonication of SH1000 atl sagA 
scaH, the FSC value drops to that of wildtype SH1000, suggesting that sonication of 
SH1000 atl sagA scaH also reverts the clusters to single cells (p < 0.0001).  
 
The virulence of SH1000 atl sagA scaH (SJF 4611) in the zebrafish embryo model of 
infection was analysed (Chapter 2.18.1). When zebrafish were injected with around 100 




significantly reduced mortality than when embryos were injected with 1500 CFU of 
unsonicated SH1000 (Figure 4.19C). However, when sonicated, SH1000 atl sagA scaH 
(1500 CFU) has an equivalent virulence to SH1000, matching the results of the double 






Figure 4.19 Analysis of growth and virulence of SH1000 atl sagA scaH 
 
(A) Growth of parental SH1000 (SJF 682, black circles solid line) or parental SH1000 sonicated (open black circles 
and broken line) in TSB compared to SH1000 atl sagA scaH (SJF 4611, brown squares) and sonicated SH1000 atl 
sagA scaH (brown open squares, broken lines). (B) Comparison of the median forward scattered (FSC) light values 
of parental SH1000 (white bar) and SH1000 atl sagA scaH (unsonicated brown bar, sonicated white and brown 
bar) (n = 3, **** p < 0.0001). Error bars show ±SD, Median FSC values were compared using a one-way ANOVA 
with Tukey multiple comparison test, strains were sonicated for 20 seconds at an amplitude of 5 microns. (C) 100 
particles of unsonicated SH1000 atl sagA scaH (consisting of 1500 bacteria, solid brown line), 1500 CFU of 
sonicated SH1000 atl sagA scaH (broken brown line) or 1500 CFU of parental SH1000 (solid black line). 3 (repeats, 




4.3.9.9 Virulence phenotype of SH1000 atl sagA scaH 
 
In this experiment, the genetic background SH1000 was used to analyse the virulence of 
SH1000 atl sagA scaH (SJF 4611) to allow comparisons to be made with other 
glucosaminidase mutants. The wildtype strain used contained a kanamycin resistance 
cassette to allow selection of S. aureus from organ homogenate to determine CFU. 
SH1000 kanR (SJF 3674) has been shown to have equivalent virulence to the wildtype 
SH1000 (SJF 682) (McVicker et al., 2014).  
 
Mice were injected with unsonicated or sonicated SH1000 kanR (SJF 3674) or SH1000 atl 
sagA scaH (SJF 4611). Number of bacteria in a sample was determined by sonication of 
the inoculum and plating to determine CFU, and number of particles was determined by 
plating unsonicated inoculum. Mice were injected with 1.65 x 107 bacteria in 1.47 x 107 
particles of unsonicated SH1000 kanR (SJF 3674), and 1.62 x 107 CFU of sonicated SH1000 
kanR (SJF 3674). Mice received 1.43 x 107 bacteria in 5.5 x 106 particles of unsonicated 
SH1000 atl sagA scaH (SJF 4611) and 1.51 x 107 CFU of sonicated SH1000 atl sagA scaH 
(SJF 4611). 
 
Mice injected with unsonicated SH1000 kanR (SJF 3674) show a significantly greater 
weight loss than mice injected with SH1000 atl sagA scaH (SJF 4611, p = 0.0314), 
indicating a reduced virulence in the SH1000 atl sagA scaH (SJF 4611) mutant. Mice 
infected with sonicated SH1000 atl sagA scaH (SJF 4611) show a trend for causing 
reduced weight loss than the sonicated wild type SH1000 kanR (SJF 3674) (Figure 4.20A). 
Both sonicated and unsonicated SH1000 atl sagA scaH (SJF 4611) show significantly 
fewer CFU recovered from the livers of mice infected with the corresponding SH1000 
kanR (SJF 3674) strains (Figure 4.20B, unsonicated p = 0.0003, sonicated p = 0.0014). In 
fact, mice infected with SH1000 atl sagA scaH (SJF 4611) had no recoverable CFU from 
the liver, indicating that CFU present were below 600 particles, the limit of detection for 
the assay. Given that SH1000 atl sagA scaH (SJF 4611) is known to form clusters, the 




be detected in both SH1000 atl sagA scaH (SJF 4611) infected groups. However, 
significantly fewer unsonicated and sonicated SH1000 atl sagA scaH (SJF 4611) CFU were 
recovered than the corresponding SH1000 kanR (SJF 3674) group (Figure 4.20C, 
unsonicated p = 0.0364, sonicated p = 0.0009).  
 
There is a trend for fewer CFU recovered from kidneys of mice infected with SH1000 atl 
sagA scaH (SJF 4611) than unsonicated SH1000 kanR (SJF 3674) (Figure 4.20D). 
Significantly fewer CFU are recovered from the kidneys of mice infected with sonicated 
SH1000 atl sagA scaH (SJF 4611) than sonicated SH1000 kanR (SJF 3674, p = 0.0096). This 
is also seen when infected kidneys are sonicated, where kidneys infected with 
unsonicated or sonicated with SH1000 atl sagA scaH (SJF 4611) have significantly fewer 
recovered CFU than SH1000 kanR (SJF 3674) (Figure 4.20E, unsonicated p = 0.0364, 
sonicated p = 0.0009). In all cases (Figure 4.20 A, B, C, D and E) no significance could be 
found between recovered CFU values (and weight changes) from mice infected with 
sonicated and unsonicated inoculum bacteria of the same strain. This would suggest that 
unlike in the zebrafish embryo model, sonication of bacteria has no impact on virulence 











Figure 4.20 The role of Atl, SagA and ScaH in virulence in a murine sepsis model of infection 
 
S. aureus SH1000 kanR (SJF 3674) or SH1000 atl sagA scaH (SJF 4611) were injected intravenously into mice 
(n=10). Approximately 1 x 10
7 
bacteria were injected in unsonicated and sonicated groups. Sonication had no 
effect on SH1000 kan
R
, but 1 x 10
7 
bacteria in 5 x 10
6 
particles of unsonicated SH1000 atl sagA scaH was 
injected. Weight loss 72 hpi (A, * p = 0.0314), liver CFU (B, ** p = 0.0014, *** p = 0.0003) and kidney CFU (D, 
** p = 0.0096) were determined. Organ homogenates were also sonicated to get a better representation of 
bacterial load in livers (C, p values on graph) and kidneys (E, * p = 0.0364, *** p = 0.0009). Groups were 
compared using a Kruskal-Wallis test with multiple comparisons (Unsonicated SH1000 kan
R
 – black circles, 
sonicated SH1000 kan
R
 – open black circles, unsonicated SH1000 atl sagA scaH - brown squares and 
sonicated SH1000 atl sagA scaH – open brown squares). Strains and organ homogenates were sonicated for 




4.3.9.10 Augmentation of SH1000 atl sagA scaH 
 
Mice were injected with 1 x 107 CFU of sonicated SH1000 atl sagA scaH (SJF 4611). This 
dose is 10-fold higher than the low dose for SH1000 for augmentation (Boldock et al., 
2018) but was used as this strain is highly attenuated (Figure 4.20). Augmented doses 
also contained 250 µg of wild type SH1000 (SJF 682) purified peptidoglycan (wild type 
peptidoglycan) or 250 µg of SH1000 atl sagA scaH (SJF 4611) purified peptidoglycan 
(mutant peptidoglycan). The weight of mice injected with SH1000 atl sagA scaH (SJF 
4611) were roughly constant during the 72 hours of the experiment, while those mice 
co-injected with SH1000 atl sagA scaH (SJF 4611) with wild type (p = 0.0159) or mutant 
peptidoglycan (p = 0.0079) showed significant greater weight loss 72 hpi (Figure 4.21A). 
The CFU recovered from the livers of mice co-injected with SH1000 atl sagA scaH (SJF 
4611) with wild type or mutant peptidoglycan were significantly higher than those of 
mice only infected with SH1000 atl sagA scaH (SJF 4611) (Figure 4.21B, p for both = 
0.0159). Significantly higher CFU were also recovered from the kidneys of augmented 
mice groups compared to mice injected with SH1000 atl sagA scaH (SJF 4611) alone 
(Figure 4.21 C, p = 0.0159, p = 0.0317). For spleens, lungs and hearts, no significant 
difference between recovered CFU could be seen between groups (Figure 4.21 D, E and 
F respectively).  
 
The results of this experiment demonstrate that SH1000 atl sagA scaH (SJF 4611) can be 
augmented by purified S. aureus peptidoglycan. Peptidoglycan of SH1000 atl sagA scaH 
(SJF 4611) can augment an infection, indicating that any change in peptidoglycan due to 







Figure 4.21 Augmentation of S. aureus SH1000 atl sagA scaH using wildtype and mutant 
peptidoglycan 
Mice (n=5) were injected with approximately 1x10
7
 CFU sonicated S. aureus SH1000 atl sagA scaH (SJF 4611) 
alone, or with 250 µg SH1000 PGN (SJF 682, WT PGN) or 250 µg SH1000 atl sagA scaH PGN (mutant PGN). 
Weight loss 72 hpi (A, ** p= 0.0079, * p = 0.0159) and CFUs recovered from livers (B,* p = 0.0159) , kidneys (C, p 
values on graph) , spleen (D) , lungs (E) and heart (F) were determined. Groups were compared using a Mann-
Whitney U test. (SH1000 atl sagA scaH only – black circles, SH1000 atl sagA scaH with wild type PGN - red 
squares SH1000 atl sagA scaH with mutant PGN – blue triangles). One mouse in the SH1000 atl sagA scaH and 




4.3.9.11 The role of macrophages in SH1000 atl sagA scaH host interaction 
 
During augmentation it is thought that peptidoglycan interacts within macrophages to 
potentially neutralise the effect of ROS on staphylococcal cells (Boldock et al., 2018). As 
SH1000 atl sagA scaH (SJF 4611) infection has been shown to be augmented by 
peptidoglycan, macrophages may also play a role in the attenuation of this strain. To test 
this hypothesis, the zebrafish embryo infection model was utilised, with clodronate 
depletion of macrophages (Chapters 2.18.1 and 2.18.3). 
 
Figure 4.22A shows the effect of sonicating bacteria on the virulence of parental SH1000 
(SJF 682) in zebrafish embryos pre-treated with clodronate containing, or control, 
liposomes. There is no significant difference in the mortality of zebrafish embryos 
treated with empty control liposomes infected with sonicated or unsonicated SH1000 
(SJF 682, p = 0.5141). This is also true of clodronate treated zebrafish embryos, 
suggesting that there is no impact of sonication on the virulence of SH1000 (SJF 682, p = 
0.8262). There was a significantly higher mortality in embryos treated with clodronate 
liposomes than the control liposomes, for groups infected with either unsonicated (p = 
0.0057) or sonicated (p = 0.0455) SH1000 (SJF 682). Figure 4.22A serves as a control to 
show that sonication has no impact on wildtype SH1000 (SJF 682) virulence, but 
clodronate does increase the mortality observed in zebrafish embryos.  
 
In embryos treated with control liposomes, sonicated SH1000 atl sagA scaH (SJF 4611) 
causes significantly more mortality than unsonicated SH1000 atl sagA scaH (SJF 4611, p 
= 0.0013), corroborating with previous results (Figure 4.19C; Figure 4.22B). There is 
significantly less mortality in embryos treated with control liposomes and infected with 
unsonicated SH1000 atl sagA scaH (SJF 4611), than embryos that are clodronate treated 
and infected with unsonicated SH1000 atl sagA scaH (SJF 4611, p = 0.0005). No 
difference can be seen in clodronate treated embryo mortality infected with sonicated 




observed between clodronate treated fish injected with unsonicated SH1000 atl sagA 
scaH (SJF 4611) and fish receiving control liposomes infected with sonicated SH1000 atl 
sagA scaH (SJF 4611). Finally, no difference in mortality can be seen in embryos infected 
with sonicated SH1000 atl sagA scaH (SJF 4611), whether they have received clodronate 
or control liposomes. These results show that sonication or clodronate treatment can 
restore the virulence of SH1000 atl sagA scaH (SJF 4611). However, the action of 
sonication and clodronate together do not further increase the mortality observed in 
zebrafish embryos, suggesting the effect of sonication is lost (or redundant) upon the 
loss of macrophages. This implies that a change in interaction with macrophages play a 
role in the attenuation of SH1000 atl sagA scaH (SJF 4611).  
 
The experiment was repeated by infecting two-day old fish, which have a more 
developed innate immune system, to test if the same results would be seen in a more 
immune competent embryo (Figure 4.22C). Embryos were treated with control 
liposomes or clodronate at 24 hpf but were not infected with bacteria until around 54 
hpf. The results in Figure 4.22C match those of 4.22B with the exception that clodronate 
treated embryos have a significantly higher mortality than those treated with control 






Figure 4.22 The role of macrophages in the zebrafish model in the attenuation of S. aureus atl 
sagA scaH 
 
At around 24 hpf, all zebrafish embryos were injected with either empty liposomes or clodronate containing 
liposomes. (A) At approximately 30 hpf embryos were injected with approximately 150 CFU of sonicated or 
unsonicated SH1000 (SJF 682) (3 repeats, n>20, * p =0.0455, ** p = 0.0057). (B) At approximately 30 hpf 
embryos were injected with approximately 150 CFU of sonicated or 150 bacteria in 10 particles of 
unsonicated SH1000 atl sagA scaH (SJF 4611) (3 repeats, n>20, ** p = 0.0013, *** p = 0.0005). (C) At 
approximately 54 hpf embryos were injected with approximately 150 CFU of sonicated or 150 bacteria in 10 
particles of unsonicated SH1000 atl sagA scaH (SJF 4611) (3 repeats, n>20, ** p = 0.0021, *** p = 0.0004, 
**** p < 0.0001). (Blue lines – empty liposomes, red lines – clodronate treated, solid lines – unsonicated 






The virulence of a wide range of S. aureus glucosaminidase strains have been 
investigated as a part of my study, using different animal models of infection. These 
results have been summarised in Table 4.1. 
 
4.4.1 The role of SagB in virulence 
 
The data presented in this chapter shows that a sagB mutant has a reduced growth rate 
compared to the wildtype (Figure 4.2) and is attenuated in the zebrafish model of 
infection (Figure 4.3). This attenuation can be seen in the murine sepsis infection model 
(Figure 4.6). The sagB mutant was less able to survive within human MDMs than a wild 
type strain (Figure 4.9), suggesting the attenuation was due to a change in the 
interaction with macrophages. However, while clodronate depletion of macrophages in 
mice increased the virulence of the sagB mutant, it was still significantly less than a 
wildtype (Figure 4.11) suggesting that factors other than macrophages also play a role in 
the attenuation.  
 
The sagB mutant showed a reduced growth rate in vitro (Figure 4.2), which is also seen 
in vivo (Figure 4.4). While SH1000 sagB (SJF 4608) has a reduced CFU increase in vivo 
compared to wildtype (Figure 4.4B), this trend is not so clear for NewHG sagB (SJF 4912) 
(Figure 4.5D). However, zebrafish embryos do clear the NewHG sagB inoculum, while 
embryos do not clear wildtype NewHG. S. aureus without active SagB shows longer 
glycan chains, and a stiffer cell wall than wild type when measured by AFM (Wheeler et 
al., 2015). The inability of the sagB mutant to process glycan strands may lead to a 
reduction in the ability of cells to increase in volume, in turn reducing the growth rate. 
During an infection, this reduced growth rate is exacerbated by the stringent in vivo 
conditions, potentially resulting in the attenuation of the strain in zebrafish and murine 





As well as growth defects, work by Chan et al. (2016) shows changes in the secretome of 
sagB mutants. Secreted proteins, including those important to virulence, such as: 
staphylococcal complement inhibitor, staphylococcal superantigen-like protein 1 (SSL1), 
SSL7, SSL11 and Coa were found in reduced concentrations in the culture medium when 
compared to wild type (Chan et al., 2016b). As these proteins are important virulence 
factors, this could explain the reduction in virulence seen in a sagB mutant in both 
zebrafish embryo and murine sepsis models of infection (Figures 4.3A, 4.5B and 4.6). The 
secretion defect was also found to include the increased secretion of 251 proteins, 
90.5% (227 proteins) of which were predicted to be cytoplasmic proteins (Chan et al., 
2016b). The increased secretion of cytoplasmic proteins would help to explain both the 
reduced growth rate in vitro and reduced virulence, as intracellular proteins erroneously 
excreted to the extracellular environment cannot perform their function. S. aureus sagB 
mutants have been reported to not show an autolysis phenotype (Chan et al., 2016b), so 
lysis is unlikely to be an explanation for the presence of cytoplasmic proteins outside of 
the cell. S. aureus atl mutants have also been found to have an aberrant secretion of 
extracellular proteins (Pasztor et al., 2010). A wildtype S. aureus was found to excrete 22 
typically cytoplasmic proteins, but an atl mutant showed a reduction in the excretion of 
these proteins as well as a reduction in extracellular proteases, but the increased release 
of PG hydrolases (Pasztor et al., 2010). 
 
Invasion of, and survival within, host phagocytes may be a fundamental part of S. aureus 
disease (Kubica et al., 2008; Prajsnar et al., 2012; Pollitt et al., 2018), providing a 
reservoir for infection. While my study has shown that sagB mutants are less able to 
survive within MDMs than wild type S. aureus (Chapter 4.3.7) it has not determined if 
there is a change in bacterial uptake. With an altered glycan structure from the loss of 
SagB (Wheeler et al., 2015), it is possible that the mutant is less readily phagocytosed by 
host phagocytes due to a change in the recognition of bacterial peptidoglycan (Peterson 





The results of my study have raised further questions on the impact of SagB on 
virulence. It has been shown through Figures 4.9, 4.10 and 4.11 that sagB mutants (SJF 
4608 and SJF 4912) have a different interaction with the host macrophages than the 
parental S. aureus strains (SJF 682 and SJF 3680), resulting in the mutant being less able 
to survive within host macrophages. This could be caused by a change in the 
acidification of the macrophages that S. aureus are contained within during an infection. 
The structure of PG made by cells without sagB may be more susceptible to the 
oxidative burst of phagocytes (Chapter 1.7.2). This could also be a result of the aberrant 
protein secretion described for sagB mutants (Chan et al., 2016b) resulting in the 
incorrect localisation of proteins required for defence against the oxidative burst. This 
may also have an impact on the secretion of proteins required for the protection against 
the action of antimicrobial peptides, resulting in the reduced survival of sagB strains in 
vivo (DeLeo et al., 2009; Buchan et al., 2019). The change in glycan structure may alter 
host recognition of peptidoglycan by receptors such as NOD2, possibly resulting in 
increased cytokine signalling by an increased expression of NF-κB and the subsequent 







Table 4.1 Summary of virulence phenotypes of different S. aureus glucosaminidase 
mutant strains  
Summary of observed virulence phenotypes for S. aureus in the zebrafish embryo and murine sepsis 




4.4.2 The impact of clustering on S. aureus virulence 
 
Single mutations of atl, sagA or scaH have no impact upon virulence (Figure 4.13), 
although Figure 4.12A does show the clustering of atl mutants that has previously been 
described (Takahashi et al., 2002; Wheeler et al., 2015). Despite the clustering, it is 
interesting to note that a single atl mutant is not attenuated in the zebrafish model of 
infection. This result matches the finding that a JE2 atl mutant had no difference in 
virulence to wildtype JE2 in a murine device-related infection model (McCarthy et al., 
2016). SH1000 atl sagA (SJF 5261) and SH1000 atl scaH (SJF 5262) mutants were found 
to be attenuated in a zebrafish embryo model of infection, but virulence was restored 
upon sonication of the strains (Figure 4.16A, B and C). No difference in virulence was 
found for SH1000 sagA scaH (Figure 4.16D). SH1000 atl sagA scaH (SJF 4611) was also 
found to cluster and had a reduced growth rate. For clustering mutants, it was found 
that sonication restored bacteria to single cells and restored virulence in the zebrafish 
embryo model of infection, but not in the murine sepsis model of infection. The impact 
of clustering in the zebrafish model of infection have been summarised in Figure 4.23. 
Finally, it was found that depletion of macrophages by clodronate treatment in zebrafish 
embryos resulted in the same level of embryo mortality when injected with unsonicated 
SH1000 atl sagA scaH (SJF 4611) as control liposome treated embryos injected with 
sonicated SH1000 atl sagA scaH (SJF 4611) (Figure 4.22B). 
 
It is curious that an atl mutant is not attenuated, but if both atl and sagA or scaH are 
inactivated, attenuated is observed. This is also compounded by the fact that a sagA 
scaH double mutant is not attenuated. This demonstrates the functional redundancy of 
the glucosaminidases as reported by Wheeler et al. (2015). The glucosaminidases SagA, 
ScaH and SagB can compensate for the loss of Atl activity in virulence (despite the 
clustering). However, once SagA or ScaH activity is also lost, the remaining enzymes 
cannot perform the function. A SH1000 sagA scaH mutant is also not attenuated, 
presumably because the activities of Atl and SagB provide enough glucosaminidase 





Figure 4.23 Summary of the impact of clustering on S. aureus virulence in the zebrafish 
model of infection 
Parental SH1000 (SJF 682) does not show cell clustering and is virulent in the zebrafish model of infection. 
Single mutations in atl, sagA or scaH are not attenuated, but SH1000 atl (SJF 1367) does show a clustering 
phenotype. Both SH1000 atl sagA (SJF 5261) and SH1000 atl scaH (SJF 5262) show a clustering phenotype. 
While in clusters, the strains are attenuated, but sonication to disrupt the clustering restores virulence. SH1000 
sagA scaH (SJF 5217) does not show clustering and is virulent regardless of sonication. SH1000 atl sagA scaH 
(SJF 4611) also displays clustering and is attenuated when injected into zebrafish embryos, but virulence is 




The attenuation of SH1000 atl sagA scaH can partly be explained due to the loss of 
several glucosaminidases, but Atl has also been shown to have other activities, including 
amidase activity. It has been found that Atl is able to bind to fibronectin, heparin 
(Porayath et al., 2018) and DNA (Grilo et al., 2014). The ability of Atl to bind to 
fibronectin is likely due to the repeat sequences of Atl (R1, R2 and R3) (Houston et al., 
2011). The binding of Atl to these molecules has been found to be involved in the 
establishment of biofilms (Bose et al., 2012). Loss of Atl may therefore cause a reduction 
in the ability of S. aureus to produce a biofilm in vivo. SagA and ScaH are both poorly 
studied enzymes, which may also have other, yet undiscovered, roles in the cell. 
 
The increase in particle size (measured by FSC) of SH1000 atl sagA scaH (Figure 4.19C) 
matches that found with atlA mutants of Enterococcus faecalis (Salamaga et al., 2017). 
The lack of AtlA in E. faecalis produces chains of bacteria rather than the clusters seen in 
SH1000 atl sagA scaH, which are also found to be attenuated in the zebrafish embryo 
model of infection. When chains of E. faecalis ΔatlA were sonicated or incubated with 
purified AtlA, virulence was restored in the zebrafish embryo model of infection. The 
reason for attenuation of E. faecalis ΔatlA was determined to be an increase in uptake 
by phagocytes (Salamaga et al., 2017). 
 
Sonication of SH1000 atl sagA scaH (SJF 4611) did not restore virulence in the murine 
model of infection, while it did in the zebrafish. This discrepancy could be explained by 
the nature of S. aureus infection dynamics. S. aureus is thought to go through 
bottlenecks during infection, with only a small number of the starting inoculum going on 
to seed the characteristic abscesses or lesions, depending on the infection model 
(McVicker et al., 2014; Pollitt et al., 2018). This may explain the need for such high CFU 
for infection in mammalian models of S. aureus disease (Pollitt et al., 2018). The immune 
bottleneck is associated with phagocytes in both zebrafish and murine models of 
infection. The bacteria that survive this phagocyte mediated bottleneck, go on to form 
abscesses. As previously described (Chapter 1.8.2, 4.1) zebrafish below 5 dpf have only 




immune system, including adaptive immunity, and infection progression is more 
complex (Figure 4.1). There are more bottlenecks that SH1000 atl sagA scaH (SJF 4611) 
must go through in mice than the zebrafish embryos. SH1000 atl sagA scaH (SJF 4611) 
will continue to form clusters when it grows and divides even after mechanical 
separation by sonication. Sonicated SH1000 atl sagA scaH (SJF 4611) can cause mortality 
in zebrafish embryos, as it passes through fewer bottlenecks causing mortality before 
the mutant becomes clustered and therefore attenuated. In the mice however, the 
sonicated SH1000 atl sagA scaH (SJF 4611) must contend with a more complex infection 
process. Host lysozyme, a muramidase (Chapter 1.4.3.1) may act on the PG of S. aureus 
during an infection, and this may modify its structure. While the loss of 
glucosaminidases results in a clustering phenotype, it is possible that host lysozyme 
would provide muramidase activity that could result in the reversal of the bacterial 
clustering, restoring virulence. It would therefore be pertinent to investigate the 
sensitivity of the glucosaminidase strains to lysozyme, and the strains’ clustering status 
in vivo during an infection.  
 
The Atl autolysin has also been associated with cell division and virulence in other 
staphylococcal species. Staphylococcus lugdunensis is a commensal skin organism, but 
like S. aureus can adapt to a pathogenic lifestyle, causing abscess and wound infections, 
endocarditis, urinary tract infections, and infections of catheters and other medical 
devices (Frank et al., 2008). AtlL of S. lugdunensis is also bifunctional like Atl of S. aureus 
(Bourgeois et al., 2009). Loss of AtlL activity results in clustering in S. lugdunensis, 
reduction in the ability to form biofilms, as well as reduced virulence in a C. elegans 
model of infection (Gibert et al., 2014). Loss of AtlE of Staphylococcus epidermidis has 
also been associated with clustering and a reduction in biofilm formation (Heilmann et 
al., 1997; Biswas et al., 2006). 
 
Glucosaminidases have been shown to play a role in cell separation in rod shaped 
bacteria as well as spheroid bacteria like staphylococcal species. Clostridium perfringens 
is a Gram-positive, spore-forming rod shaped bacterium implicated in foodborne 




Amidases and muramidases are important for the sporulation and germination of C. 
perfringens (Chen et al., 1997; Miyata et al., 1997). The C. perfringens PG hydrolase Acp 
has been shown to have glucosaminidase activity and is predominantly expressed during 
vegetative growth (Camiade et al., 2010). A loss of Acp activity resulted in the 
observation of long chains of undivided C. perfringens (Camiade et al., 2010), matching 
the clustering of S. aureus, suggesting a role in other species for glucosaminidases in cell 
division and separation. 
 
4.4.3 The combined role of glucosaminidases  
 
The loss of glucosaminidase activity suggests that there will be a reduction in the 
concentration of peptidoglycan turnover products, such as soluble muropeptides. It is 
known that Pseudomonas aeruginosa senses and responds to peptidoglycan from Gram-
positive bacteria to upregulate virulence factors and increase pathogenesis (Korgaonkar 
et al., 2013). S. aureus has regulatory systems, such as PknB, that can respond to 
components of the cell wall (Hardt et al., 2017). PknB is a eukaryotic-like 
serine/threonine kinase that is believed to be involved in the regulation of cell wall 
metabolism, virulence and antibiotic susceptibility (Beltramini et al., 2009; Débarbouillé 
et al., 2009). PknB consists of a C-terminal extracellular receptor region that has three 
PASTA (PBP and serine/threonine kinase–associated) domains (thought to bind PG), a 
transmembrane domain and an intracellular kinase domain at the N-terminus (Ohlsen 
and Donat, 2010). The kinase domain of PknB has been shown to be activated by binding 
lipid II, specifically the L-Lys-D-Ala-D-Ala motif (Hardt et al., 2017). PknB has been found 
to be able to phosphorylate WalR, activating it, and upregulating the expression of PG 
hydrolases important for PG turnover (Chapter 1.4.3) (Hardt et al., 2017). PknB was also 
found to phosphorylate FtsZ, regulating its polymerisation, and subsequent recruitment 
of the divisome (Hardt et al., 2017).  
 
This chapter has given important insight into the individual and collective role of 




and the attenuation of S. aureus in zebrafish and murine models of infection, which has 
been linked to a change in macrophage interaction.  The individual loss of atl, sagA or 
scaH is not enough to cause attenuation, despite the clustering phenotype of an atl 
mutant, which is likely because of the high degree of redundancy seen in bacterial PG 
hydrolases.  The simultaneous loss of atl and another glucosaminidase results in 
clustering and the attenuation of strains in a zebrafish model of infection, with virulence 
restored when the clusters are mechanically disrupted.  A mutant lacking atl, sagA and 
scaH also displayed a clustering phenotype associated with attenuation in the zebrafish 
model, with virulence being restored with sonication. The attenuation of this mutant 





Chapter 5  




Cell wall PG must be cleaved to allow growth associated with the insertion of new material 
by the action of PG synthases (Vollmer et al., 2008b). Penicillin binding proteins (PBPs) with 
transglycosylase activity add new muropeptides by polymerising new glycans into existing 
cell wall material. New crosslinks between the glycans can be added by some PBPs by 
transpeptidation. S. aureus possesses four native PBPs: PBP1, PBP2, PBP3 and PBP4. Of 
these PBP3 and PBP4 are non-essential (Sauvage et al., 2008).  
 
MRSA strains also encode the non-native mecA gene, producing the non-essential PBP2A 
responsible for high level β-lactam antibiotic resistance (Blázquez et al., 2014). S. aureus 
COL, an MRSA strain, is viable with only PBP1 and PBP2 (Reed et al., 2015). This PBP minimal 
strain does not show a growth defect in rich or minimal media, and cells show normal cell 
morphology when observed by TEM and Structured Illumination Microscopy (SIM). While 
growth rate and morphology were unaffected, the minimal strain is highly sensitive to cell 
wall targeting antibiotics such as β-lactams, compared to the wildtype (Reed et al., 2015). 
The loss of non-essential PG synthesis enzymes also results in the attenuation of the strain 
compared to the wildtype in a Drosophila model of infection, which was suggested to be 
caused by reduced PG crosslinking resulting in more susceptibility to host killing (Reed et al., 
2015). Collectively PG synthesis enzymes therefore play a role in virulence, but their 
individual functions are unknown. 
 
PBP4 is the only low molecular mass PBP of Staphylococcus aureus, a type-5 PBP with 
transpeptidase activity (Sauvage et al., 2008). The transpeptidase activity of PBP4 is required 
to produce the high level of crosslinking found in S. aureus PG (Wyke et al., 1981a). 




antibiotics (Henze and Berger-Bächi, 1995), an important virulence phenotype in clinical 
settings. Upregulation of PBP4 has been associated with a reduction in S. aureus sensitivity 
to β-lactam antibiotics (Hamilton et al., 2017). The increased resistance to β-lactam 
antibiotics from PBP4 has also been established in community-acquired MRSA strains that 
do not encode for PBP2a (Memmi et al., 2008; Chan et al., 2016), but the mechanism 
remains unclear (Hamilton et al., 2017). PBP4 is therefore important in a clinical setting and 
may also play a role in virulence. A PBP4 deletion mutant was associated with larger skin 
lesions in a mouse skin model of infection (Müller et al., 2015), suggesting an increased 
virulence from exacerbated disease presentation. A fitness cost is associated with the 
acquisition of antibiotic resistance (Geisinger and Isberg, 2017) as well as PG metabolism, 
but the trade-off between PBP4 and in vivo fitness has not been studied. 
 
Less information is known about the role of PBP3 in the cell (Reed et al., 2015). Recent work 
has shown an interaction between PBP3 and RodA, which is thought to be important for the 
localisation of both proteins to the mid-cell for PG insertion (Reichmann et al., 2019). The 
loss of PBP3 does not alter the muropeptide composition of the cell wall, and causes no 
change in the resistance of the cell to methicillin (Pinho et al., 2000). Observations of cell 
morphology by TEM suggest that PBP3 may play a role in septum formation and separation 
(Pinho et al., 2000), as when cells are treated with selective inhibitors of PBP3 cells failed to 
separate after division (Georgopapadakou et al., 1986; Okonog et al., 1995). Due to the high 
level of redundancy of the PG synthases (Reed et al., 2015) it is possible that when studied 
in vitro other synthases may be able to substitute for loss of PBP3 function, hence the lack 






5.2 Aims of this chapter 
 
The aim of this chapter was to characterise the role of PBP3 and PBP4 of S. aureus in animal 
models of infection. The specific aims of this chapter were to: 
 
i. Investigate the role of S. aureus PBP3 and PBP4 in virulence 







5.3.1 Role of non-essential PBPs in growth 
 
The growth rates of pbp3 and pbp4 mutants have previously been analysed, with no 
difference in growth being reported (Curtis et al., 1980; Pinho et al., 2000).  
 
Using the S. aureus SH1000 genetic background, SH1000 pbp3 (SJF 4422), SH1000 pbp4 
(SH1000 4425) and SH1000 pbp3 pbp4 (SJF 4423) were tested for growth in liquid TSB 
(Figure 5.1). SH1000 pbp3 (doubling time 33.6) shows no difference in growth rate to 
parental SH1000 (SJF 682, doubling time 33.7 min, Figure 5.1A). SH1000 pbp4 (doubling time 
34.9 min) also shows the same growth kinetics in vitro as the wildtype SH1000 (doubling 
time 35.3, Figure 5.1B). A SH1000 pbp3 pbp4 (doubling time 36.8) double mutant also shows 
no difference in growth rate compared to SH1000 (doubling time 36.8, Figure 5.1C). The 









Figure 5.1 Role of S. aureus SH1000 PBPs in growth 
 
Growth of parental SH1000 (SJF 682, black circles) in TSB compared to (A) SH1000 pbp3 (SJF 4422, red squares), 
(B) SH1000 pbp4 (SJF 4425, blue squares) and (C) SH1000 pbp3 pbp4 (SJF 4423, purple squares). Bacterial cultures 




5.3.2 Role of S. aureus PBP3 and PBP4 in the zebrafish model of infection 
 
SH1000 pbp3 (SJF 4422), SH1000 pbp4 (SJF 4425) and SH1000 pbp3 pbp4 (SJF 4423) strains 
were analysed for virulence in the zebrafish embryo infection model (Chapter 2.18.1). 1500 
CFU of each strain were injected into the circulation valley of 30 hpf embryos and compared 
to the mortality caused by SH1000 (SJF 682) (Figure 5.2). SH1000 pbp3 caused 63 % 
mortality 90 hpi compared to 55 % caused by the wildtype SH1000, which was found to not 
be significantly different (Figure 5.2A, p = 0.9505). There was no significant difference in 
mortality seen between SH1000 pbp4 and SH1000 (Figure 5.2B, p = 0.3154), despite SH1000 
pbp4 causing a higher mortality (64 %) than SH1000 (54 %). The mortality caused by SH1000 
pbp3 pbp4 (47 %) was found to not be significantly different from that of SH1000 (53 %) 
(Figure 5.2C, p = 0.7958). The loss of non-essential PBPs has no overall impact on virulence 







Figure 5.2 Role of PBPs in S. aureus virulence in the zebrafish infection model 
 
Approximately 1500 CFU of bacteria (mutant or wild type) was injected into the circulation valley of LWT zebrafish 
embryos around 30 hpf. (A) Survival curves comparing the virulence of parental SH1000 (SJF 682, WT, black lines) to 
SH1000 pbp3 (SJF 4422, red lines) (3 repeats, n>20). (B) Survival curves comparing the virulence of parental SH1000 
(SJF 682, WT, black lines) to SH1000 pbp4 (SJF 4425, blue lines) (3 repeats, n>20). (C) Survival curves comparing the 






5.3.3 Construction of a S. aureus NewHG pbp4 strain 
 
SH1000 pbp4 (SJF 4425) shows a trend for increased virulence in the zebrafish infection 
model (Figure 5.2B). PBP4 is known to be responsible for the high level of S. aureus PG 
crosslinking (Wyke et al., 1981a). For these reasons, it was decided to further investigate the 
role of PBP4 in virulence in the NewHG genetic background, as described in Chapter 4.3.4, 
as it is a well-established strain in the murine sepsis model of infection (Pollitt et al., 2018). 
 
The SH1000 pbp4 (SJF 4425) strain is derived from the Nebraska Transposon library, which 
uses a bursa aurealis transposon to inactivate non-essential genes of S. aureus (Fey et al., 
2013). This insertion in the pbp4 gene (Figure 5.3B) was transduced into the NewHG genetic 
background (SJF 3663) using bacteriophage ϕ11 to produce NewHG pbp4 (SJF 5103). The 
transduction was confirmed using PCR, where amplification of the pbp4 gene produced the 






Figure 5.3 Verification of NewHG pbp4 by PCR 
 
(A) 1% (w/v) TAE agarose gel showing PCR amplification of the pbp4 gene from wildtype NewHG 
(lane 2), positive control SH1000 pbp4 (lane 3) and NewHG pbp4 (SJF 5103) (lane 4) using primers 
pbp4-1 (forwards) and pbp4-5 (reverse). The wildtype band of 1535 bp can be seen in lane 2. The 
expected mutant band of 4773 bp, shown in lane 3 and indicated with a black arrow, is also seen in 
lane 4. Relevant sizes of DNA ladder (Quick load purple 2-log DNA ladder, NEB) are shown in kb (lane 
1). (B) Map showing the pbp4 gene (blue, 1296 bp) and the location of the transposon within the 




5.3.4 Virulence of NewHG pbp4 in the zebrafish embryo model of infection 
5.3.4.1 NewHG pbp4 virulence phenotype 
 
The virulence of NewHG pbp4 (SJF 5103) compared to the wildtype NewHG (SJF 3663) was 
analysed using the zebrafish model of infection. When 1500 CFU of bacteria were injected, 
NewHG pbp4 caused 64 % mortality in embryos, which was not significantly different to the 
50% mortality caused by NewHG (Figure 5.4A, p = 0.1364). While not significant, the trend 
for increased killing for a pbp4 mutant, as for the SH1000 background (Figure 5.2B), is 
present in the NewHG background. 
 
5.3.4.2 NewHG pbp4 in vivo growth kinetics 
 
The zebrafish model of infection was used to determine the in vivo growth kinetics of 
NewHG pbp4 (SJF 5103) compared to parental NewHG (SJF 3663). 1500 CFU were injected 
into embryos and the CFU of infected embryos were recovered over time. When embryos 
are infected with NewHG, the CFU recovered at later timepoints from living embryos are 
higher than (up to 107 CFU), or equal to that of the initial inoculum. One living embryo at 24 
hpi had CFU below the limit of detection. Dead embryos infected with NewHG had between 
~1 x 103-7 recovered CFU (Figure 5.4B). Embryos injected with NewHG pbp4 showed similar 
results to the wildtype strain. Living embryos had recovered CFU similar or greater than (up 
to 107) the initial inoculum CFU. Two living embryos were found to have cleared the 
infection, one at 48 hpi and one at 67 hpi. Dead embryos infected with NewHG pbp4 were 
found to have ~1 x 103-7 recovered CFU (Figure 5.4C). The in vivo growth of NewHG pbp4 is 





Figure 5.4 The role of PBP4 in S. aureus virulence and growth in the zebrafish model of infection 
 
(A) Approximately 1500 CFU of bacteria (mutant or wild type) were injected into the circulation valley of LWT 
zebrafish embryos around 30 hpf. Survival curve produced to compare the virulence of parental NewHG (SJF 3663, 
WT, black line) to NewHG pbp4 (SJF 5103) (3 repeats, n>20). Bacterial CFU were recovered and determined at 
specified timepoints after LWT zebrafish embryos were infected with (B) NewHG (SJF 3663) or (C) NewHG pbp4 (SJF 




5.3.5 Analysis of NewHG pbp4 virulence in the murine model of infection 
5.3.5.1 The murine sepsis model 
 
The virulence of NewHG pbp4 (SJF 5103) was further interrogated using the murine sepsis 
model of infection (Chapter 2.18.2). NewHG kanR (SJF 3680) was used as the wildtype strain 
as previously described (Chapter 4.3.6.1).  
 
The virulence of NewHG pbp4 was examined by injecting groups of 10 mice with 1 x 107 CFU 
of NewHG pbp4 or NewHG kanR (Figure 5.5). No significant difference in the weight change 
between the two groups of mice could be seen after 72 hours (Figure 5.5A, p = 0.8421). 
NewHG pbp4 has significantly higher CFU recovered from the livers of infected mice than 
those infected with NewHG kanR (Figure 5.5B, p = 0.0294). No significant difference could be 
seen in the CFU recovered from the kidneys of mice infected with NewHG kanR or NewHG 
pbp4 (Figure 5.5C, p = 0.4829). The CFU recovered from spleens, lungs and hearts all show 
no significant difference whether mice were injected with NewHG kanR or NewHG pbp4 
(Figures 5.5D, E and F, p = 0.7612, 0.4336 and 0.1223 respectively). These results show an 
increased colonisation for NewHG pbp4 specifically within the liver of the murine infection 






Figure 5.5 Role of PBP4 in S. aureus pathogenesis in the murine sepsis model of infection. 
 
Mice (n=10) were injected with approximately 1x10
7
 CFU S. aureus NewHG kan
R
 (WT, SJF 3680) or 
NewHG pbp4 (SJF 5103). Weight loss 72 hpi (A) and CFUs recovered from livers (B), kidneys (C), 
spleen (D), lungs (E) and heart (F) were determined. Groups were compared using a Mann-Whitney 
U test (NewHG kan
R
 – black circles, NewHG pbp4 blue squares) (* p = 0.0294) One mouse was found 
dead 72 hpi in the NewHG kan
R




5.3.5.2 A low dose infection in the murine sepsis model 
 
If NewHG pbp4 (SJF 5103) is able to colonise the livers of mice more effectively, then a 
lower infectious dose may make an increase in mutant virulence more apparent.  
 
Groups of 10 mice were injected with 5 x 106 CFU of NewHG kanR (SJF 3680) or NewHG pbp4 
(SJF 5103) (Figure 5.6). No significant difference was found between the weight change in 
mice infected with either NewHG kanR or NewHG pbp4 after 72 hours (Figure 5.6A, p = 
0.3930). Mice infected with NewHG pbp4 show a higher number of recovered CFU from the 
liver than mice infected with NewHG kanR (Figure 5.6B, p = 0.0051), confirming the 
increased colonisation of the liver. No significant difference could be seen between 
recovered CFU in the kidneys of mice infected with NewHG kanR or NewHG pbp4 (Figure 
5.6C, p = 0.2878). While there is no significant difference between CFU recovered from 
spleens infected with NewHG kanR or NewHG pbp4 (Figure 5.6D, p = 0.5314) less clearance 
can be seen in spleens infected with NewHG pbp4. Significantly more NewHG pbp4 is 
recovered from the lungs of infected mice than from lungs of mice infected with NewHG 
kanR (Figure 5.6E, p = 0.0410). No significant difference can be seen between the recovered 





Figure 5.6 Role of PBP4 in S. aureus infection at low dose in the murine sepsis model 
 
Mice (n=10) were injected with approximately 5x10
6
 CFU S. aureus NewHG kan
R
 (WT, SJF 3680) or 
NewHG pbp4 (SJF 5103). Weight loss 72 hpi (A) and CFUs recovered from livers (B), kidneys (C), 
spleen (D), lungs (E) and heart (F) were determined. Groups were compared using a Mann-Whitney 
U test (NewHG kan
R




5.3.6 Construction of pbp4 strains for clonality experiments 
 
To investigate the dynamics of a NewHG pbp4 (SJF 5103) infection, two marked strains were 
constructed, by transducing the pbp4 mutation into NewHG kanR (SJF 3680) and NewHG tetR 
(SJF 3681). Both NewHG kanR and NewHG tetR have been shown to have the same virulence 
as NewHG (SJF 3663) in the murine sepsis model, so can be used as the marked strains with 
no effects on virulence (Prajsnar et al., 2012; McVicker et al., 2014).  
 
5.3.6.1 Construction of NewHG kanR pbp4  
 
The pbp4 mutation from SH1000 pbp4 (SJF 4425) was transduced into NewHG kanR (SJF 
3680) using bacteriophage ϕ11 to produce NewHG kanR pbp4 (SJF 5136). This was 
confirmed by PCR, where amplification of pbp4 gene of NewHG kanR pbp4 produced the 
expected wild type band (Figure 5.7A). The mutant was also able to grow in the presence of 
standard levels of kanamycin (Chapter 2.3). 
 
5.3.6.2 Construction of NewHG tetR pbp4 
 
Using bacteriophage ϕ11, the pbp4 mutation was transduced into NewHG tetR (SJF 3681), 
producing strain NewHG tetR pbp4 (SJF 5135). The amplification of the pbp4 gene in NewHG 
tetR pbp4 gave the mutant band (Figure 5.7B), confirming transduction. The strain was also 





Figure 5.7 Verification of kanamycin and tetracycline resistant NewHG pbp4 strains 
 
(A) 1% (w/v) TAE agarose gel showing PCR amplification of the pbp4 gene from NewHG kan
R
 (lane 2, SJF 3680), 
positive control SH1000 pbp4 (lane 3) and NewHG kan
R 
pbp4 (SJF 5136) (lane 5) using primers pbp4-1 (forwards) 
and pbp4-5 (reverse). The wildtype band of 1535 bp can be seen in lane 2. The expected mutant band of 4773 bp, 
shown in lane 3 and indicated with a black arrow, is also seen in lane 5. (B) 1% (w/v) TAE agarose gel showing PCR 
amplification of the pbp4 gene from NewHG tet
R 
(lane 2, SJF 3681), positive control SH1000 pbp4 (lane 3) and 
NewHG tet
R
 pbp4 (SJF 5135) (lane 4) using primers pbp4-1 (forwards) and pbp4-5 (reverse). The wildtype band of 
1535 bp can be seen in lane 2. The expected mutant band of 4773 bp, shown in lane 3 and indicated with a black 
arrow, is also seen in lane 4. Relevant sizes of DNA ladder (Quick load purple 2-log DNA ladder, NEB) are shown in 




5.3.7 Analysis of NewHG pbp4 infection dynamics in the murine sepsis model 
5.3.7.1 Ratios of NewHG and NewHG pbp4 variants in mice organs over time 
 
The dynamics of a NewHG pbp4 (SJF 5103) infection was interrogated using established 
protocols (Pollitt et al., 2018). The liver is the first infectious site in the murine sepsis model 
of infection, with S. aureus being taken up from the blood by liver Kupffer cells. Within 
Kupffer cells S. aureus can be killed, but a small number survive the killing and pass through 
this immunological bottleneck and are able to form a micro abscess (Pollitt et al., 2018). 
Bacteria can escape from the micro abscess, from whence they can disseminate to other 
organs such as the kidneys, a process that involves neutrophils (Pollitt et al., 2018). 
 
20 mice were injected with a 1:1 ratio of NewHG kanR (SJF 3680) and NewHG tetR (SJF 3681) 
totalling 1 x 107 CFU, and 20 mice were injected with a 1:1 ratio of NewHG kanR pbp4 (SJF 
5136) and NewHG tetR pbp4 (SJF 5135) totalling 1 x 107 CFU. Mice were culled at 2, 24, 48 
and 72 hpi and the CFU of the differently marked strains (kanR or tetR) were determined in 
the liver, right kidney, left kidney, spleen, lung and heart of each mouse for wildtype and 
pbp4 strains (Figure 5.8).  
 
The ratios of each variant that was recovered from each organ at different time points post 
infection are shown in pie charts where green represents the proportion of recovered kanR 
strain, and blue the tetR strain (Figure 5.9). Mice injected with a 1:1 ratio of NewHG kanR (SJF 
3680) and NewHG tetR (SJF 3681) show a drop in recovered CFU in the liver between 2 and 
24 hpi, but an increase at 48 and 72 hpi (Figure 5.8A). At 48 and 72 hpi, the murine organs, 
excluding the liver, are shown to be predominantly infected with one variant of NewHG, 
indicating clonality in the infection (Figure 5.9). Mice infected with a 1:1 ratio of NewHG 
kanR pbp4 (SJF 5136) and NewHG tetR pbp4 (SJF 5135) maintain CFU in the liver between 2 
and 24 hpi (Figure 5.8A). At 72 hpi, all murine organs infected with NewHG kanR pbp4 and 







Figure 5.8 Total recovered CFU of S. aureus NewHG strains in the murine sepsis model 
over time 
Mice (n=20) were injected with a 1:1 ratio (totalling approximately 1 x 107 CFU) of 2 resistance 
marker tagged NewHG variants (black circles), or 2 resistance marker tagged NewHG pbp4 
variants (blue squares). 5 mice were culled at each time point and the CFU ratios in the (A) liver, 
(B) spleen, (C) left kidney, (D) right kidney, (E) lungs and (F) heart were determined. Total CFU of 
recovered NewHG kanR (SJF 3680) and NewHG tetR (SJF 3681) are seen in black circles for each 
organ. Total CFU of recovered NewHG kanR pbp4 (SJF 5136) and NewHG tetR pbp4 (SJF 5135) are 





Figure 5.9 The distribution of S. aureus NewHG strains in the murine sepsis model over time 
 
Mice (n=20) were injected with a 1:1 ratio (totalling approximately 1 x 10
7
 CFU) of two resistance marker tagged 
NewHG variants. 5 mice were culled at each time point and the CFU ratios in the liver, left kidney, right kidney, 
spleen, lungs and heart were determined. (A) The proportions of NewHG kan
R 
(SJF 3680, green) and NewHG tet
R
 (SJF 
3681, blue) recovered at each time point from each organ in each mouse. (B) The proportions of NewHG kan
R
 pbp4 
(SJF 5136, green) and NewHG tet
R
 pbp4 (SJF 5135, blue) recovered at each time point from each organ in each mouse. 
The number in each pie chart represents the log number of bacteria recovered (i.e. 10
6 
CFU = 6). H.P.I: hours post 





5.3.7.2 Ratio of NewHG and NewHG pbp4 variants in liver abscesses at 72 hpi 
 
While dissecting livers of mice at 72 hpi, some livers were found to have superficial 
abscesses that could be cleanly isolated from the liver tissue. Mice 17, 20 and 37 were found 
to have such abscesses. These abscesses were individually homogenised and plated, to 
determine the ratio of each antibiotic variant within an individual abscess, compared to the 
whole liver (Figure 5.10). Mice 17 and 20 were infected with NewHG kanR (SJF 3680) and 
NewHG tetR (SJF 3681), while mouse 37 was infected with NewHG kan
R
 pbp4 (SJF 5136) and 
NewHG tet
R
 pbp4 (SJF 5135). All three of the tested abcesses were found to contain a single 
variant from the infected inoculum, showing that for both NewHG and NewHG pbp4, a 






Figure 5.10 The ratio of S. aureus NewHG in liver abscesses in the murine sepsis model 
 
CFU and strain ratios were determined from liver abscesses found in mice 17, 20 and 37 from Figures 
5.8 and 5.9. “Liver” shows the CFU/proportions found in the remaining liver, “abscess” the 
CFU/proportions from the abscess and “total” the liver and abscess CFU/proportions combined (the 
total is reported in Figure 5.8). Mice 17 and 20 proportions of NewHG kan
R
 (SJF 3680, green) and 
NewHG tet
R
 (SJF 3681, blue), and mouse 37 show proportions of NewHG kan
R
 pbp4 (SJF 5136, green) 
and NewHG tet
R 




5.3.7.3 Species evenness of NewHG pbp4 in the murine model compared to the wildtype 
 
The proportion of each strain recovered (Figure 5.9) was used to calculate the species 
evenness index for each organ (Chapter 2.24) (Mulder et al., 2004). This metric is used to 
determine how even populations of different organisms are within an environment, with an 
evenness of 1 equating to an equal ratio of strains in the environment, and 0 equating to 
one organism being present within an environment (Pollitt et al., 2018). Population 
evenness is based on Shannon’s diversity index, commonly used in studies (Morris et al., 
2014; Pollitt et al., 2018), and can be used to analyse species that are uncommon and 
abundant within a sample. This is important as in this study organs could contain evenly 
mixed populations or only a single variant. After calculating population evenness for each 
organ, a mean linear regression was calculated for each data set (using Prism version 8.3.0) 
and compared for each strain (Figure 5.10). To remove skew caused by low numbers of 
recovered CFU, only organs that had at a total of least 10 colonies counted (consisting of 
either marked strain) were included in this analysis. 
 
In the livers, both NewHG kanR (SJF 3680), NewHG tetR (SJF 3681) (wildtype strains), and 
NewHG kan
R
 pbp4 (SJF 5136), NewHG tet
R
 pbp4 (SJF 5135) (pbp4 strains) infections become 
more clonal over time. The linear regressions for both wildtype (p = 0.0448) and pbp4 strains 
(p = 0.0036) are significantly decreasing in population evenness (Figure 5.11A). The wildtype 
and pbp4 strains do not have a significantly different decrease in population evenness from 
one another (p = 0.6077). The spleens show a significant decrease in population evenness 
for both wildtype strains (p = 0.0001) and pbp4 strains (p = 0.0049), but these decreases are 
not significantly different from one another (Figure 5.11B, p = 0.2339). The left kidney does 
not show a significant decrease in evenness for wildtype strain (p = 0.0878) or pbp4 strains 
(p = 0.2248), and these lines are not significantly different from one another (Figure 5.11C, p 
= 0.7691). In the right kidney, wildtype strains show no significant change in population 
evenness (p = 0.5730) whereas pbp4 strains show a significant decrease (p = 0.0441), which 
are not significantly different from one another (Figure 5.11D, p = 0.6604). While a trend for 
a decrease in population evenness is seen in the lungs for both wildtype strains (p = 0.2503) 




one another (Figure 5.11E, p = 0.6758). The same pattern can be seen in the heart (Figure 
5.11F), with neither wildtype strains (p = 0.5809) or pbp4 strains (p = 0.6494) showing a 
significant decrease in population evenness. No significant difference could be seen in the 
heart between the population evenness change between the two groups (p = 0.9300). Wild 
type and pbp4 strains show no difference in infection dynamics from one another within 
each organ. NewHG pbp4 therefore goes through the same immunological bottleneck as 






Figure 5.11 S. aureus NewHG kanR and NewHG pbp4 population evenness in the 
mouse sepsis model over time 
 
The population evenness from each mouse at different time points for NewHG kan
R
 (SJF 3680) 
and NewHG tet
R
 (SJF 3681) (black circles and line) and NewHG kan
R
 pbp4 (SJF 5136) and 
NewHG tet
R
 pbp4 (SJF 5135) (blue squares and lines) for (A) livers, (B) spleen, (C) left kidney, 
(D) right kidney, (E) lungs and (F) heart. Lines are mean linear regression, which were 
calculated and compared using Prism software. All linear regressions were found to be non-
significant, so the slopes of the lines are not significantly different from one another. Livers p = 
0.6077, Spleen p = 0.2339, Left kidney: p = 0.7691, Right kidney p = 0.6604, Lungs p = 0.6758 




5.3.8 Fitness of NewHG pbp4 compared to NewHG kanR in the murine sepsis model 
5.3.8.1 Population ratios of NewHG pbp4 to NewHG kanR in the murine sepsis model  
 
It was hypothesised that the NewHG pbp4 (SJF 5103) had a greater relative fitness in the 
livers of mice compared to the wildtype strain. To test this hypothesis, 20 mice were 
injected with a 1:1 ratio (totalling 7 x 106 CFU) of NewHG kan
R
 (SJF 3680) and NewHG pbp4 
(SJF 5103). Mice were infected for a period of 72 hours, before being culled and organs 
dissected. The total number, and ratio of each strain, recovered from each organ was 
calculated (Figure 5.12). The pie charts show that at 72 hpi, most of the organs are 




















































































































































































































































































































5.3.8.2 Relative fitness of NewHG pbp4 compared to NewHG kanR  
 
To determine if the ratios of the two strains recovered (Figure 5.12) are significantly 
different from the infectious dose, the relative fitness of NewHG pbp4 (SJF 5103) was 
calculated using the formula 𝑤 = ( )
( )
 (where w = relative fitness, X1 = starting mutant 
proportion and X2 = ending mutant proportion) (Pollitt et al., 2014). This gives a numerical 
value for the relative fitness of NewHG pbp4, where a value of 1 indicates an equal fitness 
between NewHG pbp4 and NewHG kanR (SJF 3680), a value greater than 1 shows a greater 
relative fitness for NewHG pbp4, and a value less than 1 a greater relative fitness for NewHG 
kanR (Pollitt et al., 2014). These values were plotted for each organ of each mouse (Figure 
5.13). Relative fitness within each organ was analysed using a one sample Wilcoxon signed 
rank test, comparing the results to a theoretical median of 1, testing if strains deviate from 
equal fitness. 
 
In the livers of mice infected with NewHG pbp4 (SJF 5103) and NewHG kanR (SJF 3680), the 
median relative fitness of NewHG pbp4 is significantly greater than 1 (p = 0.0105), 
demonstrating that NewHG pbp4 has a greater fitness relative to NewHG kanR in livers 
(Figure 5.13A). NewHG pbp4 also shows significantly higher relative fitness in the spleens of 
mice infected with both strains (Figure 5.13B, p = 0.0476). No difference in fitness was 
found between NewHG pbp4 and NewHG kanR in the left kidneys of infected mice (Figure 
5.13C, p = 0.3258). However, a significantly higher relative fitness can be observed for 
NewHG pbp4 in the right kidney (Figure 5.13D, p = 0.0327). No significant difference in 
fitness was observed between NewHG pbp4 and NewHG kanR in the lungs or hearts of 
infected mice (Figures 5.13 E, F, p = 0.3396 and 0.4375 respectively). The results show there 
is a fitness cost associated with having a functional pbp4 gene in the livers and spleen of the 







Figure 5.13 The relative fitness of NewHG pbp4 compared to NewHG kanR in different organs in 
the murine sepsis model  
 
The relative fitness of NewHG pbp4 (SJF 5103) against NewHG kan
R
 (SJF 3680) was calculated from the data 
in figure 5.12 using the formula 𝑤 = ( )
( )
 (where w = relative fitness, X1 = starting mutant proportion and 
X2 = ending mutant proportion). This was calculated for the liver (A, * p = 0.0105), spleen (B, * p = 0.0476), 
left kidney (C, p = 0.3258), right kidney (D, * p = 0.0327), lungs (E, p = 0.3396) and heart (F, p = 0.43275). Line 
on graph depicts the median. Statistical significance was determined using a one sample Wilcoxon signed 





5.3.9 The role of phagocytes in NewHG pbp4 infection 
5.3.9.1 The ability of NewHG pbp4 to survive in human macrophages  
 
As previously described (Chapter 4.3.7), bacteria are first phagocytosed by Kupffer cells in 
the liver during the murine sepsis model (Boldock et al., 2018; Pollitt et al., 2018). As 
NewHG pbp4 (SJF 5103) has been shown to have a greater relative fitness in the liver of 
mice this could be due to a change in the strain’s interaction with macrophages. The 
interaction of NewHG pbp4 with MDMs was investigated to test this hypothesis. 
 
MDMs (2 x 105) were infected with 1 x 106 CFU NewHG pbp4 (SJF 5103) or NewHG kanR (SJF 
3680) (MOI of 5) for 4 hours. Extracellular bacteria were killed by the addition of gentamycin 
for 30 min, which was then removed. MDMs were lysed at specified time points to 
determine the intracellular CFU of S. aureus strains (Chapter 2.20.1). In the first 30 min after 
gentamycin treatment, there is a significant drop in recovered intracellular NewHG kanR CFU 
(Figure 5.14, p = 0.0194). At 5 – 6.5 hpi, the intracellular NewHG kanR CFU remains constant, 
likely due to MDMs being unable to further kill, and the remaining S. aureus able to 
withstand MDM killing. Intracellular numbers of NewHG pbp4 show a non-significant (p = 
0.0802) decrease in the first 30 min after gentamycin treatment. At 5 hpi, there was 
significantly more intracellular NewHG pbp4 within MDMs than NewHG kanR (p = 0.0008). At 
5.5 and 6.5 hpi, there are no significant differences between intracellular CFU of NewHG 


















Figure 5.14 Survival of S. aureus strains in human MDMs 
 
MDMs were infected with S. aureus NewHG kan
R
 (SJF 3680, black circles) or NewHG pbp4 (SJF 5103, 
blue squares) at a MOI of 5 (1 x 10
6 
CFU) for 4 hours before being treated with gentamycin for 0.5 
hours to kill extracellular bacteria. MDMs were lysed at specific time points and intracellular 
bacterial numbers were determined. A two-way ANOVA with Tukey’s multiple comparison post-test 
was used to compare the first two time points for each strain, while paired two-tailed t-tests were 
used to compare between the strain CFU at subsequent time points. (*** p = 0.0008). Error bars 




5.3.9.2 The ability of NewHG pbp4 to survive in human neutrophils  
 
Circulating neutrophils have been shown to play a role in disseminating S. aureus to other 
organs from the liver in a murine sepsis model of infection (Pollitt et al., 2018). As a 
significantly increased fitness was only observed in the right kidney of mice (Figure 5.13D) 
but not in the left kidney, lungs or heart (Figures 5.13 C, E and F), neutrophils are unlikely to 
play a role in the NewHG pbp4 (SJF 5103) increase in liver colonisation. This hypothesis was 
tested by co-incubating human neutrophils with S. aureus strains (Chapter 2.20.2). 
 
Approximately 2.25 x 105 neutrophils were incubated with NewHG kanR (SJF 3680) or 
NewHG pbp4 (SJF 5103) at a MOI of 5 (1.125 x 106 CFU). No significant difference could be 
seen in the CFU recovered in the pellet (internalised in neutrophils) 30 min after co-
incubation with NewHG kanR or NewHG pbp4 (Figure 5.15A, p = 0.2107), showing no 
difference in internalisation.  
 
After 60 min of co-incubation, no significant difference could be found between intracellular 
NewHG kanR and NewHG pbp4 CFU (Figure 5.15B, p = 0.9869). No significant difference was 
also found between intracellular NewHG kanR and NewHG pbp4 CFU after 120 min of co-





Figure 5.15 Survival of S. aureus strains in human neutrophils 
 
(A) The number of internalised NewHG kanR (SJF 3680, black bars) and NewHG pbp4 (SJF 5103, blue 
bars) and the number remaining in the extracellular supernatant after 30 min of co-incubation with 
human neutrophils. Error bars represent the standard deviation of the mean. (n = 4, each consisting 
of 3 intra-assay repeats). Results analysed with a one-way ANOVA with Tukey’s multiple comparison 
post-test. (B) Intracellular NewHG kanR (SJF 3680, black circles) and NewHG pbp4 (SJF 5103, blue 
squares) CFU after co-incubation with neutrophils for 60 or 120 minutes. (n = 4, each consisting of 3 
intra-assay repeats). Error bars represent the mean and standard deviation of the mean. Results 




5.3.10 Role of macrophages in the murine sepsis model  
 
As previously described (Chapter 4.3.8, 4.3.8.2) clodronate was used to deplete the 
macrophages within the murine sepsis model of infection (Chapter 2.18.2, 2.18.3). Groups 
of 10 mice were injected with either clodronate, or control, liposomes 24 hours before 
being intravenously injected with 1 x 105 CFU NewHG kanR (SJF 3680) or NewHG pbp4 (SJF 
5103) (Figure 5.16). No significant difference could be found in the weight change 72 hpi for 
mice injected with control liposomes and NewHG kanR or NewHG pbp4 (p = 0.7812) or for 
mice injected with clodronate liposomes and NewHG kanR or NewHG pbp4 (Figure 5.16A, p 
= 0.3865). No significant differences could be found in the CFU recovered from the liver (p = 
0.1196), kidneys (p = 0.8592) or spleen (p = 0.9150) of mice treated with control liposomes 
and infected with and NewHG kanR or NewHG pbp4 (Figures 5.16B, C and D respectively). 
Despite the lack of significance, a trend for increased CFU recovered from the livers and 
spleens of mice infected with and NewHG pbp4 can be seen. The lack of significance may be 
due to low inoculum CFU.  
 
Clodronate treatment led to a dramatic increase in recovered CFU for both strains, allowing 
the bacterial strains, and effect of clodronate to be compared (Figure 5.16). When mice are 
treated with clodronate no significant difference can be seen in CFU recovered from the 
livers of mice infected with NewHG kanR or NewHG pbp4 (Figures 5.16B, p = 0.5659). No 
significant difference can be seen in the CFU of kidneys (Figures 5.16C, p = 0.0626) or 
spleens (Figures 5.16D, p = 0.2245) of clodronate treated mice infected with NewHG kanR or 







Figure 5.16 The role of macrophages in S. aureus host-pathogen interaction in the murine sepsis model 
 
Mice (n=10) were injected with approximately 1 x 10
5 
CFU of NewHG kan
R
 (SJF 3680) or NewHG pbp4 (SJF 5103) 24 
hours post treatment with empty liposomes or clodronate containing liposomes. 72 hpi, mice were sacrificed and 
the weight change (A) and liver (B), kidney (C) and spleen (D) CFU were determined. Groups were compared using 
Mann-Whitney U tests (NewHG kan
R
 – black circles, NewHG pbp4 - blue squares). One mouse in the NewHG kan
R
 
clodronate treated group and one in the NewHG pbp4 clodronate treated group were culled at 48 hpi due to 




5.3.11 Augmentation of NewHG pbp4 in the murine sepsis model 
 
Augmentation has previously been described in Chapter 1.7.4 and Chapter 4.3.6.2, where 
the addition of purified peptidoglycan to an S. aureus inoculum greatly increases virulence. 
The addition of PG allows greater survival of S. aureus within macrophages (Boldock et al., 
2018). 
 
Groups of 5 mice were injected with 1 x 106 NewHG kanR or NewHG pbp4 with or without 
the addition of 250 µg purified NewHG kanR PG (Figure 5.17). If mice were injected with 
NewHG kanR or NewHG pbp4, mice maintained their weight over 72 hours, with one NewHG 
pbp4 infected mouse at 82.7 % of its original weight (Figure 5.17A). This difference was not 
statistically significant (p = 0.3095). When only injected with bacteria, the CFU of NewHG 
pbp4 recovered from livers are significantly higher than the recovered CFU from mice 
infected with NewHG kanR (Figure 5.17B, p = 0.0397). No significant difference could be 
found between recovered CFU in kidneys and spleens of mice infected with NewHG kanR or 
NewHG pbp4 only (Figures 5.17C, D, p = 0.5397 and 0.2857 respectively). When NewHG 
kanR or NewHG pbp4 were co-injected with 250 µg PG, no significant difference can be seen 
in the recovered CFU for either strain (Figure 5.17B, p = 0.2857). No significant differences 
could be found in kidneys (p = 0.4127) and spleens (p = 0.6508) injected with NewHG kanR 










 CFU S. aureus NewHG kan
R
 (WT, SJF 3680) or NewHG pbp4 (SJF 5103) with or without 250 
μg WT S. aureus PG injected intravenously into mice (n=5). Weight loss 72 hpi (A) and CFUs recovered from livers 
(B), kidneys (C) and spleen (D) were determined. Groups were compared using Mann-Whitney U tests (NewHG 
kan
R
 – black circles, NewHG pbp4 blue squares) (* p = 0.0397). One mouse (infected with NewHG pbp4 and 250 
μg PG) was culled at 56 hpi due to reaching severity limits, so was culled. This data is represented as a green 




5.3.12 The combined role of peptidoglycan synthases and hydrolases in S. aureus  
 
The cell wall is a dynamic structure that requires both the hydrolysis and synthesis of PG to 
produce the correct cell wall structure (Vollmer et al., 2008a). It was hypothesised that 
mutations in both a hydrolase and synthase could have an impact on growth and virulence. 
This was tested by using NewHG sagB pbp4 (SJF 5147). 
 
 
5.3.12.1 Construction of NewHG sagB pbp4 
 
Bacteriophage ϕ11 was used to transduce the sagB mutation into NewHG pbp4 (SJF 5103), 
producing strain NewHG sagB pbp4 (SJF 5147). Amplification of the sagB gene in NewHG 
sagB pbp4 produced the mutant band (Figure 5.18A), confirming transduction. The strain 
also had a mutated pbp4 gene after being amplified by PCR, confirming inactivation of sagB 
and pbp4 genes (Figure 5.18A). 
 
5.3.12.2 Role of SagB and PBP4 in growth 
 
NewHG sagB pbp4 (SJF 5147), NewHG (SJF 3663), NewHG pbp4 (SJF 5103) and NewHG sagB 
(SJF 4912) were grown in liquid TSB (Figure 5.18B). NewHG had a doubling time of 30.9 min, 
which is similar to the growth of NewHG pbp4 (doubling time 33.0 min). As previously 
described (Chapter 4.3.1) sagB mutants have a decreased growth rate, which is seen in 
NewHG sagB (doubling time 37.5 min). NewHG sagB pbp4 shows a slight decreased growth 
rate (doubling time 34.2 min) compared to parental NewHG, which is a higher rate than 






5.3.12.3 Role of SagB and PBP4 in the zebrafish embryo model of infection 
 
NewHG (SJF 3663), NewHG pbp4 (SJF 5103), NewHG sagB (SJF 4912) and NewHG sagB pbp4 
(SJF 5147) were injected into embryos 30 hpf at a dose of 1500 CFU (Figure 5.18C). When 
injected with NewHG, 46 % of embryos survive infection. Embryos injected with NewHG 
pbp4 showed a survival rate of 34 %, which shows no significant difference to the wildtype 
(p = 0.2002). As seen previously (Chapter 4.3.5.1), embryos injected with NewHG sagB have 
a significantly higher survival rate than injection with NewHG (66 %, p = 0.0157). When 
injected with NewHG sagB pbp4, embryos have a survival rate of 54 %, which is not 
significantly different to survival when injected with NewHG (p = 0.1602). This shows that 
NewHG sagB pbp4 has equivalent virulence to wildtype NewHG. 
 
5.3.12.4 Particle size of NewHG sagB pbp4 
 
The particle size of NewHG sagB pbp4 (SJF 5147) was analysed using flow cytometry, as 
previously described (Chapters 2.22 and 4.3.9.6). The FSC value for each mutant was 
determined and compared to wildtype NewHG (SJF 3663) as a measure of relative particle 
size (Figure 5.18D). 
 
NewHG pbp4 (SJF 5103) shows no significant difference in FSC compared to the wildtype 
NewHG (SJF 3663, p = 0.3545). NewHG sagB (SJF 4912) was found to have a significantly 
lower FSC than parental NewHG (p = 0.0002). NewHG sagB pbp4 (SJF 5147) shows no 
significant difference in FSC, and therefore particle size, to wildtype NewHG (p = 0.7463), 





Figure 5.18 Analysis of growth and virulence of NewHG sagB pbp4 
 
(A) 1% (w/v) TAE agarose gels showing PCR amplification of the pbp4 and sagB genes from S. aureus. Lane 2 
shows wild type pbp4 band (1296 bp) expected from the primer set (pbp4-1 and pbp4-5). The expected 
mutant band (donor strain SH1000 pbp4, 4773 bp), shown in lane 3 and indicated with a black arrow, is also 
seen in lane 4 of the NewHG sagB pbp4 mutant (SJF 5147). Lane 6 shows the wild type sagB band (777 bp) 
expected from the primer set (psagB_F and psagB_R). The expected mutant band (1700 bp), indicated with 
an arrow, from SH1000 sagB (SJF 4608) can be seen in lane 7, and in lane 8 for NewHG sagB pbp4 (SJF 5147). 
(B) Growth of parental NewHG (SJF 3663, black circles) in TSB compared to: NewHG sagB (SJF 4912, red 
squares), NewHG pbp4 (SJF 5103, blue diamonds) and NewHG sagB pbp4 (SJF 5147, purple triangles). 
Bacterial cultures were prepared in triplicate and error bars represent the standard deviation of the mean. 
(C) Approximately 1500 CFU of bacteria (mutant or wild type) was injected into the circulation valley of LWT 
zebrafish embryos around 30 hpf. A survival curve was produced comparing the virulence of parental NewHG 
(SJF 3663, black line) to: NewHG sagB (SJF 4912, red line), NewHG pbp4 (SJF 5103, blue line) and NewHG 
sagB pbp4 (SJF 5147, purple line). (3 repeats, n>20, * p = 0.0157). (D) Comparison of the median forward 
scattered (FSC) light values of parental NewHG (SJF 3663, white bar), NewHG pbp4 (SJF 5103, blue bar), 
NewHG sagB (SJF 4912, red bar) and NewHG sagB pbp4 (SJF 5147, purple bar) (n = 3, *** p = 0.0002). Error 





5.3.12.5 Pathogenesis of NewHG sagB pbp4 in the murine sepsis model of infection 
 
The virulence of NewHG sagB pbp4 (SJF 5147) was compared to NewHG kanR (SJF 3680), as 
previously described (Chapter 5.3.5) (Figure 5.19).  
 
No difference in weight change 72 hpi could be seen between NewHG kanR (SJF 3680) and 
NewHG sagB (SJF 4912, p = 0.0524), NewHG pbp4 (SJF 5103, p = 0.8534) or NewHG sagB 
pbp4 (SJF 5147, p = 0.5787) (Figure 5.19A). While there is greater clearance observed in the 
livers of mice infected with NewHG sagB, no significant difference between the recovered 
CFU compared to the CFU livers infected with NewHG kanR could be detected (Figure 5.19B, 
p = 0.3171). As previously seen (Figures 5.5 and 5.6) significantly more CFU were recovered 
from the livers of mice infected with NewHG pbp4 than NewHG kanR (p = 0.0119). No 
significant difference could be seen in recovered liver CFU between mice infected with 
NewHG sagB pbp4 or NewHG kanR (p = 0.8654).  
 
Significantly fewer CFU were recovered from the kidneys of mice infected with NewHG sagB 
than NewHG kanR (Figure 5.19C, p = 0.0053). No significant difference could be seen 
between the recovered kidney CFU of mice infected with NewHG pbp4 or NewHG kanR (p = 
0.2544). Despite a higher level of clearance in the kidneys of mice infected with NewHG 
sagB pbp4, no significant difference could be detected between the recovered CFU of 
NewHG sagB pbp4 and NewHG kanR (p = 0.3752). No significant differences between 
NewHG kanR and the mutant strains could be seen in the recovered CFU from the spleen, 





Figure 5.19 The role of PG synthases and hydrolases in S. aureus virulence in the murine 
sepsis model of infection.  
 
Mice (n=10) were injected intravenously with approximately 1x10
7
 CFU S. aureus NewHG kan
R
 (WT, 
SJF 3680), NewHG sagB (SJF 4912), NewHG pbp4 (SJF 5103) or NewHG sagB pbp4 (SJF 5147). Weight 
loss 72 hpi (A) and CFUs recovered from livers (B, * p = 0.0119), kidneys (C, * p = 0.0055), spleen (D), 
lungs (E) and heart (F) were determined. Groups were compared using a Mann-Whitney U test 
(NewHG kan
R
 – black circles, NewHG sagB – red squares, NewHG pbp4 blue diamonds, NewHG sagB 






5.4.1 The role of PBP4 in S. aureus pathogenesis 
 
NewHG pbp4 (SJF 5103) shows greater colonisation of mouse livers in the murine sepsis 
model of infection (Figures 5.5, 5.6). While NewHG pbp4 goes through the same 
immunological bottle neck as its parent (Figure 5.11), it has a greater relative fitness (Figure 
5.13). A proposed model for NewHG pbp4 infection dynamics is summarised in Figure 5.20. 
Bacteria injected intravenously results in free bacteria entering the circulation (Pollitt et al., 
2018). Both wildtype and pbp4 are then taken up by Kupffer cells (resident macrophages) in 
the liver (Pollitt et al., 2018). A greater number of NewHG pbp4 are recovered from the 
livers of mice than those infected with NewHG (Figures 5.5, 5.6). This is likely due to a 
change in interaction within macrophages, as seen by an increased resistance to early 
macrophage killing (Figure 5.14), leading to increased NewHG pbp4 survival and release 
from macrophages (Figure 5.20). The free bacteria can form liver abscesses, increasing the 
observed recovered liver CFU. 
 
A pbp4 mutant causes increased size of skin lesions in mice infected using the skin infection 
model, which was suggested to be caused by an increase in production of IL-1β (Müller et 
al., 2015). In this model, strains with a reduction in crosslinked muropeptides were more 
susceptible to macrophage killing and degradation (Müller et al., 2015). This was not found 
in my study, with NewHG pbp4 being more resistant initially to macrophage killing (Figure 
5.14). Müller et al. (2015) show no evidence for increased killing of pbp4 deletion strains 
within macrophages. The increased liver colonisation of NewHG pbp4 matches the observed 
phenotype when S. aureus is augmented by the addition of purified peptidoglycan to the 
inoculum; an increase in CFU recovered from the livers of mice (Boldock et al., 2018). 
Without PBP4, PG is less crosslinked than the wildtype (Wyke et al., 1981a). As the PG is less 
crosslinked, it can be hypothesised that cleavage of PG by hydrolases is more likely to 
release muropeptides into the environment, as there are fewer bonds to keep the 
muropeptides linked to the sacculus. The increase in release of muropeptides, if released 
within macrophages, may neutralise ROS (Boldock et al., 2018) and augment NewHG pbp4 




cause for the observed increase in liver colonisation seen with the pbp4 mutant. In a 
Drosophila model of infection, a S. aureus strain with no PG synthases except the essential 
PBP1 and PBP2 is attenuated (Reed et al., 2015). The Drosophila PG recognition protein SA 
(PGRP-SA) recognises PG and activates the Toll pathway, clearing bacteria (Chang et al., 
2004). Without PGRP-SA, the synthase depleted strain has restored virulence, suggesting 
the reduced crosslinking of the strain changes its recognition by the host (Reed et al., 2015). 
The reduction in crosslinking associated with pbp4 mutants (Wyke et al., 1981a) could cause 
a change in the interaction with mammalian extracellular receptors such as Toll-like 
receptor 2 (Dziarski and Gupta, 2005) and cytosolic, muropeptide detecting NOD2 (Carneiro 
et al., 2008). A change in interaction with these PG receptors, possibly caused by the 
increased proportion of monomeric muropeptides, would change downstream signalling, 
altering the host response with differing inflammasome activation, potentially through 
cytokines, such as IL-1β (Shimada et al., 2010; Müller et al., 2015).  
 
PBP4 has been shown to contribute to β-lactam resistance in S. aureus (Memmi et al., 2008; 
Chan et al., 2016; Hamilton et al., 2017), which is usually associated with a reduction in 
fitness (Andersson and Hughes, 2010; Geisinger and Isberg, 2017). NewHG pbp4 has a 
greater relative fitness in the liver and spleens of mice compared to the wildtype (Chapter 
5.3.8.2), which could indicate that there is a fitness cost for producing highly crosslinked PG 
(Wyke et al., 1981a), and this structure is not required in the mouse sepsis model of 
infection. However, as pbp4 is in the core genome of S. aureus, it can be assumed that PBP4 
is required to produce highly crosslinked PG for environments outside of a murein sepsis 
infection. 
 
The increased fitness of NewHG pbp4 in the livers of mice is unusual, as many species lose 
fitness when PBPs are inactivated. Vibrio cholerae lacking PBP1a shows a reduced growth 
and survival in an infant mouse intestine (Dörr et al., 2014). The same is true for Listeria 
monocytogenes, with bacteria missing Lmo0540, Lmo1438, Lmo2229 (all encoding PBPs) or 
PBP5 showing attenuation within macrophages and the spleens of infected mice (Guinane et 
al., 2006). Acinetobacter baumannii with a transposon inactivation of pbpG (encoding 




strain demonstrated attenuation in both rat soft-tissue and pneumonia models of infection, 
as well as being killed when cultured in 90 % human serum in vitro. The attenuation 
phenotype was described to have been caused by an increased susceptibility to 
complement (Russo et al., 2009). In the three examples however, the loss of virulence was 
associated with growth defects in vitro, not observed for NewHG pbp4 (Figure 5.1B). In 
Streptococcus pneumoniae, strains have been isolated that possess β-lactam resistance 
(Rieux et al., 2001). These strains showed mutations within the pbp2b and pbpX genes 
responsible for the acquisition of resistance, but these mutations were also associated with 
avirulence (Rieux et al., 2001). 
 
Neutrophils are thought to be involved in the dissemination of S. aureus to other organs 
during sepsis (Thwaites and Gant, 2011). Mice infected with NewHG pbp4 do not show 
increased CFU recovered from the kidneys, suggesting no change in dissemination, which is 







Figure 5.20 Proposed infection dynamics of NewHG pbp4 compared to wildtype NewHG in the murine 
sepsis model 
When mice are intravenously infected with S. aureus, free bacteria are released into the blood stream that are 
phagocytosed by Kupffer cells (resident macrophages) in the liver. Macrophages contain and kill the S. aureus, but 
some bacteria survive, escaping the macrophage and form extracellular micro-abscesses. It is proposed that more 
NewHG pbp4 survive within the macrophages than NewHG. The same amounts of both strains are phagocytosed and 
killed by neutrophils, resulting in the same level of dissemination to different organs. Arrow sizes indicated the 




5.4.2 NewHG sagB pbp4 phenotype 
 
It was previously shown that NewHG sagB (SJF 4912) was attenuated in zebrafish embryo 
infection (Figure 4.4B) and murine sepsis (Figure 4.5). NewHG pbp4 was shown to be more 
effective at liver colonisation in the murine sepsis model (Figures 5.5, 5.6). As hydrolases 
and synthases are both needed to maintain the PG sacculus (Vollmer et al., 2008b), it was 
hypothesised that NewHG sagB pbp4 (SJF 5147) could have its own distinct phenotype.  
 
When analysed in vitro, NewHG sagB pbp4 (SJF 5147) has a slightly reduced growth rate 
compared to parental NewHG (Figure 5.17B). While NewHG sagB (SJF 4912) has a decreased 
particle size compared to wild type NewHG, NewHG sagB pbp4 has no difference in particle 
size to the wildtype (Figure 5.17D). In vivo, NewHG sagB is attenuated in the zebrafish 
model of infection, whilst NewHG sagB pbp4 is not (Figure 5.17D). In the murine sepsis 
model of infection, despite significantly higher CFU recovered from the livers of mice 
infected with NewHG pbp4 (SJF 5103) and significantly lower from kidneys infected with 
NewHG sagB, no differences could be seen between NewHG sagB pbp4 and the wildtype 
(Figure 5.18). Overall, NewHG sagB pbp4 shows no differences, except a slightly slower 
growth rate, to parental NewHG. 
 
A sagB mutant has an increased cell wall stiffness (Wheeler et al., 2015), aberrant protein 
trafficking and secretion and morphological defects (Chan et al., 2016b), and it has been 
hypothesised that this may be a cause for the attenuation of this strain in animal models of 
infection (Chapter 4.4.1). The inability to process the glycans results in longer and stiffer 
chains (Wheeler et al., 2015), with an associated reduction in the ability to increase in cell 
volume. This is supported by the particle size of NewHG sagB (Figure 5.17D) being 
significantly lower than wildtype NewHG. Previous studies have shown that pbp4 mutants 
have reduced cell wall stiffness compared to a wild type strain (Loskill et al., 2014), likely 
due to the reduction in crosslinking (Wyke et al., 1981a). NewHG sagB pbp4 has the same 
particle size as NewHG, suggesting the increased cell wall stiffness is reversed by the pbp4 
mutation (Figure 5.17D), resulting in an increase in cell volume, and the same virulence as 




the change in PG (Chan et al., 2016), which could also be a cause of the attenuation. As pbp4 
mutations cause reduced crosslinking (Wyke et al., 1981a) and a reduced cell wall stiffness 
(Loskill et al., 2014), it is possible that the loss of PBP4 can cause changes in the cell wall 
structure that may revert its biophysical properties to a wildtype state. If this is true, the 
protein secretion defect associated with sagB which could be a cause of attenuation, may 






Chapter 6  
General Discussion 
 
S. aureus is a current healthcare issue due to the emergence of multiple antibiotic resistant 
strains such as MRSA (Jensen and Lyon, 2009). The rise of antimicrobial resistant nosocomial 
S. aureus infections is a challenge, both in terms of available treatments and the cost of 
care. Therefore, new treatments must be developed to combat potentially fatal S. aureus 
disease. A large proportion of antibiotics target the cell wall of bacteria, specifically PG 
biosynthesis (Zaman et al., 2017). The structure of S. aureus PG is relatively well studied 
(Jonge et al., 1992a; de Jonge and Tomasz, 1993; Kim et al., 2013; Lund et al., 2018), but the 
focus has been on in vitro growth, which does not truly reflect the conditions of an 
infection. My research aimed to fill this gap in our knowledge by providing data for the 
structure of S. aureus PG during pathogenesis. PG has also been shown to play a role in 
disease (Boneca, 2005; Boldock et al., 2018), so the study of its metabolism and structure is 
important to fully understand the infection process. This may provide insight into potential 
new treatments and drug targets that could help in the fight against antimicrobial resistance 
and prevent the onset of the so-called post antibiotic era. 
 
Using a combination of RP-HPLC, MS and TEM, my study has shown that during an infection 
S. aureus cells are smaller with a thicker (but less crosslinked) PG cell wall than exponential 
phase cells (Table 3.2). It has previously been found that S. aureus cells in stationary phase 
have a thicker cell wall with reduced PG crosslinking (Watson et al., 1998; Zhou and 
Cegelski, 2012), hypothesised to be due to a change in available nutrients, which my study 
also demonstrates. This observation suggests that during an infection S. aureus cells have a 
similar cell wall structure to that of stationary phase cells, which could also be caused by a 
change in nutrient availability during an infection.  
 
The impact of PG metabolism on virulence was also investigated using glucosaminidase and 




impact upon pathogenesis. A sagB mutant was shown to be attenuated in both zebrafish 
and murine models of infection (Figures 4.3A, 4.5B, 4.6), and this was associated with a 
reduced ability of the sagB mutant to survive in human MDMs (Figure 4.9). Other 
glucosaminidase mutants, atl, sagA and scaH, are not attenuated in a zebrafish model of 
infection (Figure 4.13). When in combination, attenuation is associated with a clustering 
phenotype (Figure 4.23), with virulence being restored in the zebrafish model (but not the 
murine) when bacterial clusters are disrupted by sonication. These results suggest that 
autolysin activity is required during infection to produce the correct cell wall architecture 
and to separate daughter cells, which in turn permits pathogenesis to occur.  
 
A pbp4 mutant shows increased colonisation, and relative fitness, in the livers of mice 
during sepsis (Figures 5.7, 5.8, 5.13). The pbp4 mutant was shown to have greater survival in 
human MDMs than a wildtype (Figure 5.14). However, as the increased fitness was only 
seen within the livers and spleens of mice (Figure 5.13), the change in crosslinking is only 
beneficial within these tissues. This difference across host tissues could be due to a result of 
differing host nutritional status, such as heterogenous levels of iron, within each organ of 
the body (Cassat et al., 2018). It has also been described that abscesses within the same 
organ can have different nutritional statuses and within a single abscess microdomains of 
differing concentrations of calcium, phosphorus and manganese exist (Cassat et al., 2018). 
The differences in fitness in each organ could also be due to varying immune responses 
between organs. Using the methodology developed in my study, it will be important to 
investigate the PG structure of S. aureus infecting organs other than the kidney, to see if the 
potential differences in immune response and nutritional status result in the same PG 
structure as described in my study. 
 
As the loss of hydrolases was shown to reduce fitness, but the loss of a synthase was shown 
to increase fitness, the impact of the simultaneous loss of hydrolases and synthases on 
virulence was investigated.  A S. aureus strain lacking both sagB and pbp4 had the same 




the reduction in fitness caused by a sagB mutation can be reversed by a reduction in 
crosslinking caused by pbp4 inactivation. 
 
Overall, my results show that during infection, S. aureus has reduced PG crosslinking and a 
thicker cell wall, much like that of stationary phase. My work demonstrates the importance 
of cell wall structure in virulence, as a reduction in crosslinking results in the increased 
fitness of S. aureus in the livers and spleens of mice. While it has been speculated that these 
changes may be due to changes in the nutrient availability for S. aureus within a host, these 
changes could be due to changes in the cell wall architecture and the host response.  
 
6.1 Cell morphology and peptidoglycan architecture 
 
Throughout this study, the importance of PG structure in S. aureus infection has been 
highlighted. During infection, the morphology of the cell, cell wall and PG all show a distinct 
difference compared to exponentially growing cells (Table 3.2). In addition to this, 
mutations in genes required for PG metabolism change the outcome of infection, with loss 
of putative glucosaminidases resulting in attenuation, and the loss of the synthase pbp4 
resulting in increased fitness (Chapter 5.3.5). While the causes of these changes are only just 
being understood, it can be speculated that a change in the PG architecture is a factor. The 
architecture of PG has been briefly discussed in Chapter 1.5. Using molecular resolution 
AFM, more insight has been acquired (Figure 6.1) (Pasquina-Lemonche et al., 2020). The 
Gram-positive cell wall contains a single macromolecule of PG that is tens of nanometres 
thick (Matias and Beveridge, 2007; Turner et al., 2014). While being essential for viability by 
resisting internal turgor (Vollmer and Seligman, 2010), the cell wall has a porosity that 
allows the acquisition of nutrients from the environment, as well as the secretion of 
molecules, such as toxins, into the environment (Green and Mecsas, 2016). The external PG 
forms the interface with the environment and adopts a “mature” architecture, consisting of 
pores up to 60 nm in diameter and up to 23 nm deep (Pasquina-Lemonche et al., 2020). 
These pores narrow as they reach the cell membrane, and the inner face of the PG can be 




single glycan chains, whereas the mature external surface is described as a porous gel 
formed of randomly orientated strands consisting of multiple bunched glycan chains 
(Pasquina-Lemonche et al., 2020). The cytoplasmic facing PG of division septa has a tight 
disordered mesh reminiscent of the internal surface previously described. The PG within the 
septum forming the external division plane is seen to be organised into dense concentric 
rings. This immature ring architecture is seen on the surface of PG of recently divided cells, 
consisting of circumferentially oriented densely packed strands (Turner et al., 2010a; 
Pasquina-Lemonche et al., 2020). The interface between the mature mesh and nascent ring 
is sharp, suggesting that the transition from ring to mature mesh takes place within a single 
division cycle (Turner et al., 2010a; Pasquina-Lemonche et al., 2020). The varied and 
dynamic PG architecture across a cell raises the question of what the PG architecture is 
during an infection, and if this infectious architecture plays a role in supporting virulence. 
 
The final architecture of the cell wall is specified by the activities of both PG synthases and 
hydrolases as seen by mutant studies. When sagB is inactivated, PG is initially thinner, and a 
transition between the ring and the mature mesh can be visualised, suggesting a role for 
sagB in this transition. A pbp4 mutant was found to have a denser ring structure, which was 
observed to occasionally persist past a division cycle (Pasquina-Lemonche et al., 2020). It 
could be suggested that the crosslinking introduced by PBP4 is required for the efficient 
conversion of ring architecture PG to the mature mesh, as the results obtained from the 
sagB mutant (Pasquina-Lemonche et al., 2020) suggest that hydrolase activity is required for 
the maturation of PG to the mesh architecture. As a sagB mutant was seen to be attenuated 
in zebrafish (Chapter 4.3.2) and murine models of infection (Chapter 4.3.6), and a pbp4 
mutant showed increased fitness in murine livers (Chapter 5.3.5) it is reasonable to 
hypothesise that the change in the PG architecture may influence host-pathogen 
interactions, leading to the observed changes in virulence. It was suggested in Chapter 3.4 
that the increase in cell wall thickness and increase in undivided cells with a complete 
septum observed in S. aureus recovered from a kidney could be due to a decrease in the 
expression of PG hydrolases. If this is true, then the PG architecture during infection may 
show a similar phenotype to the sagB mutant (Pasquina-Lemonche et al., 2020), with a 





Figure 6.1 The 3D structure of S. aureus peptidoglycan using AFM  
The architecture of S. aureus PG derived from AFM observations. Representative AFM images show 
the different PG architectures and areas with distinct morphology found in the cell during division. 




6.2 Host response to S. aureus infection 
 
An alteration in PG architecture resulting in a change in host-pathogen interaction has been 
suggested by recent work comparing the effects of exponential and stationary phase S. 
aureus on human dendritic cells (DCs) (Balraadjsing et al., 2019). Exponential phase S. 
aureus cells were found to be highly phagocytosed by DCs, which promoted the secretion of 
IL-12 and an intracellular clearance response (Figure 6.2) (Balraadjsing et al., 2019). This was 
also found when murine DCs were used (Lund et al., 2016). Stationary phase S. aureus cells 
were phagocytosed less than exponential phase cells, resulting in the reduced production of 
IL-12, and a shift to IL-23 production, and an extracellular host response (Figure 6.2) 
(Balraadjsing et al., 2019). The phagocytosis of S. aureus leads to the intracellular activation 
of NOD2 and TLR2, resulting in cytokine production (Balraadjsing et al., 2019). The cause for 
the reduced phagocytosis of stationary phase S. aureus cells was not confirmed, but 
speculated to be caused by factors such as ClfA that inhibit phagocytosis (Higgins et al., 
2006; Balraadjsing et al., 2019). However, a presumed change in PG architecture between 
stationary and exponential phase cells may alter phagocytosis of S. aureus (van Kessel et al., 
2014). PG architectural dynamics during infection may lead to a differential DC and 





Figure 6.2 Schematic of dendritic cell response to S. aureus infection 
The stimulation of DCs by S. aureus results in the production of T cell polarising cytokines to modify 
the host response. The production of IL-12 results in the production of Th1 cells, which produce 
INFγ, resulting in the increased expression of factors required for intracellular clearance of S. aureus. 
The production of IL-23 stimulates the formation of Th17 cells producing IL-17 to recruit neutrophils 
and result in the clearance of S. aureus from the extracellular environment. DCs – Dendritic cells; INF 




A sagB mutant was found to be less able to survive in human MDMs than wildtype S. aureus 
(Chapter 4.3.7), and is associated with a different PG architecture and biochemistry 
(Wheeler et al., 2015; Pasquina-Lemonche et al., 2020). A contributing factor to sagB 
mutant attenuation could be the altered host recognition of the mutant PG architecture 
resulting in the increased expression of intracellular bactericidal factors and explaining the 
decreased survival of sagB in human MDMs. Research has shown that PG is naturally shed 
during growth in Gram-positive bacteria (Borisova et al., 2016). The PG from a pbp4 mutant 
could be more readily shed into the extracellular milieu due to the decreased number of 
crosslinks in the sacculi. When DCs were preincubated with purified S. aureus PG, it was 
found that IL-12 expression was inhibited, and IL-23 production was stimulated, resulting in 
an increased Th17 response (Balraadjsing et al., 2019). A reduction in IL-12 results in the 
shift to an extracellular clearance response by neutrophils (Figure 6.2), rather than 
activation of phagocytes for intracellular bacterial clearance, which may explain increased 
survival in MDMs (Chapter 5.3.9.1). 
 
The increased fitness of the pbp4 mutant in murine livers should be further investigated. 
Clodronate can be used to deplete macrophages from mice (Chapter 4.3.8.2), and these 
macrophage depleted mice could be used to compare the relative fitness of NewHG pbp4 to 
the wildtype, as in Chapter 5.3.8.2. If increased fitness in the murine liver of pbp4 is a result 
of changes in macrophage interactions, the depletion of the macrophages should result in 
no difference in relative fitness being observed. This could be further investigated by using 
qPCR to quantify the levels of pbp4 expressed by S. aureus within the isolated infected 
kidneys (Rivera et al., 2015; Taylor et al., 2019). The qPCR experiment could be performed 
using samples collected over the whole course of the experiment, to see when (and if) the 
expression of pbp4 changes. Poorly crosslinked PG is known to result in the increased 
production of IL-1β host cells (Müller et al., 2015), and a pbp4 mutant shows reduced PG 
crosslinking (Wyke et al., 1981b). It would therefore be important to perform cytokine 
analysis on the serum of mice infected with S. aureus NewHG pbp4 compared to the 





Results presented in Chapter 4 show that clustering of bacteria due to the loss of PG 
hydrolases results in attenuation in zebrafish and murine models of infection. Subsequent 
research should aim to find why clustering causes attenuation. The attenuation likely results 
from a differing interaction with host macrophages and neutrophils. Uptake and killing 
assays using these host cells and SH1000 atl sagA scaH (SJF 4611) could be utilised to help 
refine the cause of attenuation. 
 
My work has produced the first PG structure from S. aureus, or any bacterium, during an 
infection. This, paired with TEM analysis, has helped to elucidate the structure of the S. 
aureus cell wall during an infection. This paves the way for a fuller understanding of how S. 
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Raw data relating to Chapter 3 for the identification of muropeptide species. The identified peaks 
were integrated (Chapter 2.17) using the UV chromatogram, giving the area of the peak, which is 
presented as a percentage of the total of identified muropeptides for each repeat.  
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